Development of synthetic strategies towards libraries of heterocyclic and bicyclic inhibitors of Cdc25A & development of solid phase synthesis of cyclic peptides by Luo, Hao
  
Development of synthetic strategies towards libraries  
of heterocyclic and bicyclic inhibitors of Cdc25A 
& 
Development of solid phase synthesis of cyclic peptides 
 
 
 
 
 
 
Von der Naturwissenschaftlichen Fakultät der  
Gottfried Wilhelm Leibniz Universität Hannover 
 
 
 
 
 
 
zur Erlangung des Grades 
 
Doktor der Naturwissenschaften (Dr. rer. nat.) 
 
 
 
 
genehmigte Dissertation 
 
von 
 
Dipl.-Chem. Hao Luo 
 
 
geboren am 15.06.1982 in Chongqing, China 
 
 
 
 
 
 
 
 
[2015]  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referent: Prof. Dr. Markus Kalesse 
Korreferent: Prof. Dr. Andreas Kirschning 
Tag der Promotion: 19.05.2015 
  
  
Abstract (english) 
Hao Luo 
Development of synthetic strategies for libraries 
of heterocyclic and bicyclic inhibitors of Cdc25A  
& 
Development of solid phase synthesis of cyclic peptides  
Key words: Cdc25A, Hantzsch pyrrole synthesis, Hantzsch thiazole synthesis, 
Paar-Knorr pyrrole synthesis, 1,3-dipolar cycloaddition, Native chemical ligation 
(NCL), cysteine, Fmoc solid phase peptide synthesis (Fmoc-SPPS), latent 
thioester linker, cyclization. 
Cdc25A is a phosphatase, which is treated as a novel target for tumor therapy. Dr. 
R. Frank and Dr. I. Hoffmann recently proposed lead structures of two new 
Cdc25A inhibitors, which were acquired from combinatorial chemical methods. 
The detailed SAR studies of these new Cdc25A inhibitors have to be done in 
order to elucidate the mode of action. For the SAR studies, in this work, a library 
containing a large number of Cdc25A inhibitor derivatives is accessed by 
conventional organic chemical methods. The synthesis of these heterocyclic 
Cdc25A inhibitors consists of two major steps: formation of the thiazole from an 
α-halo ketone and a thioamide through a classical Hantzsch thiazole synthesis  
and the conjugated pyrrole ring was formed either by a modified Hantzsch pyrrole 
synthesis or by classical Paal-Knorr pyrrole synthesis. The important pyrrolidine 
ring system of the lead structure of the bicyclic Cdc25A inhibitor was 
straightforwardly constructed by a 1,3-dipolar cycloaddition from the north 
fragment and the south fragment. 
Native chemical ligation is a method, which joins two peptides through an amide 
bond between an N-terminal cysteine and a C-terminal amino acid without any 
coupling reagents. The C-terminal peptide thioester, which is required for NCL, 
could be synthesized exclusively by the Boc-SPPS method, but utilization of this 
method is relatively inconvenient. Unfortunately, the C-terminal peptide thioester 
is not accessible by the Fmoc-SPPS. To apply the Fmoc-SPPS anyway, in this 
work, a latent thioester linker strategy was used. The C-terminal peptide ester, 
which contains a special linker, was prepared by Fmoc-SPPS. This special linker 
allows the C-terminal thioester to be formed in situ from the C-terminal peptide 
ester precursor and facilitates the NCL transformation. A few linear model 
sequences containing the latent thioester linker were prepared in this work, 
followed by the study of on-resin NCL-cyclization of these linear model 
sequences. After initial investigations, some important factors, which manipulate 
the quality of the NCL cyclization, were identified. So far, the overall yield of 
model reactions were generally poor and thus further studies and optimizations 
are necessary. 
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Schlagworte: Cdc25A, Hantzsch-Pyrrol-Synthese, Hantzsch-Thioazol-Synthese, 
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(NCL), Cystein, Fmoc-Festphasenpeptidsynthese (Fmoc-SPPS), latente Thioester-
Linker, Cyclisierung. 
Das Cdc25A ist eine Phosphatase, welche wird seit Jahrzehnten als neues Target für 
die Tumortherapie intensiv erforscht. Vor kurzer Zeit wurden zwei neue Leitstrukturen 
von Cdc25A-Inhibitoren von Dr. R. Frank und Dr. I. Hoffmann vorgeschlagen. Die 
Leitstrukturen sind frisch aus den kombinatorischen chemischen Methoden erworben, 
daher muss die SAR-Studie von Cdc25A-Inhibitoren noch durchgeführt werden, 
damit der Wirkungsmechanismus aufgeklärt werden kann. Für die SAR-Studie, in 
dieser Arbeit wird die Bibliothek, welche eine große Anzahl von Cdc25A-Inhibitor-
Derivaten umfasst, durch herkömmliche organisch-chemische Methoden zugänglich 
gemacht. Die Synthese von heterocyclischen Cdc25A-Inhibitoren besteht aus zwei 
Hauptschritten: die Bildung des Thiazols sollte aus einem α-Halogen-Keton und 
einem Thioamid über eine klassische Hantzsch-Thiazol-Synthese dargestellt werden. 
Danach wurde der konjugierte Pyrrol-Ring entweder durch eine modifizierte 
Hantzsch-Pyrrol-Synthese oder durch die klassische Paal-Knorr-Pyrrol-Synthese 
gebildet. Das wichtige Pyrrolidin-Ringsystem von der Leitstruktur des bicyclischen 
Cdc25A-Inhibitors konnte problemlos durch eine 1,3-dipolare Cycloaddition aus 
Nordhälfte und Südhälfte konstruiert werden. 
Die Native Chemical Ligation ist eine Methode, die zwei Peptide durch eine 
Amidbindung zwischen einem N-terminalen Cystein und einer beliebigen C-
terminalen Aminosäure ohne Kupplungsreagenzien kupplt. Der für die NCL benötigte 
C-terminale Peptidthioester könnte ausschließlich durch die relativ unbequeme Boc-
SPPS Methode synthetisiert werden. Um die Fmoc-Festphasenpeptidsynthese 
anzuwenden, wurde in dieser Arbeit eine latente Thioester-Linker-Strategie 
verwendet. Der C-terminale Peptidester wurde durch die Fmoc-SPPS dargestellt. 
Dieser C-terminale Peptidester enthält einen speziellen Linker, welcher den C-
terminalen Peptidthioester in situ bildet, um die NCL zu ermöglichen. Durch die 
Fmoc-SPPS-Methode wurden einige Model-Sequenzen dargestellt, welche auch den 
latenten Thioester-Linker enthielten. Danach erfolgte die Untersuchung der NCL-
Cyclisierung auf dem Harz der verschiedenen linearen Peptide. Nach den 
anfänglichen Untersuchungen wurden einige wichtigen Faktoren festgestellt. Weitere 
Studien und Optimierungen zur Erhöhung der bisher generell sehr niedrigen 
Ausbeuten sind nötig. 
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Abbreviation 
Å   angstrom (100 pm) 
AA   amino acid 
Ac  acetyl 
ACN   acetonitrile 
AcOH  acetic acid 
ADMET Absorption, Distribution, 
  Metabolism and Excretion  
Ala   alanine 
AlMe3  trimethylaluminium 
Ar  aryl 
Arg   arginine 
BHA   benyhydrylamine 
Boc   tert-butylcarboxylic 
Br  bromine 
Bzl   benzyl 
Cbz   carboxybenzyl 
Cdc  cell division cycle 
CDI   arbonyldiimidazole 
Cdk1  cyclin dependent-kinase 1 
CLEAR  cross-linked ethoxylate  
   acrylate 
CNG  center nerve system 
Cys   cysteine 
DCC   N,N-dicyclohexylcarbodiimide 
DCM  dichlormethane 
DIC  N,N'-diisopropylcarbodiimide 
DIPEA  N,N-diisopropylethylamine 
DMAP  4-dimethylaminopyridine 
DME  1,2-dimethoxyethane 
DMF  N,N´-dimethylformamide 
 
DMG   dimethylglycine 
DMSO  dimethyl sulfoxide 
DKFZ  Deutsches Krebsforschungszentrum  
Dtt  dithiothreitol 
EDC  1-ethyl-3-(3    
  dimethylaminopropyl)carbodiimide 
Et  ethyl 
et. al.  et alias 
EtOH  ethanol 
F  fluorine 
Fmoc  fluorenylmethyloxycarbonyl 
chloride 
GdmCl  guanidium chloride 
Gly  glycine 
HATU  1-[bis(dimethylamino)methylene]-1H-
  1,2,3-triazolo[4,5-b]pyridinium  
  3-oxid hexafluorophosphate 
HBt  benzotriazole 
HBTU  N,N,N′,N′-tetramethyl-O-(1H-
  benzotriazol-1-yl)uronium 
  hexafluorophosphate 
HCl  hydrogen chloride 
HF  hydrogen fluoride 
HOBt  hydroxybenzotriazole 
HPLC  high performance liquid  
Chromatography 
HR  high-resolution 
Ile  isoleucine 
HZI  Helmholtz Centre for 
Infection Research 
I  iodine 
iPrMgCl·LiCl isopropylmagnesium 
chloride lithium chloride 
  
J  coupling constant 
KOH  potassium hydroxide 
KSCN  potassium thiocyanate 
L  liter 
Leu  leucine 
LC-MS  liquid chromatography–mass 
  spectrometry 
M  molar 
MBHA  4-methylbenzhydrylamine 
mM  minimolar 
Me  methyl 
MeI  methyl iodide 
MeMgBr methylmagnesium bromide 
MeOH  methanol 
MESNa 2-sulfanylethanesulfonate 
MPAA  (4-carboxymethyl)thiophenol 
MSA  methanesulfonic acid 
MTB ether methyl tert-butyl ether 
NaBH4  sodium borohydride 
NCL  native chemical ligation 
NH3  ammonia 
NMP  N-methyl-2-pyrrolidone 
NMR  nuclear magnetic resonance 
PAM  phenyactamidomethyl 
PEG  polyethylene glycol 
PEGA  polyethylene glycol-poly-
N,N-  dimethylacrylamide 
PEG-PS poly(ethylene glycol)- 
  polystyrene 
PG  protecting group 
Ph  phenyl 
ppm  parts per million 
PS  polystyrene 
PS-POE polyethylene glycol- 
  polystyrene 
PTM  post-translational 
modifications 
RAM  Rink amide 
RP  reverse phase 
QSAR               quantitative structure activity 
                         relationship 
Rf  retention factor 
RT ambient temperature 
SAR  structure-activity relationship 
SPPS  solid phase peptide 
synthesis 
StBu  tert-butyl sulfide 
TAMPAL trityl-associated-mercaptopropionic 
acid-leucine 
TBS  tert-butyldimethylsilyl 
TBTU  O-(Benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium tetrafluoroborate 
t-BuOH  tert-Butyl alcohol 
TECP  tris(2-carboxyethyl)phosphine 
TFA  trifluoroacetic acid 
TFMSA  trifluoromethanesulfonic acid 
THF  tetrahydrofuran 
TLC  thin layer chromatography 
TLC  thin layer chromatography 
tR  retention time 
Tyr  thyronine 
UV  ultraviolet 
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Part I. Development of synthetic strategies for libraries of 
heterocyclic and bicyclic inhibitors of Cdc25A  
1. Introduction  
1.1 Heterocyclic compounds 
The carbocyclic compounds like benzene, cyclopentane and cyclohexane are 
very common in the day-to-day organic chemistry routines. The chemists are 
usually familiar with these carbocyclic compounds since they are well presented 
almost everywhere: as solvents, reagents or catalysts. In case, one or more of 
the carbon atoms are replaced by other elements, they are considered as the 
heterocyclic compounds. The other elements involve in this replacement are 
regularly oxygen, nitrogen and sulfur, but not only restrict to these, other 
heterocyclic compounds bearing the boron, phosphorus and silicon could also be 
seen in rare cases.[1] Over two centuries the heterocyclic compounds have been 
studied and the heterocyclic compounds family has been largely extended. 
Almost half of the known organic compounds are made of heterocycles.[2] In 
general the heterocyclic compounds could be classified into two categories. [3] The 
aromatic and aliphatic heterocyclic compounds. The determination of aromatic 
and aliphatic heterocyclic compounds complies with the Hückel´s rule. The 
aliphatic heterocyclic compounds are commonly considered as the cyclic 
derivative of the ether, thiolether and amine while the aromatic heterocyclic 
compounds behave themselves in the similar way like the benzene. The chemical 
properties of aliphatic heterocyclic compounds don't differ greatly from their linear 
counterparts, however the ring strain and steric factor of individual compounds 
could significantly change their chemical reactivity. Because the chemical 
properties of the aliphatic heterocyclic compounds are largely similar to their 
linear counterpart, the main research interest was focused on the study of the 
aromatic heterocyclic compounds. The ring size of heterocyclic compounds 
normally ranged between three and ten. The 3- and 4-membered heterocyclic 
compounds are relatively uncommon due to their strong ring strain. The mainstay 
of the heterocyclic compounds are these 5, 6 and 7-membered rings because of 
their suitable ring size. In order to systematically name these heterocyclic 
compounds, Hantzsch and Widman individually developed a similar 
nomenclature system,[4] collectively called Hantzsch-Wideman nomenclature. The 
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assignment of heterocyclic compound with ring size smaller than ten follows this 
pattern. The heterocyclic compounds, which were already given the trivial names, 
do not follow this system. In the day-to-day organic chemistry the 5- and 6-
membered heterocyclic compounds are well presented everywhere. Among them 
the most important heterocyclic compounds are these containing oxygen, 
nitrogen and sulfur atoms.  
1.1.1 Notable 5-membered heterocyclic compounds 
5-Membered heterocyclic compounds contain 5 atoms in the ring system, from 
which one or two atoms are heteroatoms. Frequently the unsaturated compounds 
are more stable due to the additional aromaticity, which they usually achieve. The 
notable 5 membered compounds are pyrrol, furan and thiophene and their 
saturated counterparts pyrroline, tetrahydrofuran and thiolane. These unsaturated 
5 membered compounds fulfill the Hückel´s rule through an unused free π-
electron pair on the heteroatom and thus form the π-excessive ring.[5] Their 
stability are rationalized by the valence bond resonance throughout the entire ring 
system (Scheme 1). 
 
Scheme 1. Resonance of the pyrrole 
Because of the resonance the carbon atoms within the ring often have a higher 
electron density compare to benzene and consequentially they could be easily 
attacked by electrophiles rather than nucleophiles. To generate these aromatic 5-
membered heterocyclic compounds, many synthesis routes have been described. 
Pyrrole could be synthesis readily through Hantzsch-pyrrole synthesis,[6] Knorr-
pyrrole synthesis[7] and Paal-Knorr synthesis.[8] The latter is also applicable for 
synthesis of furan and thiophene (Scheme 2). 
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Scheme 2. Established methodes for pyrrole synthesis  
Classically, furan and thiophene can be obtained via the reaction of 1,4-diketones 
with Lawesson's reagent as main and side products[9] (Scheme 3).  
 
Scheme 3. Preparation of thiophene and furan from 1,4-diketione and 
Lawesson´s reagent 
Other notable 5-membered heterocyclic compounds are the thiazoline and 
thiazole, which especially the latter could be regularly saw in some special 
natural products (notably in vitamine B1 ) as well as in the synthetic compounds. 
The thiazole contains two heteroatoms, the sulfur and nitrogen atoms in 1,3 
positions, thus it belongs to the azole family. The structure is very similar to the 
imidazole. The thiazole is aromatic due to its π electron delocalization. 
 
Figure 1. Electron density in thiazole 
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A strong aromatic ring current is developed as the consequence of the large 
delocalization and this changes the electron density within the ring. Among these 
carbon atoms, the C2 carbon atom is calculated strong electrophilic whereas the 
C5 is nucleophilic (Figure 1), therefore the thiazole can undergo different type of 
reactions. Classically the thiazole can be obtained through the Hantzsch thiazole 
synthesis,[10] Robinson-Garbriel-synthesis[11] and Cook-Heilbron thiazole 
synthesis.[12] Moreover at present days 1,2,3-triazole gradually becomes the one 
of the most important 5-membered heterocyclic compounds due to its broad 
applications in medicinal chemistry[13] and biological science.[14] It can be readily 
synthesized through the 1,3-dipolar cycloaddition from an alkyne and an azide. 
1.1.2 Notable 6-membered heterocyclic compounds 
Import six-membered heterocyclic compounds are these bearing the nitrogen 
atom. The rings bear only one nitrogen atom are called the piperidine and 
pyridine, in which the piperidine is a sterical hindered base routinely used for the 
organic synthesis (notably in Fmoc peptide synthesis), its unsaturated form 
pyridine is an analogue to benzene, but its hexagonal ring system is slightly 
deformed due to the shorter C-N bond.  
 
Scheme 4. Resonance form of the pyridine 
Unlike its 5-membered counterpart pyrrole, it has a free electron pair totally 
unrelated to the aromaticity. It possesses a permanent dipole, in which the 
nitrogen atom bears the partial negative charge, while the 2, 4- and 6-carbon 
atom are electron-deficient (Scheme 4). The 3,5-positions are normally 
considered neutral. The nucleophilic attack would prefer to take place in these 
electron-deficient positions whereas the electrophilic substitution would initialize 
in the 3 and 5 positions. The heterocyclic compounds could derive from fusion 
with other rings either the carbocyclic ring or other heterocyclic ring to form the 
bicyclic or multicyclic systems. The practice of fusion of the different ring systems 
is often pharmacological active (quinoline, benzazepine). Indole is such classic 
example and a common precursor to many pharmaceuticals. It consists of one 
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pyrrole fused to one benzene ring and the new bicyclic system still retains the 
aromaticity. For a century many indole synthesis strategy has been emerged, 
among them the most significant methods are the original Fisher-indole 
synthesis,[15] and Leimgruber–Batcho indole synthesis by using the Raney-Nickel 
and hydrazine as reductant[16] (Scheme 5) 
 
Scheme 5. Fisher and Leimgruber-Batcho indole synthesis 
1.1.3 Heterocyclic compounds in medicinal field 
Heterocyclic compounds are applicable in many areas especially in the medicinal 
field.[5] These molecules containing the heterocyclic compound fragments often 
show more biologically activity than their counterparts, which only carry the 
carbocyclic compounds. For this reason the heterocycles are often presented in a 
large range of the commercially available synthetic medicines including antibiotic 
(Penicillin G), antibacteria (Norfloxacin), antidepressant (Cymbalta), antimalarial 
(Chloroquine), antitumor,  anti-HIV (Zidovudine), antidiabetic (Actos) drugs 
(Figure 2).  
 
Figure 2. The common medicines containing heterocycles 
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The research interest of the indole and pyrrole is mainly focused on the medicinal 
area. Many indole containing compounds have been synthesized to treat various 
center nerve system (CNS) diseases.[17] Furan ring is often contained in 
terpenoids and its derivative 2-(5H)furanone is the main scaffold of various 
antibiotic, anti-tumor agents,[18] whereas pyridine is substantially involved in the 
treatment of muscular disorder (muscular rheumatism).[19] 
The natural occurring heterocyclic compounds are mainly alkaloids, from which 
many contain the nitrogen atoms. Ergotamine bears the indole backbone and 
inhibits antimigraine activity.[20] Posaconazole is based on triazole scaffold and 
shows biological activity against microorganism candida.[21] Cinchonine, which is 
a member of the quinolone family, inhibits high activity against malaria (Figure 
3).[22]  
 
 
Figure 3. Hetercyclic compounds with large medicinal significance. 
The large interest of developing novel heterocyclic compounds emerged in the 
past because of their wide pharmaceutical applicability. In the future, more 
biological active heterocyclic compounds will appear in one way or another while 
this interest still remains. 
1.2 Combinatorial chemistry in the drug discovery 
Today, in pharmaceutical research, the lead structures for drug design generally 
originate from two major sources: Natural occurring compounds and 
combinatorial chemistry. Combinatorial chemistry is a novel method, which is 
designed to reduce the time and cost in effective drug discovery.  
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In general, combinatorial chemistry generates a large collection of molecules, 
also called chemical library and the individual bioactivity of each molecule is 
determined by high throughput screening. Unlike the conventional organic 
chemistry, each single compound in this chemical library is not synthesized one 
after another but preferentially in parallel manner or in a one-pot reaction 
(Scheme 6). By doing this a lot of time can be saved and a huge quantity of 
compounds can be generated in short time.  
 
Scheme 6. Two different ways of generation of chemical compounds. 
In practice, there are several ways to effectively establish a chemical library, 
either chemically or biosynthetically. In the chemical approach, both the solution 
phase and the solid phase methods can be applicable. In solution phase the 
synthesis is performed on small scale, each vial in the array is filled with different 
reagents and various reactions of the same kind are allowed to take place 
simultaneously. Immediate after the reaction the unpurified products can be 
directly screened. The solid phase peptide synthesis has already been introduced 
by the Merrifield back in 1960´s, but not until early 1990´s it was firstly deployed 
to generate a peptide library.[23] The starting material in this case is anchored on 
the resin beads through coupling reactions, then the reagent is added to the 
solvent, after each reaction the by-product and the excess unreacted reagent can 
be easily washed out while the desired product still attaches to the resin. In the 
solid phase two different synthetic strategies are deployed, either parallel 
synthesis[24] or the split and mix method (Scheme 7).[25] 
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Scheme 7. Parallel synthesis vs. the split and mix strategy 
The parallel synthesis on solid phase is not much different than the parallel 
synthesis in the solution phase. The starting material fixed on the resin is 
partitioned to n ways, each portion reacts stepwise and simultaneously with 
different building blocks in a giving order and after the designed steps a new 
combinatorial library with high diversity are established. In the split and mix 
synthesis, the starting material is split to n portions in the beginning and each 
portion is allowed to react with different building blocks, then all resin beads will 
be recombined and again divided into n portion before the conversion with next 
building blocks begins (see scheme 4). In comparison to the parallel synthesis, a 
large combinatorial library could be much easier achieved by utilizing the split 
and mix method but some drawbacks limited the application of this method: 
 The material could only be made in very small amount. 
 Screening on the resin could be deceiving, highly active compound could 
be masked by less active compounds 
 Highly complex mixture could be formed. 
After the establishment the chemical library, the next immediate step is the 
determination of individual bioactivity through screening. There are two basic 
types of the screen methods:[26]  
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 Random screening: detection of lead without knowing any structural 
information.  
 Directed screening: evaluation of analogue of the lead to generation 
structure-activity-relationship. I 
1.2.2 Discovery of the lead structure through the combinatorial chemistry 
 
Scheme 8. Work-flow of the discovery of the lead structure 
At the present days, the identification of the optimal molecule structure for the 
drug development within the framework of the combinatorial chemistry is 
achieved by following standard procedure:  
1. A mixture contains large degree of diversity (normally 100,000 to 
3,000,000 compounds), called random library, is generated either through 
high throughput parallel solution phase or combinatorial solid phase 
synthesis. This whole random library will be then high throughput screened 
to identify the hits.  
2. If the screening identifies any hits, one focus library (contains 100 to 1000 
compounds) will be established with the high throughput parallel solution 
phase synthesis to validate the hit and initially explore the Structure 
Activity Relationship (SAR).  
3. The confirmed hit will be further optimized through the study of one smaller 
focus library (contains 20 to 100 compounds, which obtained from 
medicinal chemistry methods), after the study complete SAR, and ADMET 
(Absorption, Distribution, Metabolism, Excretion and Toxicity) properties of 
the lead structure will be elucidated. 
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1.2.3 Structure-activity relationship (SAR) study  
 
Figure 4. 3-D QSAR palm model.[27] 
The structure-activity relationship describes the connection between the structure 
and its biological activity. In drug discovery, the analogues with similar structure 
to original structure are often expected have similar biological activity but 
sometimes also comes up with undesired side effects.[28] In order to determine 
which part of the compound (formally called: pharmacophore) is responsible to its 
beneficial biological activity, the structural difference between the original 
structure and its analogues is investigated. After the study, the information 
extracted from the investigation could be used to redesign the drug-like original 
compound to increase its beneficial biological activity and meanwhile reduce or 
even eliminate the undesired side effect. The SAR study assesses the influence 
of these analogues, which are derived from the original structures through some 
minor changes, on the biological activity. These minor changes may alter the 
biological activity, though the new analogue should still retain large structural, 
chemical and biochemical similarities to the original compounds.  
Frequently three basic types of changes are conducted in the SAR study: 
1. The change of size and shape of the carbon scaffold. 
 Additional methylene groups inside the chain or ring system could enlarge 
the size and repectively enhance the lipophilicity. The more lipophilic 
analogues may have better membrane penetration ability. 
 The number of the unsaturated carbon bonds could be adjusted. Removal 
of some C-C double bonds may make the resulted analogue 
conformational flexible and could be more fit onto the active or receptor 
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sites much easier but sometimes this could also cause the alternation of 
the biological activity of the analogue. Moreover, insertion of the double 
bonds in the carbon scaffold leads to E- and Z-isomers, which generally 
exhibit different biological activity.  
 Introduction or removal of the alicyclic ring system could adjust the 
molecular size and make it better fit onto the binding pocket of the target. 
Additional aromatic rings will increase the rigidity of the analogue and may 
improve the resistance to metabolism.  
2. Alternation of the substitution or change of the number of the substitutions. 
This change sometimes could substantially modify the biological properties 
and activity of the new analogues. 
 Introduction of the methyl group and the halogen would increase the 
lipophilicity and reduce the water solubility. Besides the methyl group 
could improve the binding of molecular to the pocket site, but meanwhile it 
could lead to the steric hindrance. Furthermore the methyl group has the 
considerable influence on the metabolism rate, depends on in which part 
of the molecular it is incorporated. 
 Insertion of the hydroxyl group will improve the water solubility but makes 
the new analogue less membrane penetrable. Meanwhile the binding to 
the target site could benefit from the new hydrogen bonds.  
 The basic groups in the molecule generally refer to various amines, these 
amines could be readily converted into salt form and thus the entire 
molecule is water soluble. Additional basic groups in the molecule would 
also vastly increase the water solubility.  
 Introduction of COOH and SO3H groups could improve the binding to the 
target site through the hydrogen bond and acid base interaction. 
3. Change of the stereochemistry. The stereochemistry mainly regulates the 
binding affinity to the binding site. Different stereochemistry leads to the 
diverse biological activity. 
Despite previous knowledge the effect on the biological activity of those changes 
are hardly predictable, in practice there are always exceptions, the investigation 
of the biological activity changes could only be concluded after the actual 
molecule is synthesized and tested. 
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1.2.4 Quantitative structure-activity relationship (QSAR) 
In order to quantitative describe the relationship between the biological activity 
and measurable pharmacological parameters a mathematic model is established 
through regression analysis. In this model the relationship between the activity 
and parameters is described by the mathematic equation: 
                                  
The parameters (size, shape, electron distribution) are generally considered have 
major influence on the biological activity, and the biological activity is the value to 
the variable parameters. With help of this model, the activity could be predicted. 
By the defined range of activity the respond value of parameters could also be 
calculated, this could help the medicinal chemist to decide, which compounds 
need to be synthesized thus reduce the cost and time. 
1.3 Cancer and the Cdc25s inhibitors 
Cancer is a serious disease and associates closely to unregulated cell growth. It 
is a collective name of several deadly diseases. Annually it causes tens of 
millions fatalities and is the leading killer of the human beings reported by the 
World Health Organization (WHO) as of 2014.[29] It is almost incurable in the past 
time but the situation has been changed since the introduction of the novel target 
therapy of tumor cell, different parts of tumor cell have been used as targets for 
tumor treatments 
Even so the repression of the fast tumor cell growth remains as the difficult part 
of the tumor therapy. Recently the G2 / mitosis transition phase within the cell 
division cycle aroused a great deal of interest of tumor therapy, if this transition 
could be efficiently blocked or repressed, the tumor cell might eventually cease to 
grow. The transition between G2 and mitosis phases progresses only under the 
coordinated regulation of Cdk1 (cyclin dependent-kinase 1).[30] The Cdk1 is a 
highly conserved protein, which functions as a serine / threonine kinase, and is 
vital for the G2 / M transition. Commonly, the Cdk1 rests in its inactive state, 
because its theronine 14 and tyronine 15 residues, which locate within the ATP 
binding loop, are phosphorylated by the WEE1 and MYT1 kinases (Figure 5).[31]  
In order to function as the G2 / M transition regulator, Cdk1 must bind to the 
activator Cyclin B and form the complex Cdk1 / Cyclin B, upon formation of the 
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complex the active center of Cdk1 will open and available for the subsequent 
transformation. 
 
Figure 5. Cyclin A / CDK 1 complex.[32] 
During the entry phase of the G2 / M transition, the Cdk1 / Cyclin B complex 
locates in the cytosol, whereas the threonine 14 and tyrosine 15 residues of Cdk1 
are still phosphorylated, thus the complex shows no enzymatic activity. 
Subsequently, the relocation of the Cdk1 / Cyclin B complex to the nucleus takes 
place, meanwhile the thronine 16 residue of Cdk1 is activated through the 
phosphorylation by the Cdk-activiting kinase (CAK; Cdk7 in metazoans). 
Sequentially the inhibitory threonine 14 (T14) and tyrosine 15 (Y15) residues of 
Cdk1 are dephosphorylated and consequently the CdK 1 / Cyclin B complex is 
constitutionally active and this is followed immediately by condensation of the 
chromosome.[33] 
  
Sheme 6. Activation and deactivation of the CDK1 / Cyclin B complex.[34] 
The dephosphorylation of the T14 and Y15 residues is specifically regulated by a 
dual specific phosphatase cell division cycle 25 phosphatase homologue A 
(Cdc25A).  
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Figure 6. The Cdc25A phosphatase.[34] 
Cdc25A along with other two homologes B and C constitute the Cdc25 
phosphatase family in the mammalian cells:[35] The existence of human Cdc25 
genes was firstly described by Sadhu[36] then two main homologes A and B of 
Cdc25s were isolated and individually identified.[37] The Cdc25 phosphatase 
contains two domains, from which one is the catalytic domain and the other is the 
regulatory domain (Figure 6). The catalytic domain is highly conserved, whereas 
the regulatory domain is more versatile, the phosphorylation / dephosphorylation 
of the regulatory domain changes the catalytic or inhibitory ability of the 
regulatory domain. The deactivated Cdk1 could bind additional Cyclin B in the 
cells while the Cdc25A is overexpressed, therefore the G2 / M transition is 
promoted. In many cancer cases the expression or overexpression of the 
Cdc25A and Cdc25B was observed thus the Cdc25s especially the Cdc25A and 
Cdc25B are generally classified as oncogenes. Their overexpression often 
associates to the premature assemble and activation of the Cdk1 / Cyclin B 
complex and the acceleration of the cancer cells division. In these cases the 
overexpress of the Cdc25A or B is fatal, however through the slight interference 
of short hair-spin RNA, the Cdc25 phosphatases could be repressed and 
consequentially the amount of activated Cdk1 / Cyclin B complex would decrease. 
Lacking of Cdk1 / Cyclin B complex, the G2 / M transition would not progress thus 
the cancer cell division ceases. 
Since a decade, Cdc25A emerged as a new target for the tumor therapy due to 
its crucial role in the cell division. Besides the broad phosphatase inhibitors 
(Figure 7), a handful of novel small to middle sized molecules, which show 
inhibitory effects against Cdc25A, have already been tested and some were even 
released in the market for the further research.  
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Figure 7. Common Ser / Thr, acidic and alkaline phosphatase inhibitors 
Some commercially available inhibitors distinguished themselves with their 
notable inhibitory ability: NSC 95397,[38] NSC 663284 (aka: Cdc25 Phosphatase 
Inhibitor II)[39] as well as Cpd 5 (Figure 8).[40] They are cell-permeable, 7-
substituted quinolinedione compounds and function as the potent, irreversible, 
mixed competitive inhibitors of the Cdc25 phosphatase family. NSC 95397 and its 
monohydroxyl-NSC 95397, dihydroxyl-NSC 95397 derivatives showed inhibition 
of human hepatoma and breast cancer cells in vitro.  
NSC 663284 blocks spreading of many human tumor cell lines and is usually 
deployed as an anti-proliferation reagent by inhibiting Cdc25s.[41] 
In rat hepatocytes both hepatoma cell growth and DNA synthesis are inhibited by 
Cpd5 in vitro. 
Disadvantageously they are all broad Cdc25 inhibitors, so that they did not show 
sufficient inhibitory ability against Cdc25A. 
 
Figure 8. Some broad Cdc25 inhibitors in the market. 
Furthermore a few compounds, which are derived from the yohimbine alkaloids 
have also been reported as Cdc25A inhibitors (Figure 9).[42] 
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Figure 9. Structures of the yohimbine alkaloids Cdc25A inhibitors. 
Most recently, two new selective Cdc25A inhibitors (Figure 8) have been 
synthesized and identified through the combinatorial chemical method and 
partially characterized by PD. Dr. Ingrid Hoffmann (DKFZ) and Dr. Ronald Frank 
(HZI). They identified the hits on the target Cdc25A and validated them through 
the previous procedures. However most biological and medicinal properties 
especially the structure-activity relationship (SAR) remains unknown. In order to 
get full spectra of details and eventually turn the hit to the lead, a library contains  
a small number (20-100) of diverse derivatives will be required, these carried out. 
But one effective chemical synthetic route toward these compounds prior to the 
intensive research must be needed, which becomes the main objective of this 
thesis.  
 
Figure 10. Two novel Cdc25A inhibitors
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2. The retro synthetic analysis and the design of the synthetic route 
2.1 Retro synthetic analysis of the heterocyclic inhibitor 
This work starts with the synthesis of the heterocyclic inhibitor 19. The synthesis 
towards compound 19 will encounter construction of the conjugated heterocyclic 
system. Two compounds (pyrrole and thioazole) are recognized to be the backbone 
of the inhibitor 19 and the synthesis of 19 will focus on the building of these two 
heterocyclic systems. The Hantzsch pyrrole synthesis is a classic method to furnish 
the pyrrole ring. Inspired by the classic Hantzsch pyrrole synthesis the pyrrole ring is 
commonly generated through the reaction between an α-halo ketone and an enamine, 
in which the enamine is formed in situ.[6] But in this synthetic route the enamine 1, 
which is needed for the heterocyclization, will be formed beforehand and then 
allowed to react with the α-halo ketone 2. The enamine 1 could be readily obtained 
by condensation of the fragments 3 and 4. The bromoketone 2, which contains the 
thiazole ring, could be formed within the frame of Hantzsch thiazole synthesis[10] from 
the respective haloketone 5 and thioamide 6 (Scheme 9).  
 
Scheme 9. Retro synthetic analysis of heterocyclic inhibitor 
2.1.1 The initial synthetic plan of the heterocyclic inhibitor 
The fragments 3 and 4 are commercially available so the initial synthesis will 
concentrate on the syntheses of fragments 5 and 6.  
The monobrominediketone 5 was made through simple monobromination of the 
diketone 7.[43] Meanwhile the fragment thiophenethioamide 6 could be synthesized by 
an acidic catalyzed Fried-Crafts-acylation of the thiophene 8.[44] 
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Scheme 10. Generation of starting materials 5 and 6. 
Afterwards the fragments 5 and 6 could be assembled into ketone 9 through the 
thiazole formation.[45] 
 
Scheme 11. Plan of generation of intermediate 9 
The intermediate 9 would then form fragment 2 through bromination.[45] 
 
Scheme 12 Plan of bromination of intermediate 9 
In case of difficulties with the bromination of the intermediate 9, a backup plan is also 
considered. In this case, the starting material 7 would be dibrominated to the 
dibrominediketone 10,[46] which then could also form fragment 2 through the same 
pathway.[45] 
 
Scheme 13. The backup plan to achieve the intermediate 2 
In favor of further modifications, the original fragment 1 is deliberately replaced by 
new fragment enamineester 12. Formation of the ester bond could be hydrolyzed to 
the carboxylic acid and enable to prepare various amides. The formation of the 
enamineester 12 could be achieved through a condensation of ketoester 11 and 
amine 4,[47] which are commercially available. 
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Scheme 14. Plan of formation of enamineester 12 
The upcoming step is crucial in the synthetic route. The fragments 2 and 12 will be 
assembled to form the pyrrole ring system.[48] 
 
Scheme 15. Plan of formation of pyrrole ring  
After the completion of the intermediate 13, the conjugate cyclic ring system is 
established. The following steps will be generation of the amide bond: After the 
saponification of the intermediate 13,[49] the carboxylic acid 18 is converted to 
generate the lead structure 19.[50] 
 
Scheme 16. Synthetic route through 13 to the final product 19 
 
2.1.2 An alternative synthetic plan for the heterocyclic inhibitor 
A secondary route to construct the pyrrole ring will also be taken into account, if the 
Hantzsch method is not successful. This alternative method is based on the Paal-
Knorr pyrrole synthesis[8] and can be applied immediately after the completion of 
fragment 2. The changes are, instead of generating the enamine 12 the fragment 2 
would be alkylated with ketone ester 11 at first[51] and followed by the ring formation 
with fragment 4 to accomplish the pyrrole.[52] 
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Scheme 17. The Paal-Knorr route to generate intermediate 13 
 
2.2. The retro synthetic analysis of the bicyclic inhibitor 
The overall structure of the bicyclic inhibitor simply comprises of the pyrrolidine ring 
system and the imide moiety. The pyrrolidine ring is formed from part 78 and the 
southern segment 75 through the 1,3-dipolar cycloaddition. The imine fragment 78 is 
again formed from 76 and 77, whereas the imide part is formed from fragment 73 and 
74. All fragments from 74 to 77 are commercially available. (Scheme 18).  
 
Scheme 18. Retro synthetic analysis of bicyclic inhibitor 
2.2.1 The synthetic plan of the bicyclic inhibitor 
The synthesis of the bicyclic inhibitor 80 is straightforward, because all the basic 
fragments are commercially available. However, there were no details available 
about the stereochemistry, the compound 80 above is just a suggestion of the 
structure. Which specific configuration is beneficial to the biological activity remains 
unknown. At the beginning of the synthesis, this work will not aim on any specific 
stereochemistry but rather starts with any starting materials, which are available. 
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The upper fragment 78´ (fragment 78 with specific configuration) is made by 
condensation from L-Leucine methyl ester 76´ (the L configuration amino acid ester of 
fragment 76) and 2-methylbenzaldehyde 77.[53] 
 
Scheme 19. Synthesis of fragment 78 
Fragment 75 could be furnished through imide formation from the maleic acid 73 and 
the 4-aminoacetophenone 74.[54] 
 
Scheme 20. Synthesis of fragment 75 
The assembly of fragments 75 and 78´ is accomplished through a 1,3-dipolar 
cycloaddtion[55] and after the hydrolysis of the methyl ester, the first structure in this 
library will be formed.  
 
Scheme 21. Synthesis of 80´ 
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2.3. Outline of the construction of further derivatives 
2.3.1 Derivatization of heterocyclic inhibitor 
In order to establish a library, a few further modifications on lead structure 19 have to 
be carried out. Retaining the backbones (pyrrole and thioazole rings) of the lead 
structure 19, four areas can be modified (Figure 11). 
1. The primary amide can be replaced by using N-substituted amines on the 
amide formation step. 
2. The alkyl residue attached to the pyrrole ring can be varied by using ketone 
ester with different alkyl functionalities. 
3. The nitrogen atom of the pyrrole ring is able to be connected to various 
aromatic or alicyclic moieties.  
4. The thiophene on the far right side can be deliberately replaced through other 
heterocyclic compounds.  
 
Figure 9. Derivatization plan of heterocyclic inhibitor 
 
2.3.2 Derivatization of the bicyclic inhibitor 
In the case of the bicyclic inhibitor, there are four possible positions, which could be 
derivatized (Figure 12).  
1. The leucine could be replaced by different amino acids, of which both D, and 
L-amino acids should be contained.  
2. The o-tolyl group from the upper right side might be substituted by various 
aromatic ring systems. 
3. The carboxylic acid from the upper left side could be formed into diverse 
amides. 
4. The substitution pattern of the aromatic residue can be expanded by halogens 
ethers or propionyl groups. 
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Figure 12. Derivatization plan of bicyclic inhibitor
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3. Results and discussion 
3.1 Commencing with the initial plan toward the heterocyclic inhibitor 
3.1.1 Synthesis of 5 
 
Scheme 22. Monobromination of the starting material 7. 
This experiment was carried out according to the procedure of reference.[43] 
Diketone 7 was brominated with an equimolar amount of bromine. In order to 
avoid the formation of the dibrominated product, the rate of bromine drops was 
kept constantly slow, and the temperature inside the flask was maintained 
between 20 – 30 °C, and the final product was separated through fractional 
distillation with 63% yield.  
3.1.2 Synthesis of thiophene-2-carbothioamide (6) 
 
Scheme 23. Preparation of thioamide 6. 
The thioamide 6 was prepared by following the procedure of the reference.[44] 
Thiophene 8 was thioacylated through a Friedel-Crafts acylation with help of 
methanesulfonic acid. After work the raw product was isolated in 48% yield by 
using flash chromatography. The total yield could be slightly improved (by 6%), 
when the water phase was also carefully extracted with chloroform and purified 
through flash chromatography. 
3.1.3 Synthesis of 1-(2-(thiophene-2-yl)thiazol-4-yl)ethanone (9) 
 
Scheme 24. Formation of the ketone 9. 
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This experiment followed the instruction of the reference.[43] Ketone 9 was 
successfully synthesized after two steps. The raw product was purified by using 
the flash chromatography with 30% yield over two steps. The yield is not 
satisfactory due to the existence of a large amount of by-product. The TLC 
analysis showed that the by-product was very polar, which suggested that it could 
be constructed through the polymerization of 5.  
3.1.4 Synthesis of 2-bromo-1-(2-(thiophen-2-yl)thiazol-4-yl)ethanone (2) 
 
Scheme 23. Failed attempts to achieve the intermediate 2. 
Table 1. Monobromination under different conditions 
entry solvent temperature catalyst result 
1 chloroform RT none no product 
2 chloroform 45 °C AcOH no product 
3 DCM RT none no product 
 
The bromination of 9 was initially conducted in chloroform at RT[45], but it was not 
successful. Afterwards two more brominations were attempted under slightly 
changed conditions (Table 1),[46][56] unfortunately none of these experiments 
achieved the desired monobrominated product. In all three cases the starting 
material 9 was nearly fully recovered after the reaction, which indicated that the 
bromination did not take place at all.  
3.2 Change of the tactic 
Since the initial synthetic route could not achieve the desired product 2, the 
bromination of the ketone was instead performed prior to the thiazole formation. 
Thereafter, the secondary synthetic plan using dibromineketone 10 as starting 
material was carried out.[44] 
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3.2.1 Synthesis of dibrominediketone 10 
 
Scheme 26. Dibromination of the starting material 7. 
To diketone 7 was added two equivalent of bromine, and heated at 45 °C until no 
more gas emerged from the reaction vessel. The raw product was purified by 
recrystallization in modest 11%. isolated yield. The recrystallization of the raw 
product caused the huge loss of the substance, and the raw product was 
therefore applied without any purification.  
3.2.2 The second approach towards 2-bromo-1-(2-(thiophene-2-yl)thiazol-4-
yl)ethanone (2) 
 
Scheme 27. Successful synthesis of the 2 through the secondary route. 
This step was carried out under the same conditions as the previous reaction of 
the synthesis of the intermediate 9´.[40] Bromoketone 2 was successfully 
synthesized and the difficult bromination step of 9´ was bypassed. The raw 
product was purified through flash chromatography in 49% yield. The thiazole 
formation from fragments 6 and 10 was more effective than thiazole formation at 
the section 3.1.3, much less by-product was observed on the TLC plate during 
the experiment. 
3.2.3 The synthesis of (Z)-ethyl 3-((tetrahydrofurane-2-yl)methylamino)but-
2-enoate (12) 
 
Scheme 28. The synthesis of the enamineester 12. 
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The synthesis was carried out at RT by following the same procedure of the 
reference,[45] the raw product was isolated in 86% yield by using flash 
chromatography. 
3.2.4 The synthesis of ethyl 2-methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-
(thiophene-2-yl)thiazol-4-yl)-1H-pyrrole-3-carboxylate (13) 
 
Scheme 29. Formation of the pyrrole ring under opimized conditions 
The pyrrole ring formation was achieved after a few attempts under various 
conditions.  
Table 2. pyrrole formation under various conditions. 
entry  solvent temperature reactant yield 
3 toluene RT AcOH no reaction 
4 DMF 150 °C DIPEA no reaction 
5 DME 85 °C / 42% 
6 DME 85 °C DIPEA 32% 
 
The reaction was firstly carried out in toluene with catalytic amount of acetic acid 
(Table 2, entry 3),[57] no reaction took place. Acetic acid was a weak acid and 
apparently it did not initialize the reaction, besides RT may be too mild for this 
reaction and therefore, the reaction needs to be performed under more vigorous 
conditions. The reaction was again carried out overnight under reflux of DMF 
(150 °C) and with catalytic amount of DIPEA (Table 2, entry 4),[58] unfortunately 
the temperature was too high and the starting materials were all destroyed just 
after 1 hour. Then the reaction was carried out under reflux of DME at relatively 
milder temperature (85 °C) (Table 2, entry 5),[59] the desired product was formed 
and isolated in 42% yield. The reaction was then performed under the same 
conditions but with additional DIPEA (Table 2, entry 6), the DIPEA additive in this 
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case did not promote the yield, but instead diminished the yield by 10% when 
compared to the former experiment. 
3.2.5 The final steps toward the lead structure 19 
 
Scheme 30. Construction of the lead structure 19. 
Ester 13 was then subjected to saponification in 10% KOH ethanol,[47] The acid 
18 was successfully formed. The raw product was assessed by TLC and the 
conversion was quantitative. The raw intermediate 18 was then used for the final 
step without further purification. The formation of primary amide was achieved by 
using the common coupling reagent combinations (EDC / DMAP) [48] and the 
reaction was accomplished after 5 hours, raw product was purified by flash 
chromatography. The formation of the primary amide under those conditions was 
not highly efficient, the final product came out only in 24% yield calculated over 
two steps. 
3.2.6 The synthesis of various amides derived from 19 
 
Figure 13. Different amide derivatives of the lead structure. 
Furthermore two derivatives 20 and 21 with substituted amides were constructed 
in the same way[48] with comparable yields to the lead structure 19. 
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3.3 The alternative route to achieve the pyrrole ring 
3.3.1 The synthesis of 1,4-diolester 14 
For comparison purpose, the secondary synthetic route based on the Paal-Knorr 
pyrrole synthesis was also investigated.  
 
Scheme 31. Generation of the 1,4-dicarbonyl intermediate 14. 
The study of this route commenced with the alkylation of ketoester 11 with the 
already synthesized bromoketone 9.[51] After a few initial attempts, it was found 
that the reaction time must be kept short (within 10 min.), otherwise the 
polymerization started, which resulted in undesired polymeric products. The 
actual reaction concluded after 5 minutes and the product was separated in 42% 
yield through flash chromatography. 
3.3.2 The approach to 13 through the Paal-Knorr synthesis 
 
Scheme 32. The pyrrole formation through Paal-Knorr method. 
The 1,4-diolester 14 and starting material 4 were condensed with assistance of 
acetic acid and the pyrrole ring subsequently formed through the ring closure with 
4 (Scheme 32). The formed product 13 (53% yield) was identical to the product, 
which was formed through Hantzsch synthetic route. Combined with the previous 
step, the synthesis of 1,4-diolester 14, the calculated yield over two steps was 
22%, and apparently the Hantzsch route (42% yield) was advantageous over the 
Paal-Knorr route in term of the productivity. However
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 with the intermediate 14 in hand, the Paal-Knorr method is more versatile and 
facilitates the generation of a large number of derivatives in a short time.  
3.3.3 The generation of pyrrol with different substitutions 
 
Scheme 33. Preparation of derivatives through the same method. 
Afterwards three derivatives were constructed in the same way through the 
condensation of 1,4-diolester 14 with three different amines. The intermediates 
15 ,16 17 were converted from 1,4-diolester 14 with phenylmethanamine, 3-
fluoro-4-methylaniline or methyl 2-aminoacetate. All syntheses were successful, 
The highest yield was achieved in the case of 16 (70%). 
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3.3.4 From the intermediates 15 and 16 to the final products 
 
Scheme 34. From intermediates to the final products. 
After the completion of those intermediates, it was attempted to transform the 
intermediates 15 – 17 to amides through the same procedure of the construction 
of the lead structure 13 (Scheme 34). The intermediates 15 and 16 were 
successfully converted into the desired final product 23 and 24 in modest yield 
(28% and 21%). The intermediate 17 did not survive the saponification and 
resulted in a white solid, which was neither soluble in water nor in the organic 
solvent. Possibly both ester bonds were simultaneously saponificated to the 
carboxylic acids and then the intramolecular ring closure occurred while heating 
at 78 °C and the intermediate 17 was finally converted into a cyclic acid 
anhydride compound.  
3.4 Extension of the library by derivatization on designated positions 
3.4.1 Derivatization of the far right end with other heterocyclic compounds  
Comply with the initial synthetic plan, the thiophene on the far right end will be 
deliberately replaced by other heterocyclic compounds in order to determine, 
whether the thiophene residue contributes to biological activity of the lead 
structure. Nitrogen contained heterocyclic compounds will replace thiophene. 
One replacement for the thiophene is its nitrogen counterpart of thiophene, 
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pyrrole. A second candidate to replace thiophene is indole, which has a larger 
size and thus hopefully it could be more suitable to fit the binding pocket. 
3.4.1.1 Formation of the N-methylated heterocyclic compounds 
The sulfur atom of thiophene carries a free electron pair and thereby thiophene is  
an H-acceptor, but conversely both pyrrole and indole carry a hydrogen atom and 
present the character of the H-donor. When thiophene directly replaced by them, 
the biological property of the new formed derivatives will be substantially changed. 
In order not to alter the biological activity of the new derivatives in the opposite 
way, the nitrogen atom in both moieties will be masked by the methyl group and 
consequentially they are turned into the H-acceptors.  
 
Scheme 35. Formation of the thioamides of further heterocyclic compounds. 
N-methyl pyrrole was commercial purchased and the methylation of indole was 
accomplished by using the sodium hydride and methyl iodide.[60] The methylated 
compounds were then utilized for the thioacylation without purification. Then the 
thiolacylation were performed under previous used conditions[42] and the raw 
product were isolated in moderate yield 52% (1-methyl-1H-pyrrole-2-
carbothioamide (26)) and 32% (1-methyl-1H-indole-3-carbothioamide (28)) 
through the flash chromatography calculated over two steps.  
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3.4.1.2 Formation of the thiazole system form 26 containing N-methylated 
pyrrole. 
The previous conditions were not directly applicable for the thiozale formation 
from the intermediate 26 and 28, but rather experienced some modifications.  
 
Scheme 36. Preparation of the 29 under various conditions 
 
Table 3. Preparation of the 29 under various conditions 
 
In contrast to the previous reaction (section 3.2.2), the high temperature (78 °C) 
and protic solvent in this case were disadvantageous (Table 3, entry 8 and 9), in 
an aprotic solvent and with catalytic amount of DIPEA, the intermediate 29 was 
formed rapidly at RT within 15 minutes (Table 3, entry 11), a prolonged reaction 
duration was not beneficial, because after 2 hours the TLC analysis showed that 
the already formed product vanished (Table 3, entry 10). 
entry solvent temperature reaction time base yield 
8 EtOH 78 °C 1h  none / 
9 EtOH RT 1h none / 
10 THF RT 2 h DIPEA / 
11 THF RT 15 min. DIPEA 36% 
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3.4.1.3 Formation of the thiazole system form 28 containing N-methylated 
indole. 
 
Scheme 37. Preparation of 30 under the optimized conditions. 
Table 4. Preparation of 30 under two conditions. 
entry solvent temperature reaction time base yield 
12 THF RT 20 min. DIPEA / 
13 EtOH RT 30 min none 26% 
 
Surprisingly the same conditions, by using which the intermediate 29 was 
successfully constructed, did not work in the case of synthesis of 30 (Table 4. 
entry 12). Instead intermediate 30 was generated in ethanol without DIPEA 
additive within 30 min in 26% isolated yield (Table 4. entry 13).  
3.4.1.2 The route toward the final products 35, 36 and 37. 
Both intermediates 29 and 30 were then allowed to react with fragment 12 to 
construct the pyrrole ring system. Under the established conditions both 
intermediates were respectively converted into the intermediate 31 and 32 with 
isolated yield 37% and 41%. 
 
Scheme 38. Formation of the intermediate 31 and 32.  
Results and discussion  50 
 
Afterwards, intermediates 31 and 32 were supposed to be hydrolyzed into 
carboxylic acids by following the established conditions. However, the 
intermediate 32 was not soluble in ethanol and thus after 24 hours no reaction 
took place as judged by TLC. Instead it was dissolved in the mixture (MeOH:t-
BuOH:40% KOH water solution = 2:2 :1) and then heated at 60 °C for 36 hours, 
then the TLC showed that the starting material was completely consumed and 
the carboxylic acid was formed thereafter. The hydrolysis of the compound 31 
took four times longer (48 hours) than the established conditions (12 hours), but 
eventually the hydrolysis was accomplished. The unpurified carboxylic acids 33 
and 34 were then directly transformed through the established method into the 
amides 35, 36 and 37 respectively with isolated yield of 34%, 52% and 46% 
calculated for two steps. 
 
Scheme 39. The finalization of the syntheses of the final products 35, 36 and 37.  
3.4.2. Derivatization at the 5 position in the pyrrole ring system  
3.4.2.1 Derivatization at the 5 position with trifluoromethyl group 
In this part of the synthesis, the 5´-methyl residue in the pyrrole ring system will 
be replaced by the strong electron withdrawing trifluoromethyl group in order to 
determine the contribution of this particular position to the whole biological activity. 
Results and discussion  51 
 
Besides, based on the common knowledge, incorporation of fluorine atoms into 
the bioactive compounds often enhance its bioactivity and improve the 
pharmacological property.[28] The fluorine atom could mimic the hydrogen atom. 
Since the trifuoromethyl group is not much larger than the methyl group but 
occupies more room than the isopropyl residue, and thus it could be better filled 
into the enzyme receptor site. Furthermore the fluorine sometimes blocks certain 
reactions and in such cases these compounds subsequentially possess improved 
anti-cancer reactivity. The trifluoromethyl group significantly increases the 
lipophilicity of the bioactive compound and moreover the strong electronegativity 
of the fluorine changes the electron effect and thus enhances the thermal and 
oxidative resistance of the compound.  
The synthesis commenced with the new starting material 38, due to the additional 
trifluoromethyl group the desired enamine 39 could no longer be generated under 
the previous mild conditions (section 3.2.3). However with help of catalytic 
amount of the p-toluenesulfonic acid, the enamine acetyl ethyl ester 39 was still 
generated at 80 °C in moderate isolated yield (42%).[61] 
 
Scheme 40. The formation the enamine ester 39. 
3.4.2.1.1 Attempt of the formation of the pyrrole through the Hantzsch 
method 
The intermediate 39 was allowed to react with the fragment 9 to form the pyrrole 
ring under various conditions. 
 
Scheme 41. Failed pyrrole ring formation through the initial method.  
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Table 5. Pyrrole formation under various conditions.  
entry solvent temperature reaction time base yield 
14 DME 90 °C overnight  none / 
15 DME 90 °C overnight DIPEA / 
16 DMF 140 °C 2 h none / 
17 DMG 200 °C 2 h none / 
18 diphenyl ether 200 °C 2 h none / 
 
At first the reaction was carried out overnight under reflux of DME (Table 5. entry 
14), but no product was formed. Then the reaction was repeated under same 
condition but with additional DIPEA, (Table 5. entry 15) the starting material 
decomposed overnight without traces of the desired product. Then the reaction 
was conducted in DMF, DMG and diphenyl ether and the reaction mixture was 
heated at 140 °C, 200 °C and 200 °C for two hours respectively (Table 5. entry 
16, 17, 18). In all these cases, no reaction took place and the starting materials 
rapidly decomposed. The issue was caused by the additional strong electron-
withdrawing fluorine atoms. The double bond of the enamine under the influence 
of the fluorine atoms is extremely electron deficient and could not initiate the 
nucleophilic substitution with the haloketone 9 and thereby no follow-up steps are 
expectable. 
 
Figure 14. The trifluoromethyl group obstructed the pyrrole formation. 
3.4.2.1.2 Attempt of the formation of pyrrole through the Paal-Knorr method 
With no success of the pyrrole formation through the Hantzsch route, the Paal-
Knorr method was examined.  
The generation of the 1.4-dicarbonyl compound 41 from 38 and intermediate 9 as 
the first step of the new route was hereby investigated.  
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Scheme 42. Generation of the 1,4-dicarbonyl intermediate 41 
Again, due to the influence of the fluorine atoms, the α-carbon atom between two 
carbonyl groups is less nucleophilic and after the deprotonation, it could unlikely 
attack the haloketone 9 neither in acetone (reflux with KI)[62] nor in DMF (at RT)[63] 
and under these conditions the reaction did not occur even after 24 hours. 
Alternatively under reflux of DME, after 12 hours the 1.4-dicarbonyl compound 41 
was quantitatively formed judged by the TLC and the raw product was directly 
converted without purification. (Scheme 42) 
 
Scheme 43. Successful pyrrole formation through Paal-Knorr method. 
The pyrrole ring formation from 41 and 4 through Paal-Knorr approach was 
successful through the previous established conditions (16% isolated yield over 2 
steps) (Scheme 43), and followed by the hydrolysis of the intermediate 40 under 
the established conditions, then without purification converted to the amide 43 
through the previous reaction (Scheme 44). The isolated yield over 2 steps was 
only 4% through the EDC / DMAP activation. 
 
Scheme 44. Amide formation with EDC / DMAP activation. 
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Scheme 45. Amide formation with HOBt / DMAP activation. 
For comparison, the amide formation was performed again by using the HOBt / 
EDC coupling reagent combination (Scheme 45).[64] At first the coupling was 
conducted at RT, the reaction seemed to be finished after 1 h (TLC control), but 
surprisingly the isolated product was the active ester intermediate according to 
the NMR spectra. In this case the fluorine atoms possibly stabilize the active 
ester intermediate, which commonly exists only for an extremely short period. So 
in this case, the ammonia may need more energy to replace the HOBt residue to 
form the desired primary amide bond, accordingly the reaction was performed 
again at 50 °C with 10 folds of ammonia and after 4 hours the reaction concluded. 
This time the correct amide was formed with 16% isolated yield over 2 steps.  
Simultaneously The N-methylated amide 44 was converted at RT from 42 with 13% 
yield over 2 steps. 
 
Scheme 46. Formation of the 44 with HOBt / DMAP activation. 
3.4.2.2 Derivatization in the 5 position with methoxyethyl residue  
In order to transform the 5 position into an H-acceptor, a methoxyethyl group was 
introduced in place of the methyl residue. The synthesis still followed the Paal-
Knorr method. The 1,4-dicarbonyl compound 46 was formed in 57% yield from 
starting material 45 and fragment 9 under the established conditions with slight 
adjustment of temperature. Then the compound 46 was smoothly converted into 
the compound 47 within an hour in 82% isolated yield (Scheme 47). 
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Scheme 47. Preparation of the intermediate 47. 
The compound 47 was then hydrolyzed with KOH to the carboxylic acid 48 and 
the unpurified carboxylic acid 48 was converted into both amide 49 and the N-
methylated amide 50. The formation of the amide 49 did not work with the 
coupling reagent combination EDC / DMAP, no desired product was isolated in 
this way, however with EDC / HOBt the product was obtained in poor yield (7% 
over 2 steps). The conversion to the N-methylated amide did not encounter large 
obstacles and the N-methylated amide was readily synthesized by using EDC / 
DMAP in 42% isolated yield over 2 steps (Scheme 48). 
 
Scheme 48. The generation of the final products 49 and 50.  
3.4.3 Supplement of the library through further N-substituted pyrrole 
derivatives 
By following the previous examples (compounds 23 and 24), more derivatives 
with N- substituted pyrrole ring systems were generated through the Paal-Knorr 
method to study the influence of the side chain on the overall bioactivity. The 
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originally attached 2-methyl tetrahydrofuranyl group in the following studies will 
be replaced by a few aromatic residues. Upon these changes the side chain will 
be enlarged due to the larger ring size of the benzene and these changes will 
increase the chance to bind to the binding site. Besides the benzene ring could 
enhance the rigidity of the bioactive compound and improve the metabolism 
resistance. Moreover the benzene ring itself could carry various substitutions and 
inhibit different pharmacological properties. The generation of ester precursors 
for these derivatives was straightforward from the 1,4-dicarbonyl compound 14 
with different amines. The syntheses under the established reaction 
conditionswere generally trouble-free (Table 6).  
 
Scheme 49. General procedure of generation intermediate of N-substituted 
pyrrole derivatives 
Then all intermediates were hydrolyzed and converted to the respective amides.  
Scheme 50. General procedure of the generation of N-substituted pyrrole 
derivatives 
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Table 6. Further N-substituted pyrrole derivatives 
R-NH2 intermediate final product 
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3.5 Synthesis of the bicyclic compounds and its derivatives 
3.5.1 Synthesis of the lead structure of the bicyclic compounds  
The formation of the methyl ester of lead structure 79 was straightforward, 
because all the required starting materials were commercially available. Starting 
with the synthesis of the under building block 78´, it was easily formed through 
imide formation from maleic acid 73 and the (4-aminophenyl)ethanone (74) with 
phosphorus pentoxide to yield the cyclic imide 75 in 52% isolated yield.[54] 
Followed by the condensation of the L-leucine methyl ester 76 with 2-
methylbenzaldehyde (77) over 30 hours,[53] the raw imine 78´ was then allowed to 
react with cyclic imide 75 to yield the bicyclic methyl ester 79 with an isolated 
yield of 45% over two steps (Scheme 51).[55]  
 
Scheme 51. Synthesis of the 79 of the bicyclic inhibitor.  
3.5.2 Derivatization at the para-position of the aniline  
Instead of the commercial purchase, the derivatization of the para-position of 
aniline was about to be achieved by introduction of different moieties through the 
Friedel-Crafts acetylation. If the Friedel-Crafts acetylation worked specifically at 
the para-position, this method was capable of generation of a large number of 
para-aldehyde derivatives.  
 
Scheme 52. Derivatization of the para-position through the Friedel-Crafts 
acylation 
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The first attempt was the synthesis of intermediate 75 from 81 through Friedel-
Crafts acylation.  
 
Scheme 53. Unselective Friedel-Crafts acylation. 
Table 7. Friedel-Crafts acylation under various conditions. 
entry solvent temperature results 
19 nitrobenzene RT no reaction 
20 nitrobenzene 60 °C o and p acetylated mixture 
21 1,2-dichlorethene RT no reaction 
22 1,2-dichlorethene 60 °C o and p acetylated mixture 
 
The acetylation of the aniline was tricky, at RT the acylation took place neither in 
nitrobenzene[65] nor in 1,2-dichloroethene (Table 7. entry 19 and 21), unless the 
temperature reached 60 °C. Both ortho- and the para-positions were 
unspecifically acetylated (Table 7. entry 20 and 22) judged by the NMR analysis 
and even worth was that the resulted products had the identical polarity and it 
was impossible to separate both products through flash chromatography. 
The direct para-Friedel-Crafts acylation failed, however the para-acetyl moiety 
might be obtained indirectly from some para-substituted precursors, such as the 
para-bromo precursor through the chemical manipulation. Theoretically, the 
bromine residue could be converted into the aryl-metallic bromides and then 
added to acetyl chloride to yield the desired para-acetyl compound. Two 
approaches hereby have been examined. 
Results and discussion  60 
 
 
Scheme 54. Unsuccessful attempt of generation of 75 through para-organozinc 
compound 83. 
Table 8. Attempts to generate the organozinc compound 83 at two temperatures. 
entry temperature result 
23 RT no reaction 
24 40 °C no reaction 
 
The first experiment (Table 8, entry 23 and 24) was intended to convert the 
compound 82 into a highly active organozinc chloride 83 via Grignard reagent[66] 
and organozinc chloride 83 was then expected to react with acetyl chloride with a 
Cu(I) catalyst. Unfortunately, the transmetalation did not take place, the 
elemental magnesium seems to be insufficient reactive to transform the starting 
material to the Grignard reagent.  
In the second approach, it was intended to form the para-Grignard compound in 
situ through the transmetalation from a reactive Grignard isopropylmagnesium 
chloride lithium chloride complex 85[67] and then the para-Grignard intermediate 
84 would be added to acetyl chloride along with a Cu(I) catalyst. 
 
Scheme 55. Unsuccessful attempt to generate the para-acylated compound 
through a Grignard reaction 
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Table 9. Generation of the para-Gringard compound at different temperatures 
entry temperature result 
25 0 °C decomposition 
26 –60 °C decomposition 
27 –78 °C no reaction 
 
At –60 °C (Table 9. entry 25) and 0 °C (Table 9. entry 26), upon the addition of 
the isopropylmagnesium chloride lithium chloride complex solution into the 
compound 84, the starting material was consumed within 5 min. but formed a 
polymeric substance (very high polarity observed at TLC). The 
isopropylmagnesium chloride may attack the double bond of the cyclic imide and 
trigger the polymerization. Oppositely, at –78 °C no reaction was observed (Table 
9. entry 27). 
In order to utilize the organometallic reagent, the double bond was deliberately 
masked by furan through a Diels-Alder reaction[68] and the furan could be easily 
removed after the establishment of the para-acetyl compound through the retro 
Diels-Alder reaction. As expected, without the disturbance of the double bond the 
compound was more stable but showed very sparingly solubility in THF. 
Unfortunately at 0 °C after 8 hours no reaction happened between 86 and the 
isopropylmagnesium chloride lithium chloride complex (Scheme 56). 
 
Scheme 56. Failed attempt of generation 86 through the protected intermediate 
85 
Acetylation through the organometallic compound was found to be very difficult in 
this case study, alternatively a sophisticated idea based on the Weinreb ketone 
synthesis was thereby tested. Starting with furan protected compound 85, 
through a lithium-halogen exchange it was supposed to be transformed into an 
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organolithium intermediate, which was then allowed to react with the N-methoxy-
N-methylacetamide 87 (Weinreb amide) and was excepted to form the product 86. 
Sadly this idea could not be realized since no reaction took place in a large range 
of temperatures (–78 °C – 0 °C).[69] The iodo variation was also tested, but it did 
not change the outcome (Scheme 57). This was presumably again caused by the 
very limited THF solubility of the intermediate 85. 
 
Scheme 57. Unsuccessful attempt to generate 88 through the Weinreb ketone 
synthesis 
Conversely, the ester 89 was synthesized in 2 steps from the starting material 90 
and was successfully transformed into the Weinreb amide 91,[70] and followed by 
the methylation of this Weinreb amide to yield the product 86 (Scheme 58). 
 
Scheme 58. Unsuccessful attempt to generate 86 via Weinreb amide 91 
Table 10. Methylation of 91 under different conditions 
entry methylation reagent temperature result 
28 MeI 0 °C no product 
29 MeI –30 °C no product 
30 MeI –78 °C no product 
31 MeMgBr 1h, –78 °C, 1h 0°C  no product 
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The Weinreb amide intermediate 91 was initially constructed after a few attempts, 
but unfortunately the intermediate 91 was still very limited soluble in THF and 
thus the methylation of 91 did not work by applying either MeI (Table 10. entry 
28-30)[71] or MeMgBr (Table 10. entry 31), no product was isolated, whereas most 
starting material remained unreacted.  
The last attempt to achieve the para-acetyl residue was to turn the ester 89 firstly 
into the carboxylic acid 92 (Scheme 59), then the acid would be converted to acid 
chloride 93 with oxalyl chloride and finally methylated with methyl iodide. 
Unfortunately in practice the formed acid 92 was soluble neither in THF nor in 
DCM, therefore, the transformation of the acid 92 into acetyl chloride 93 failed. 
 
Scheme 59. Unsuccessful attempt to generate 87 via acyl chloride 91 
The attempt to achieve the para-acetyl group in the compound 83 was neither 
successful directly through the Friedel-Crafts acylation nor indirectly through 
other para-substituted precursors. The double bond from the upper side was 
found to be vulnerable in the presence of strong nucleophile such as 
organometallic compound, however protection of the double bond with furan 
made the new compound very limited soluble in many organic solvents and it was 
believed that this sparingly solubility prevented further reactions. The introduction 
of the para-acetyl group of the particular compound 81 is highly challenging, 
further para-aldehyde derivatives might unlikely be generated in the manners, 
which were tested before, but rather by direct using commercially available 
chemicals.
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4. Summary and conclusion 
In this work the lead structure of the heterocyclic inhibitor has been synthesized. 
Since there is no stereo center, the synthesis in general was straightforward and 
encountered no problems. Furthermore 23 heterocyclic derivatives have also 
been generated by using the available starting materials, the derivatization was 
found in all four designated areas, which are outlined in the earlier chapter. The 
syntheses of these derivatives were mostly successful except the synthesis of 17. 
The synthesis of the fluorine containing compound 40 was challenging. The 
trifluoromethyl group changed the electron density significantly, so that the 
Hantzsch method was no more applicable. Fortunately the compound 40 could 
still be achieved through the Paal-Knorr method but only obtained in poor yield 
(6%). Because the purpose of this work was to rapidly generate the library of the 
Cdc25A inhibitor for the biological assessment, no optimization of the yield has 
been performed. 
According to the preliminary biological assessment, the thiophene group on the 
far right side is important for the biological activity, upon exchange of thiophene 
against other heterocyclic compounds like N-methyl pyrrole or N-methyl indole, 
the biological activity dropped. The replacement of the nitrogen atom of pyrrole 
also alters the biological activity. If the benzene residue was attached to the 
nitrogen atom via the CH2 (benzyl), the biological activity was lower than the 
direct attachment of the aromatic ring system to the nitrogen atom. Moreover the 
fluorine substitution on the aromatic ring system enhanced the biological activity. 
Like expected the trifluoromethyl group at the 2-position instead of the methyl 
group also improved the biological activity.  
The study of the bicyclic inhibitor didn´t progress as deep as for the heterocyclic 
inhibitor, though the synthetic route towards the lead structure was nearly 
finished, the ester 79 only needs to be hydrolyzed to form the final product.  By 
following the same synthetic strategy further derivatives could be prepared. The 
attempt of derivatization at the para-position of the aniline failed, the idea of the 
introduction of a para-acetyl group through the Friedel-Crafts acylation could not 
be executed due to the unselective acylation at three possible positions. The 
indirect conversion from other para-substituted precursors into the para-acetyl 
aniline was not successful either. Therefore this reduced the degree of the 
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derivatization at the para-position. Nevertheless, there are sufficient amount of 
commercially available para-substituted anilines, which could be converted into a 
large library for the SAR study. 
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Part II. Development of solid phase synthesis of cyclic peptides 
1 Introduction 
1.1 Conventional and native chemical ligation methods of peptide synthesis 
1.1.1 Conventional methods of peptide synthesis 
Conventionally the amide bonds of the peptide was formed through activation of 
the respective coupling reagent, for this purpose many activators have been 
tested, evaluated and applied in the past decades. Upon adding the coupling 
reagent, the carboxylic acid, which is involved in the amide bond formation, is 
converted into the active intermediate and followed by the sequential amide bond 
formation with other amino. Since fifty years the most important activators  used 
for amide bond formation are the carbodiimides (N,N'-dicyclohexylcarbodiimide 
(DCC)[72] and N,N'-diisopropylcarbodiimide (DIC)). Carbodiimids have been 
regularly applied to generate active esters and symmetrical anhydrides or for a 
direct coupling. Upon addition of the carbodiimides into the carboxyl acid, the 
carboxyl group is converted into the O-acylisourea, which is one of the most 
reactive acylating intermediates. In the presence of free amino groups, the O-
acylisourea intermediate will be quickly converted into the respective amide 
compound and urea. But the O-acylisourea intermediate is highly reactive and 
often results in the racemization of formed product (Scheme 60).[72] 
 
Scheme 60. Racemization under basic conditions 
To reduce the extend of racemization, azolol additives (hydroxybenzotriazole 
(HOBt),[73] N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate (HBTU), 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU), and O-
(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU) etc.) 
are introduced. Through O-acylisourea intermediates or directly, azolol forms 
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active ester intermediates with the carboxyl group and then this is converted into 
the amide with respective amine. The final product, which is constructed in this 
way, can be usually obtained in high yield with much lower degree of 
racemization (Scheme 61). 
 
Scheme 61. Amide formation through active ester 
By utilization of the coupling reagents, two methodologies were developed with 
the intention of generating the long chain peptides (Scheme 62). The former is 
the stepwise coupling of each amino acid by using the in situ neutralization / 
HBTU activation protocol in the given order. This approach is a long standing and 
reliable method but lacks flexibility and is also very time-consuming. The latter is 
the condensation of different pre-made fragments through an amide bond linkage, 
which is more flexible to generate derivatives. But applications of this method 
require a large excess of fragments and often cause enormous waste of 
materials and furthermore it can potentially lead to racemization. These setbacks 
sometimes limit their widespread use and therefore, a more efficient way to 
construct long peptide was investigated in the past. 
 
Scheme 62. Two different ways of generation of peptides  
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1.1.2 Native chemical ligation (NCL)  
1.1.2.1 Birth and the main features of the NCL 
Following Wieland’s pioneering work on the activator-free formation of an unique 
valine and cysteine junction,[74] many groups have worked on the development of 
practical methodologies for peptide and protein syntheses. In 1994 Dawson, Muir 
and Kent reported a novel native chemical ligation (NCL)[75] and demonstrated 
the practical application of NCL through the synthesis of human interleukin 8 (IL-
8), which is a 72-amino polypeptide bearing four cysteine residues.  
The newly introduced native chemical ligation concept uses the idea of fragment 
condensation to generate long peptides. In this particular case the amide bond 
linkage of the fragments is achieved through a X-Cys junction and replacement 
with the thermodynamically stable amide bond. 
In order to successfully generate the peptide sequence by applying this 
methodology, at least one cysteine residue is required to be contained in the 
peptide sequence. The position, where the cysteine situated, is used as the 
junction point for the condensation. Along this X-Cys junction point the entire 
sequence can be broken into two peptidic fragments, which carry the C-terminal 
junction partner X (X could be a random amino acid) and the N-terminal cysteine. 
However, the fragment carring the C-terminal junction partner, could not be used 
directly for the NCL, but rather synthesized as a C-terminal peptide thioester with 
an adequate thiol leaving group. Frequently, the ligation is carried out in buffered 
neutral (pH = 6.5 ~ 7.5) aqueous environment, which is also suitable for many 
biological processes and modifications. After two separately synthesized 
fragments are added into the buffered solution, a thioester-mediated amide 
formation will take place (Scheme 63). 
 
Scheme 63. The native chemical ligation between two peptides 
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At first the sulfhydryl group of the N-terminal cysteine substitutes the C-terminal 
peptide thioester to construct a new thioester intermediate and then the nearby 
amino group of the N-terminal cysteine replaces the sulfhydryl group 
spontaneously to irreversibly generate a new amide bond and thus two fragments 
are linked.  
The NCL proceeds always with high regioselectivity and chemoselectivity. The 
high regioselectivity means that this method tolerates sulfhydryl side chains in the 
proceeding fragments. Technically sulfhydryl groups of every cysteine could 
participate in the transthioesterification with C-terminal peptide thioester, but this 
process is reversible and both thioesters exist in balance. The follow-up 
spontaneous S–N acyl shift will break this balance and transform the thioester 
intermediate into the final amide product. The S–N acyl shift could specifically 
take place between the thioester intermediate and the free amino group of the N-
terminal cysteine, therefore only the thioester intermediate at the junction point 
could be converted into the amide bond and thus appears as the sole final 
product (Scheme 64).  
 
Scheme 64. NCL is regioseletive. 
The chemoselectivity means that the S–N acyl shift would take place only 
between thioester intermediate and the free amino group of the N-terminal 
cysteine, not the amino groups at other positions of the peptide sequence. 
1.1.2.2 Limitation of the NCL 
Since early 90s´, the NCL methodology has been intensely investigated. In 1999, 
Dawson investigated the feasibility of NCL of cysteine with 20 other amino 
acids.[76] In the investigation, a trityl-associated-mercaptopropionic acid-leucine 
(TAMPAL) resin was converted from the Nα- Boc-MBHA resin and S-trityl 
mercaptopropionic acid, and on this formed TAMPAL resin the C-terminal Leu-
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Tyr-Arg-Ala-X thioester (X = 20 amino acids) was synthesized and af ter cleavage 
this fragment was allowed to ligate under the standard NCL condition with the 
fragment CRANK and the conversion rates of all 20 amino acids were constantly 
recorded. The X-Cys junction was observed in all cases afterwards, however the 
facility of X-Cys junction substantially depends on the ligation partner. Based on 
their effectiveness, the amino acids were then classified into four categories. The 
histidine, cysteine and glycine were found to be best suitable for the NCL, 
whereas the valine, isoleucine and proline were least favored for the NCL due to 
their β-branched side chain. The β-branched side chain severely hinders the 
progression of the NCL and thus the NCL proceeds slowly with the member of 
this group. After 48 hours, with none of these three amino acids a conversion of 
50% could be achieved. These results were confirmed through the synthesis of 
hsPLA2 and an enzymatic inactive hsPLA2.
[76] Out of 20 amino acids, 17 are 
determined to be fully compatible with NCL, whereas valine, isoleucine and 
proline could only be used for this particular method with large limitation. 
1.1.2.3 Promotion of NCL through thiol additives  
The NCL is initialized by transthioesterification, through which the C -terminal 
peptide thioester is converted to a new thioester intermediate. The C-terminal 
peptide-α-thioalkyl ester is frequently used for the synthesis, but the thioalkyls are 
generally bad leaving groups and thus often insufficient reactive for the 
transthioesterification. Unfortunately, better leaving groups, such like 5-thio-2-
nitrobenzoic acid[77] are not easily accessible. The transthioesterification is the 
rate-limiting step and thus using the C-terminal peptide-α-thioalkyl ester 
significantly prolongs the reaction time. However, the less reactive thioalkly 
residues can be replaced prior to the transthioesterification by reactive 
exogenous thiol additives in situ and results in highly reactive peptide thioester, 
consequentially the ligation rate will significantly rise. The thiol additive forms new 
thioester through substitution of original thioalkyl residue and this new thioester is 
much more reactive and can be much easier replaced by the sulfhydryl group of 
N-terminal cysteine than the inert predecessors (Scheme 65). 
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Scheme 65. Acceleration of the transthioesterification through thiol additive 
The popular thiol additives are benzyl mercaptan / thiophenol mixture and 
alkanethiol sodium 2-sulfanylethanesulfonate (MESNa) (Figure 14). Dawson 
firstly investigated the influence of benzyl mercaptan / thiophenol additive on the 
ligation rate.[78] At the beginning of the investigation, only benzyl mercaptan was 
added to replace the alkyl thioester, but the new formed peptide benzyl thioester 
was still not reactive enough, so additionally thiophenol was introduced and the 
peptide benzyl thioester intermediate was transformed further into peptide phenyl 
thioester, which is a highly reactive intermediate. By using this combination, the 
ligation time was substantially reduced. 
 
Figure 14. Two frequently used thiol additive 
Sodium 2-sulfanylethanesulfonate (MESNa) is an alkanethiol additive,[79] which is 
also regularly applied for the NCL, but in practice, MESNa was only found to 
have limited catalytic ability. Alternatively, Kent  used thiophenol,[80] which is an 
moderate leaving group and has been previously deployed for the NCL. Diverse 
electron withdrawing groups was intentionally introduced at the para-position of 
thiophenol in order to reduce the nucleophilicity of the sulfhydryl group and 
consequentially generate a perfect thiol leaving group. After a series of 
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experiments, the newly prepared (4-carboxymethyl)thiophenol (MPAA) was found 
to have the highest catalytic activity among all test subjects, besides it is good 
water soluble and thus it is very suitable for the native chemical ligation in 
buffered solution. 
Additionally, utilization of the thiol additives are advantageous, because aside 
from being the promoter, they constantly keep the N-terminal cysteine in reduced 
form and eliminate the chance of unnecessary transthioesterification, which is 
caused by the sulfhydryl group of the internal cysteine residue. 
1.2 Development of the solid phase peptide synthesis (SPPS) 
1.2.1 Development of the Merrifield resin 
In the late 50´s and early 60´s, peptides emerged as import bioactive compounds 
and thus novel methodologies are highly desired to generate peptides. At that 
time synthesis of short chain peptides through various approaches have been 
published,[81] however the synthesis of long size peptides was still an issue. 
Through elongation of the peptide chain, the solubility of the peptide in organic 
solvents decreased and the purification of the raw peptide via recrystallization 
and flash chromatography became difficult. Therefore, a suitable synthetic 
method to generate large size peptide was desired and since then various new 
ideas were tested. Unfortunately none of these ideas were practically applicable 
until Merrifield came up with the revolutionary invention.[82] 
The idea of Merrified´s novel methodology is to immobilize the first amino acid 
onto a polymer support via a covalent bond and the following amino acids are 
stepwise coupled to the first amino acid on the solid phase. The main chain 
remains on the solid phase throughout the synthesis and the excess reagents 
and soluble by-products are easily washed away, no work-up and purification 
steps are required after each coupling. The chloromethylated (or nitrated or 
brominated) copolymer of styrene (PS) was selected for the experiment, because 
it fulfilled all requirements of a proper polymer support (physical steadiness, 
insoluble in organic solvent and availability of a proper functionality (linker) to 
anchor the first amino acid). Then this polymeric support was practically deployed 
to generate a tetrapeptide (Scheme 65). The chloromethylated polymeric support 
was firstly treated with the triethylammonium salt of the first amino acid to form 
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the ester bond and then the unreacted chloromethyl groups were capped to avoid 
formation of by-products. The chain elongation proceeded with Cbz protected 
amino acids according to the deprotection / DCC activation / coupling and 
washing protocol. In order to achieve the quantitative coupling, an excess (10 
folds) amount of Cbz-protected amino acid was added for each coupling. After 
the synthesis, the ester bond between the linker and peptide chain was 
hydrolyzed by strong base (NaOH or LiOH) and the peptide was subsequently 
liberated from the polymer support. 
 
Scheme 66. First solid phase peptide synthesis on the Merrifield resin 
This was the first practical application of solid phase peptide synthesis and the 
chloromethylated copolymer of styrene was named Merrifield resin. Merrifield 
resin was in the future frequently deployed as backbone resin to develop more 
advanced polymeric support. 
This procedure had a major problem, because the stepwise Cbz group 
deprotection requires a hydrogen bromide / acetic acid mixture, which cleaves 
the peptide through hydrolysis of the ester bond. This setback could be reduced 
with nitrated or brominated polymer, however a considerable amount of the 
peptide went lost through the synthesis. Thereafter, Merrifield proposed a tert-
butyloxycarbonyl (Boc) / benzyl (Bzl) protection / deprotection scheme for the 
solid phase peptide synthesis in order to overcome this issue. [83] Boc group 
(Figure 15) was introduced by Carpino in 1957[84] and deployed firstly in the 
peptide chemistry by McKay and Albertson.[85] The Boc group is sensitive to the 
acid and can be easily removed in weak acidic condition (eg. 1 N HCl in acetic 
acid, 30 min.).  
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Figure 15. Boc protecting group 
By deploying the new protocol, Merrifield demonstrated the synthesis of a natural 
product Bradykinin on Merrifield resin. The hydroxyl group of serine was 
protected by benzyl group, which is unaffected by the 1 N HCl treatment. After 
the synthesis the peptide was liberated from the resin by using HBr-TFA mixture, 
which also led concomitant benzyl deprotection.  
In 1967 S. Sakakibara et al. showcased an effective cleavage of the peptide from 
Merrifield resin by using hydrogen fluoride.[86] Along with scavenger (normally the 
anisole in 1:9  to HF) the resin containing peptide was placed in a sealed 
corrosion-resistant all-fluorocarbon reactor. New distilled anhydrous HF was 
introduced under cooling slowly into reactor, after one hour the HF was 
evaporated and the peptide was cleaved from the resin fully unprotected. But the 
handling of HF is extremely hazardous and the size of the special reactor limited 
the utilization of the HF cleavage in large scale.  
1.2.2 Development of more advanced resins and methods 
1.2.2.a Phenyactamidomethyl (PAM) resin 
Even with this new Boc / Bzl protection / deprotection protocol, the SPPS on the 
Merrifield resin still caused peptide loss after each coupling. When a medium- or 
large-sized peptide is generated in this way, the loss will be significant at the end 
of the synthesis. In 1976 Mitchell and Merrifield worked together and 
demonstrated an advanced linker strategy to deal with the prematurely release of 
the peptide through the acidic hydrolysis.[87] An acidic stable 
phenylacetamidomethy (PAM) bridge was introduced onto the unmodified 
Merrifield resin (Figure 16).
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Figure 16. PAM linker 
The PAM bridge is a strongly electron withdrawing moiety, and thus the ester 
bond which links the first amino acid and the PAM bridge is stable upon acidic 
treatment and could not be hydrolyzed easily. The isolated yield of peptide, which 
was synthesized through this way, significantly increased. Nowadays, the PAM 
resin is widely used for the synthesis of peptide within the frame of the Boc-SPPS.  
1.2.2.b Benyhydrylamine(BHA) and 4-methylbenzhydrylamine (MBHA) resin 
In 1970, Pietta and Marshal introduced the BHA (Benzhydrylamine Hydrochloride 
Salt) resin,[88] which´s creation was entirely inspired by synthesis of a 
pentapeptide Gastrin. Gastrin is a C-terminal peptide amide, and unfortunately by 
using the Merrifield resin, the first amino acid is anchored to the resin through an 
ester bond and thus the cleaved peptide is obtainable only as the C-terminal 
peptide carboxylic acid. In order to generate Gastrin, the diphenylamine linker 
was developed from diphenylmethyl bromide or chloride support, which was used 
previously by Southward.[89] The diphenylmethyl bromide was converted into the 
diphenylamine linker by using ammonia and DCC. The first amino acid could be 
coupled through an amide bond, which is stable to the acidic treatment during 
Boc SPPS procedure. After the synthesis, the peptide can be cleaved by 
anhydrous HF and obtained as peptide amide (Scheme 67).  
Scheme 67. SPPS on the BHA resin 
In middle 70´s, Stewart and Matsueda modified this linker and introduced a p-
methyl group onto the phenyl group to enhance its stability towards TFA and its 
sensitivity towards HF.[90] This modified resin was accordingly called 4-
methylbenzhydrylamine (MBHA) resin. In the present days, both BHA and MBHA 
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resins could be regularly found in use within the frame of Boc-SPPS chemistry for 
their good acidic and basic stabilities. 
1.2.2.c 9-fluorenylmethoxycarbonyl (Fmoc) protecting group 
In the same year, Carpino and Han[91] developed the 9-fluorenylmethoxycarbonyl 
(Fmoc) protecting group (Figure 17). This group is stable under many conditions 
and only sensitive to bases. Upon exposure to a base, the β-elimination is 
triggered and the Fmoc protected amino group will be deprotected.  
 
Figure 17. Fmoc protected amino group. 
1.2.2.d Wang resin 
Two years later Wang introduced a novel p-alkoxybenzyl alcohol resin,[92] which 
was also converted from Merrifield resin. The first amino acid could be anchored 
to the resin through an ester bond (Scheme 68). 
 
Scheme 68. Preparation of Wang resin and SPPS on Wang resin 
On this resin Wang demonstrated the syntheses of a few peptides and after the 
syntheses, these peptides were isolated in high yield with very low degree of 
racemization of the first amino acid. 
1.2.2.e Introduction of the Fmoc-SPPS chemistry 
In 1978 Chang and Meienhofer outlined the Fmoc-SPPS protocol based on the 
Wang resin.[93] The first amino acid was anchored to Wang resin via the ester 
bond and the Fmoc-protected amino acids were stepwise assembled and finally 
the sequence was acidic cleaved (generally concentrated TFA) from the resin. 
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Since then different versions of this protocol were developed, various coupling 
reagent (carbodiimide / HOBt[94], Fmoc amino acid active ester,[95][96] 
phosphonium and uronium / amidinium salts) have been examined, different 
Fmoc deprotection strategies have also been investigated [97][98][99] as well as the 
investigation of diverse cleavage cocktails. Today, the Fmoc-SPPS protocol is 
more favored by peptide chemists than the Boc-SPPS for the absence of 
anhydrous HF. 
1.2.2.f Rink linker 
Within the scope of Fmoc-SPPS protocol, Rink developed a linker strategy to 
produce the unprotected peptide amide.[100] The Rink linker was introduced to the 
Merrifield resin through chemical conversion. The first amino acid is attached to 
the Rink linker through an amide bond, which is stable to the basic treatment 
throughout Fmoc-SPPS. Due to the acidic sensitivity of the Rink linker the 
peptide can be easily cleaved by TFA / DCM = 1:1 mixture as peptide amide 
(Scheme 69).  
 
Scheme 69. Preparation of the Rink linker 
1.2.2.g Sieber linker  
In the same year, Sieber also demonstrated a similar linker strategy, [101] which is 
also fully compatible with the Fmoc-SPPS protocol. The intention of using this 
new strategy was to produce fully protected peptide amide. Similar to Rink´s 
amide resin, this resin was converted from Merrifield resin as well. The first amino 
acid was also anchored to the Sieber linker through an amide bond. The Sieber 
linker is electron rich and thus extremely acidic sensitive. Consequentially the 
peptide can be cleaved as the peptide amide from the resin by 5% TFA treatment. 
Meanwhile under such mild acidic condition, most protecting groups still remain 
attached to the side-chains (Scheme 70).  
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Scheme 70. Preparation of the Sieber linker 
1.3 Latent thioester linker strategy 
Since the birth of the native chemical ligation, the C-terminal peptide thioester 
fragment, which is required for the chemical ligation, is frequently generated on 
solid phase. Because the C-terminal peptide thioester is very sensitive to 
nucleophilic attack, the C-terminal peptide thioester could only be synthesized 
through Boc-SPPS protocol, but after Boc-SPPS the HF cleavage of the final 
peptide thioester is often inevitable. The use of HF is sometimes 
disadvantageous, because a large number of glycopeptides or proteins are 
sensitive to HF treatment.[102] Moreover HF or trifluoromethanesulfonic acid 
(TFMSA) is incompatible with the post-translational modifications (PTM), which 
are required in many cases to enhance the biological activity of the original 
peptide or protein. 
Unlike its counterpart, cleavage of peptide sequence after Fmoc-SPPS only 
requires concentrated TFA, which will not damage the glycopeptides or proteins. 
But unfortunately stepwise removal of Fmoc group needs nucleophilic reagents 
(DIPEA, piperidine), which could easily hydrolyze the thioester bond and release 
the peptide sequence prematurely. Therefore the Fmoc-SPPS is apparently 
unsuitable for the synthesis of the C-terminal peptide thioester. 
In the hope of applying the Fmoc-SPPS despite the incompatibility of thioester 
linkage with Fmoc-SPPS, many latent thioester linker strategies were developed. 
According to these latent thioester linker strategies, usually the C-terminal 
peptide amide or ester, which are compatible with Fmoc-SPPS, are generated in 
advance through the Fmoc-SPPS. Then the desired C-terminal peptide thioester 
is converted from the corresponding C-terminal peptide ester or peptide amide 
either through O to S or N to S acyl transfer (Scheme 71).  
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Scheme 71. Latent thioester linker strategy 
1.3.1 O to S acyl transfer  
1.3.1.a Botti´s latent thioester linker strategy 
Botti have developed a latent thioester linker strategy, which is based on the 
principle of O to S acyl transfer.[103] The latent thioester linker was formed from 
Fmoc-Cys(StBu)-NH-Rink S RAM polymer, from which the amino group of 
cysteine was converted into a hydroxyl group. The first amino acid was anchored 
to the latent thioester linker though esterification and further amino acids were 
assembled through the Fmoc-SPPS. After the synthesis, the C-terminal peptide 
ester was cleaved off the resin and the sulfhydryl group of the linker was 
deprotected. A new thioester bond was formed in situ through O to S acyl transfer, 
then this new C-terminal peptide thioester was ligated with other N-terminal 
cysteine containing peptide fragment to construct new amide bond (Scheme 72).  
 
Scheme 72. Work-flow of the Potti´s latent thioester linker  
Disadvantageously by using this latent thioester linker in aqueous buffer medium, 
the hydrolysis of the C-terminal peptide ester also inevitably takes place. 
Thereafter Cheng et al. investigated a few latent thioester linkers of the same 
kind,[104] and they stated that the Botti´s latent thioester linker is suitable for O to 
S acyl shift and when NCL was performed at low temperature (ca. 10 °C), the 
ester bond would unlikely be hydrolyzed, whereas at higher temperature (RT or 
higher) the formation of hydrolyzed by-product was inevitable. 
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Muir reported the synthesis of thiol lactone inhibitors of Staphylococcal virulence 
by applying the Botti´s linker strategy[105] Instead of preparation of the latent 
thioester linker in solid phase, which resulted in poor yield, the same linker was 
prepared in solution phase with good yield, and by using this latent thioester 
linker they succeed in generation of a library of the thiol lactone inhibitors through 
intramolecular NCL cyclization. 
1.3.1.b Danishefsky´s latent thioester linker strategy 
At the same time, another successful latent thioester linker strategy was 
introduced by Danishefsky.[106][107] A simple latent thioester linker based on the 2-
mercaptophenol was developed. The ortho-sulfhydryl group was in the beginning 
masked by a disulfide bond and the hydroxyl group was coupled through 
esterification to the C-terminal peptide carboxylic acid, which was synthesized on 
Wang resin through Fmoc-SPPS. Upon deprotection of the ortho-sulfhydryl group, 
a new C-terminal peptide thioester was formed in situ in the same manner of 
Botti´s linker and through NCL this new C-terminal peptide thioester formed a 
new amide linkage with other suitable fragment (Scheme 73). 
 
Scheme 73. NCL through Danishefsky´s latent thioester linker 
1.3.2 N to S acyl transfer 
1.3.2.a Dawson´s aminoanilide auxiliary strategy 
The C-terminal peptide thioester fragment within the scope of Fmoc SPPS can be 
also accomplished through the N to S shift. Dawson et al. demonstrated a 
method by utilizing a novel acylation agent.[108] At the beginning, a stable 
aminoanilide auxiliary was synthesized on the resin and the first amino acid was 
coupled to this auxiliary via an amide bond, then the designed sequence was 
assembled though Fmoc SPPS, after synthesis, the aminoanilide auxiliary was 
transformed into a N–acylurea functionality by adding p–nitrophenylchloroformate, 
then this peptide N–acylurea compound could be easily converted into the 
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desired C-terminal peptide thioester by exposure to the thiol, because the N-
acylurea moiety is an excellent leaving group (Scheme 74).  
 
Scheme 74. N to S acyl transfer through Dawson´s auxiliary  
1.3.2.b Ingenito´s sulfonamide latent thioester linker strategy 
Another exceptional example was demonstrated by Ingenito. [109] A sulfonamide 
linker was attached to the solid phase through a spacer and the first amino acid 
was anchored to this linker via an amide bond. Then the Fmoc-SPPS was 
performed to elongate the peptide chain. After the synthesis on the resin, this C-
terminal peptide sulfonamide was simply treated with thiol and converted into 
respective C-terminal thioester through N to S acyl transfer (Scheme 75). 
 
Scheme 75. N to S acyl transfer through sulfonamide linker 
1.4 NCL cyclization in solution and solid phase 
Tam conducted a series of experiments of the head-to-tail NCL cyclization[110] 
and concluded that compared to the conventional cyclization with coupling 
reagent in solution phase, the NCL cyclization can be performed in solution 
phase with moderate concentration of the linear precursor without formation of 
dimers or oligomers.  
Camello and Muir demonstrated the intermolecular and intramolecular NCL of 
unprotected peptides on the resin.[111] The polyethylene glycol-poly-(N,N-
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dimethylacrylamide) copolymer support (PEGA), which was developed by 
Meldal,[112] was applied in this study. This solid support is compatible with Boc-
SPPS and thus C-terminal peptide thioester can be directly synthesized on it. 
Moreover it has excellent swelling ability in aqueous medium, in which NCL 
reaction takes place. At the beginning, the commercially available 
aminomethylated PEGA was converted into ta corresponding 3-
mercaptopropionic acid PEGA (HS-PEGA) and the first amino acid was 
immobilized to the resin via a S-propionamide thioester linkage. This backbone 
anchor linkage is stable upon HF treatment, so the global deprotection after Boc-
SPPS was achieved by using anhydrous HF in p-cresol without the cleavage of 
the peptide off the resin. The resin containing the linear precursor was then 
swollen in neutral phosphate buffer solution and the NCL cyclization took place 
with concomitant release from the resin. The isolated cyclic peptides were 
generally clean, however only in moderate yield (5 - 50%) (Scheme 76). 
 
Scheme 76. On-resin NCL cyclization of C-terminal peptide thioester 
Tulla-Puche and Barany reported the on-resin NCL cyclization from a side-chain 
linkage.[113] The second C-terminal amino acid Fmoc-Asp-OAl was firstly 
immobilized onto the solid support through its side-chain via a p-alkoxybenzyl 
ester. The peptide chain was then elongated through Fmoc-SPPS, the C-terminal 
peptide thioester was formed at the late stage since the thioester bond did not 
withstand Fmoc-SPPS. After global deprotection under mild condition the NCL 
cyclization was performed in buffer solution followed by the cleavage of the cyclic 
peptide by anhydrous HF. Three kinds of polymer supports: PEGA, cross-linked 
ethoxylate acrylate resin (CLEAR) and poly(ethylene glycol)-polystyrene (PEG-
Introduction  83 
 
PS) were investigated in the study. Two out of three resins except PEG-PS 
resulted in good yield, due to PEG resin´s sparingly swelling ability in water.  
 
Scheme 77. On-resin NCL cyclization of C-terminal peptide thioester from a side 
chain linkage 
1.5 Polymeric support 
In the on-resin NCL study, the choice of suitable polymer support is crucial. There 
are many commercially available polymeric supports on the market but not all of 
them fulfill the criteria for the on-resin NCL study. The target polymeric support 
should possess adequate swelling property in the aqueous medium, which is 
commonly used in the NCL reaction. The most common resin in SPPS is the 
cross-linked-polystyrene resin, which was developed by Merrifield back in 
1960s´.[82] It is constructed from co-polymer of styrene-divinyl benzene with 1-2% 
cross-linkages (Figure 5) and it is chemical highly stable. It can be functionalized 
with different moieties, but its poor water swelling property limits its application in 
the on-resin NCL study,[116] besides the PE resin with different functionalities are 
often commercially available in high loading (0.8 – 1.5 mmol / g), which is too 
dense for the on-resin NCL cyclization.  
Another popular polymer support in peptide synthesis is polyacrylamide, which is 
constructed from the acrylamide monomer in simple chain or cross linked form 
(Figure 17).[114] It mimics the peptide, which is attached to it and reduces the 
peptide-peptide-chain-interaction. It is a good water soluble resin but so far very 
few on-resin studies were tested on this basis.  
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Figure 17. Polystyrene and polyacrylamide polymer 
TentaGel is a polyethylene glycol-polystyrene (PS-POE) graft support, within 
which up to 70% polyethylene glycol (PEG) is attached to polystyrene (PS) matrix 
through an ethyl ether bond (Figure 18).[115] 
 
Figure 18. TentaGel polymer 
It can be swollen well in a large number of protic and aprotic solvents [116] and it 
mimics the conditions very similar to the solution phase, hence the peptide 
attached to it will behave very similar like in solution phase. This resin is usually 
available in relatively low (0.2 to 0.3 mmol / g), which is suitable for the on-resin 
NCL cyclization. Furthermore there are two more well-known polymeric supports, 
which are frequently used in SPPS and solid phase organic synthesis, The PEGA 
(poly[acryloyl-bis(aminopropyl)polyethylene glycol]) polymeric support presents 
excellent swelling property in aqueous medium[113] and available in proper 
loading capacity (0.4 mmol / g), therefore this polymeric support is an ideal 
platform for the on-resin NCL study. Barany has already succeeded in on-resin 
NCL cyclization studies by deploying this resin.[113] The cross-linked ethoxylate 
acrylate polymeric support (CLEAR) was introduced by Barany and Kempe 
(Figure 19).[117] It was reported that CLEAR resin is an excellent polymeric 
support and suitable for many challenging syntheses, especially the on-resin 
ligation cyclization of the peptide..[118] However, its availability is relatively limited 
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(not commercially available in Germany) in comparison to other polymers and 
thus could not be deployed regularly. 
 
Figure 19. The network structure of the CLEAR resin[119] 
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2. Plan for the prove-of-concept on-resin NCL cyclization study 
2.1 Motivation of development of the methodology 
This work was initially inspired by the synthesis of interesting bio-active naturally 
occurring cyclic peptides like argyrin and viopolide (Figure 20), which contain 
thioazole and thioazoline residues within their ring structure.  
 
Figure 20. Argyrin and vioprolide  
These natural products show enormous bio-activity and thus they are potential 
candidates for pharmaceutical research. But before advanced research of these 
compounds can be performed, their structure-activity relationship (SAR) studies 
need to be completed. For the SAR study, a library containing a large number of 
derivatives is required. In order to generate such library, a lot of work and time 
are needed through conventional organic synthetic chemistry. So far the 
conventional organic synthetic chemistry has already done plenty of efforts to 
yield these compounds. Ley et al.[120] published the total synthesis of the argyrin 
B and Prof. Kalesse´s group from University Hanover also dedicated themselves 
to generate some of the argyrin derivatives. In the case of the novel compound 
viopolide and its derivatives, there is no published total synthesis so far. With 
intention of rapid establishment of the library of these cyclic peptides, in this work 
an efficient route will be developed. 
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Schema 78. Retro synthesis of the argyrin from the cyclic peptide precursor 
All these cyclic peptide compounds mentioned before contain either thioazole or 
thioazoline residue, which could be converted from the cysteine containing cyclic 
peptide precursors through dehydration (and the sequentially oxidation in the 
case of thiazole, Scheme 78). The aim of this work is to establish a new 
methodology, which could rapidly generate cyclic cysteine-containing peptidic 
precursors. The design of the synthetic route will focus on the word “rapid”. In 
order to achieve the rapidity in the synthesis, all possible measures will be 
deployed to accelerate the synthetic procedure. Throughout this route the final 
product should be obtained in a short time. Synthesis of these compounds 
through the conventional organic synthesis in solution phase won´t be considered 
in this study, because the stepwise elongation of the linear peptide chain and the 
purification in solution phase are often time-consuming. Alternatively, to the 
solution phase peptide synthesis, the solid phase peptide synthesis procedure is 
an alternative choice. It is fast and devoid of the troubles that occur at the 
purification and the increasing insolubility of the long chain peptide in the organic 
solvent. When this process is fully automated by using the SPPS synthesizer 
most short or medium size sequences could be generated within one day. 
Moreover on the synthesizer different derivatives could be conveniently 
synthesized parallel and this is more advantageous over the solution phase 
peptide synthesis. For all these reasons in this work the linear peptide will be 
assembled by SPPS procedure.  
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2.2 Cyclization through on-resin Native Chemical Ligation 
In order to rapidly cyclize these cysteine-containing linear precursors, the 
ordinary head-to-tail lactam formation by using chemical coupling reagents will 
not be performed in this work. Instead the cysteine residue in sequences will be 
well used as the junction point. In order to generate the cyclic structure, a 
cysteine residue will be ligated within the scope of the native chemical ligation 
with a C-terminal amino acid X to construct the X-Cys junction and thus 
accomplish the head-to-tail cyclization. In practice, the cysteine residue would be 
placed on the N-terminus of the linear precursor, accordingly the C-terminal 
ligation partner X would be generated in C-terminus as a thioester.  
Within the frame of the SPPS, these peptide C-terminal thioester linear 
precursors could only be straightforward obtainable through the Boc-SPPS. But 
Boc-SPPS requires special facility for the HF cleavage (see section 1.2.1), which 
restricts the use of the Boc-SPPS and in the present days the Fmoc-SPPS 
protocol is more favorable among the chemistry community. But the 
straightforward application of the Fmoc-SPPS for generation of these C-terminal 
peptide thioesters faces a major obstacle, because the C-terminal thioester 
residue is unstable in the presence of nucleophilic compounds (like piperidine), 
which are necessary for the Fmoc cleavage. A few solutions to solve this problem 
have been reported in the past years (see previous chapter), this work will 
concentrate on the latent thioester linker strategy, which was firstly introduced by 
Botti (Scheme 79).  
 
Scheme 79. The latent thioester linker strategy 
According to this strategy, a special linker will be required. The latent thioester 
linker in this work will be generated by standard organic synthesis in solution 
phase through a new designed synthetic route, which is time-saving but as 
efficient as the previous reported methods.  
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Upon completion of the special linker, it will be attached onto the polymeric 
support and the first amino acid could be coupled to the linker through an ester 
bond, which is supposed to be stable to the nucleophilic treatment through the 
Fmoc-SPPS. After all amino acids are properly assembled, the linear peptidic 
precursor bearing the special linker will remain on the solid phase. The protecting 
group of the sulfhydryl group next to the ester bond will be cleaved, and a new 
thioester bond will be generated in situ through the O to S acyl transfer. 
Afterwards the NCL cyclization of the linear precursor will progress directly on the 
resin whereas the cyclized product will be cleaved simultaneously from the resin 
and simply isolated through HPLC. The on-resin cyclization-cleavage concept will 
bypass the cleavage and the work-up steps and thus avoid the handling loss and 
saves time. But theoretically the linear precursor attached to the polymeric 
support is less reactive than in solution phase, so that a slow NCL cyclization rate 
will be expected in this case.  
2.3 Choice of proper polymeric support and sulfhydryl protecting group 
To successfully apply the NCL cyclization, the unprotected form of the linear 
precursor is often required because of the large steric hindrance of the side-chain 
protecting groups. In the present days, all side-chain protection groups are so 
designed, that their cleavage is accomplished coincidently with cleavage of the 
sequence by TFA treatment. In order to perform the on-resin NCL cyclization of 
the unprotected linear precursor, only the polymeric support without cleavable 
linker will be used, because when the peptide sequence is anchored to the solid 
phase via the cleavable linker, the peptide sequence will be cleaved from the 
solid phase upon deprotection of the side chains through the concentrated THF.  
In this study, the solid support TentaGel NH2 resin, which is a PS-POE polymer 
without cleavable linker but a free NH2 group, will be applied as the solid phase. 
The latent thioester linker will be anchored onto this resin through an amide bond. 
This amide bond is stable during the Fmoc-SPPS and the deprotection cocktail 
(concentrated.TFA:triisopropylsilane:water = 95%:2.5%:2.5%) treatment. With 
this resin, the linear precursor can be fully deprotected with TFA without cleavage 
of the sequence from the resin.  
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Furthermore the sulfhydryl protecting groups of the latent thioester linker and the 
N-terminal cysteine are unique in this model study. The common trityl protected 
cysteine will not be used because of its highly acidic lability. The trityl protected 
sulfhydryl group of N-terminal cysteine could be deprotected prematurely with 
other side-chain protecting groups through the TFA treatment and could lead to 
the undesired side-products. Instead both sulfhydryl groups are accordingly 
masked by the tert-butyl disulfide moiety, which will remain intact during the TFA 
global deprotection and can only be reductively cleaved. The tert-butyl disulfide 
protected cysteine is commercially available, the construction of the tert-butyl 
disulfide protected linker could be readily synthesized as well.  
After the TFA global deprotection, the on-resin NCL cyclization is triggered by 
deprotection of both sulfhydryl groups. A handful of compounds have already 
been used to reduce the disulfide bond in the peptide and protein research. The 
frequently used compounds among them are dithiothreitol (DTT)[121] and tris(2-
carboxyethyl)phosphine (TCEP)[122] TCEP is commercially available since 1992 
and is more advantageous over the DTT. TCEP is more hydrophilic, efficient 
within a large range of pH values, odorless and more air oxidation resistant. It 
reduces the disulfide irreversibly while the DTT can form the new disulfide bond 
with the deprotected sulfhydryl group. Therefore the TCEP will be utilized in the 
model study. The general work-flow of the new methodology is as follows: 
 
Scheme 80. Outline of the synthesis of the cysteine-containing cyclic peptide 
At the beginning of the work, a model sequence (stBuS)Cys-Typ-Leu-Leu-Val-Ile-
O-latent thioester linker (Figure 21) will be constructed and the feasibility of its 
NCL cyclization will be investigated. 
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.  
Figure 21. The model sequence (stBuS)WLLVI-latent thioester linker 14 
This model sequence has its origin in a natural product and was isolated by J. 
Niggermann at the Helmholtz Center for Infection Research (HZI). It is a hexamer 
cyclic peptide and possesses the optimal configuration to form the ring structure.  
The aim of this study is to develop a methodology of the on-resin NCL cyclization. 
At the beginning of the model study, the NCL cyclization will not be performed 
directly on the polymeric support but rather in solution phase, because this latent 
thioester linker was never deployed on the solid phase to synthesize the cyclic 
peptide. In solution phase the progression of NCL cyclization can be monitored 
by analytical HPLC and if the NCL proceeds in the wrong way, these issues could 
be observed and identified, additionally the linear precursor can be cleaved and 
its quality can be examined prior to the NCL cyclization. The TentaGel S RAM 
resin, which bears a cleavable Rink linker, will be deployed for the solution phase 
model study. TentaGel S RAM resin allows the peptide sequence to be cleaved 
after synthesis, so that the quality of the linear precursor can be controlled. 
Through the solution phase model study, the optimal conditions for the NCL 
cyclization will be determined. Once the investigation of NCL cyclization in 
solution phase is completed, the model study will be performed on the solid 
phase by using these determined optimal conditions either directly or with slight 
modifications.  
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3. Results and discussion 
3.1 Organic synthetic chemistry 
3.1.1 Initial attempt of generation of the latent thioester linker 4 
Botti and Muir had already developed their own routes to generate the latent 
thioester linker.[103][105] Here, a different strategy was developed to prepare this 
linker in a rapid and simple way.  
 
Scheme 81. Synthesis of intermediate 2 
Starting with the bromopyruvat (1), bromine was replaced by the hydrogen sulfide 
at 0 °C through a SN2 displacement and the raw product was collected as the 
sodium hydrogen sulfidepyruvate salt (2) without further purification.[123] The raw 
product 2 was dried in vacuo over phosphorus pentoxide for 24 hours and directly 
used for the next step (Scheme 81). 
 
Scheme 82. Synthesis of intermediate 3 
Next selective reduction of the carbonyl group (in blue color) with sodium 
borohydride was carried out in aqueous medium.[124] Sodium borohydride was 
good soluble in water and unlike expected, that it did not react spontaneously 
with water at neutral pH but rather reduced the carbonyl group, performed by 
adding small portions of sodium borohydride every 5 min., otherwise a less polar 
by-product was observed by TLC. Rapid introduction of the sodium borohydride 
resulted in a high concentration of sodium borohydride in the reaction flask, in 
this case the β-carbonyl group could not consume the large amount of sodium 
borohydride fast enough and thus the excess amount of sodium borohydride 
began to reduce the carboxylic carbonyl group and forms the fully reduced and 
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less polar by-product. After addition of sodium borohydride, the reduction was 
completed at RT after one hour. The purification was performed by direct passing 
of the reaction mixture through two ion exchange columns (first the cation 
exchange column, followed by the anion exchange column). The cation exchange 
column (pre-loaded with H+) separated the product (still in sodium salt form) from 
other impurities and the anion exchange column (pre-loaded with acetate ion) 
acidified the sodium salt to yield the final product as a racemic mixture. The 
intermediate 3 was collected in 45% yield calculated over two steps (Scheme 82). 
 
Scheme 83. Synthesis of intermediate 4 
The sulfhydryl group was then protected through the microwave-mediated 
disulfide formation (Scheme 83).[125] 3 was dissolved in buffer solution (10 mM 
ammonium acetate solution in acetonitrile:water = 3 :2), which contains a large 
excess amount of tert-butyl mercaptane and DMSO. Afterwards, this mixture was 
allowed to react in a microwave synthesizer for 10 minutes (temperature 150 °C, 
power 150 W). This reaction progressed smoothly and fast. After 10 min. all 
starting material was completely consumed and a single product was formed as 
detected by TLC. After the reaction it was attempted to extract the product form 
the aqueous DMSO mixture with ethyl acetate. Unfortunately, the product was 
sparingly soluble in the organic phase, so alternatively the aqueous solvent and 
the leftover tert-butyl mercaptan were evaporated and the DMSO was removed 
by using the centrifuge evaporator. The purification of the raw product is optional 
for this step, because technically trace of DMSO and the ammonium chloride salt 
from the buffer solution would not interfere with the subsequent reactions. 
Otherwise the purification was conducted through RP–HPLC in 95% yield, 
because the DMSO residue in the raw product made the purification through the 
silica gel flash chromatography only in small scale possible.  
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3.1.2 Attempt of formation of depsi-peptide building block 6 in solution 
Initially the depsi-peptide building block 6 was formed from 4 and Fmoc-Ile-OH in 
solution phase, because the esterification on solid phase is generally considered 
to be more difficult, besides the formation of the product in solution phase is 
traceable. After building block 6 was completed, it is supposed to be coupled onto 
the resin through the standard HBTU activation protocol.  
At first, carbonyldiimidazole (CDI) was deployed as the coupling reagent. [126] Two 
equivalents of Fmoc-Ile-OH was activated in THF by CDI beforehand and then 
latent thioester linker 4 was added and the mixture was stirred at RT overnight. 
Surprisingly, nothing happened (Scheme 84). The mixed anhydride, which was 
formed from CDI and 4, was presumably insufficient reactive for the esterification. 
 
Scheme 84. Synthesis of depsi-peptide building block 6 through CDI 
Alternatively, Fmoc-Ile-OH was pre-activated by thionyl chloride and 
benzotriazole (HBt) and converted into the active ester 7.[127] The active ester 7 
was highly stable and separable via flash chromatography, then the isolated 
active ester 7 was added to thioester linker 4 in 7 exceed folds along with 10 
folds of DMAP, after 24 hours thioester linker 4 was completely consumed as 
judged by TLC (Scheme 85).  
 
Scheme 85. Synthesis of 6 through benzotriazole and SOCl2 activation. 
This reaction generated a large number of products and after isolation of each 
single product through HPLC, the desired ester building block 6 (characterized by 
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HRMS) was found only existed as trace (≤ 1%). The reaction was repeated with 
less active ester 7 (2.8 eq.) and DMAP (3.3 eq.), but this didn´t result in the 
correct formation of the ester building block 6 either (still as trace). The 
generation of the desire ester building block 6 in solution phase could be 
achieved by neither of these methods, it was more difficult than estimated thus 
the esterification had to be performed on the resin after the immobilization of the 
linker 4 .[103][105] 
3.1.3. First attempt of generation of the sequence 10 through Fmoc-SPPS 
 
Scheme 86 The synthetic route towards linear precursor 10 by using linker 4 
At the beginning, the latent thioester linker 4 was immobilized onto the TentaGel 
S RAM resin overnight in slight excess (1.1 equivalent) through HBTU activation, 
after the coupling the unreacted free amino groups of the resin remained 
uncapped, because in this particular case, capping of the free amino groups by 
ethyl acetic anhydride will also acylate the secondary alcohol of latent thioester 
linker 4, which is supposedly to be coupled with the first amino acid. Fmoc-Ile-OH 
was then coupled to the latent thioester linker 4 through the esterification, which 
was carried out with either DCC activation or HBTU activation (Table 11, entry 1 
and 2). After esterification, the coupling quality was determined by the Fmoc 
release UV assay (procedure see experimental section), the coupling was found 
highly efficient. In both cases the coupling achieved the high degree of loading 
(96% and 100%)  
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Table 11. Attempts of the synthesize of linear precursor 10 by using linker 4 
entry equivalent of 4 coupling reagent of 
esterification 
product 10 found 
1 1.1 DCC / DMAP no 
2 1.1 HBTU  no 
After coupling of Fmoc-Ile-OH, the sequence was elongated in the given order on 
the automated peptide synthesizer. The synthesizer was programmed to execute 
the Fmoc-SPPS protocol and the pre-loaded resin was filled in small syringes 
(suitable for up to 25 µmoL batch) with filter, the peptide sequence was 
generated stepwise by following the batch flow-through principle.  
One complete coupling cycle is comprised of following steps: 
-Fmoc cleavage 
The pre-loaded resin was treated twice with 20% piperidine / DMF solution (700 
µL for each 2 min. and 8 min.) to liberate the amino group and then the resin 
washed with DMF thoroughly  
-Activation and coupling  
500 µL of the amino acid stock solution (0.5 M in NMP) is introduced into the 
small syringe and followed by 500 µL 0.5 M TBTU stock solution, then 500 µL 
DIPEA is also added. The small syringe is then incubated for one hour with 
occasional shake. After the coupling is completed the solution is drained, the 
resin is thoroughly washed with DMF and is ready for the next coupling.  
According to this procedure the remaining amino acids of sequence 10 were 
assembled.  
After the cleavage with the cleavage cocktail (TFA:triisopropylsilane:water = 
95%:2.5%:2.5%), the LC-MS analysis of the crude product was rather 
disappointing (Figure 14).  
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Figure 14 LC-MS analysis (UV: 190 – 600 nm) of the crude product mixture after 
cleavage 
No trace of the desired linear product 10 was found, instead one main peak in the 
UV spectra (Figure 14) was then identified by its mass spectrum as the peptide 
amide product (Figure 15). None of mass of other peaks matched the desired 
product either. 
 
Figure 15. The detected sole peptide amide by-product 
This peptide amide by-product could only exist, when Fmoc-Ile-OH bypassed the 
latent thioester linker 4 and was directly coupled to the TentaGel S RAM resin 
(Scheme 87).  
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Scheme 87. The emergence of the wrong product through the wrong pathway 
Additionally, it could also be the case that the model sequence 10 decomposed 
during the concentrated TFA treatment. In order to validate this assumption, the 
influence of concentrated TFA on the model sequence 10 was examined. The 
model sequence 10 was then prepared again through the same procedure but on 
the Silber S RAM resin,[101] the cleavage of the linear precursor with conducted 
by using 5% TFA in DCM, which should be compatible to the model sequence 10 
(Scheme 88).  
 
Scheme 88. Fmoc-SPPS on the Silber resin resulted in the same by-product. 
After the cleavage, the LC-MS analysis of the crude product mixture identified the 
same by-product as the previous experiment. No trace of correct product was 
found and the by-product peptide amide remained one of the main products. But 
this result suggested that the concentrated TFA treatment was not responsible for 
the failed synthesis. 
Based on these facts, the linker 4 was considered not to be suitable for the 
synthesis, because the standard SPPS protocol suggests that the first amino acid 
(in this case, the latent thioester linker 4) should be coupled to the resin in a large 
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excess (3-5 equivalent), though the latent thioester linker 4 carries a free hydroxyl 
group, when the coupling of the linker 4 is carried out in high concentration (3-5 
folds excess), the intermolecular esterification might become inevitable. Besides 
the acetylate (capping) of the unreacted free amino functionalities of the resin 
after the coupling is impossible as long as the free secondary hydroxyl group still 
exits.  
Loading of 1.1 equivalent of the latent thioester linker 4 onto the resin might be 
highly insufficient and left a lot of unreacted free amino groups on the resin. 
Without capping, these free amino groups involved in the amide formation with 
Fmoc-Ile-OH under same esterification conditions. The quantitative loading of 
isoleucine (according to the Fmoc release UV assay) was deceiving, because the 
isoleucine was loaded directly onto the resin and falsified a perfect loading. That 
might be the reason, why after the cleavage the peptide amide instead of the 
desired product 10 was found as the main product. 
To verify this hypothesis, the loading of the latent thioester 4 onto the resin was 
examined semi-quantitatively by the Kaiser test. 
The Kaiser test is a color test,[128] which allows to semi-quantitatively and if 
necessary quantitatively detect the presence of the terminal free amino groups, 
was regularly applied in the SPPS to assess the coupling quality. 
At presence of the free amino group, the Kaiser reagent (mainly ninhydrin) will be 
converted into a blue dye molecule through a serial of the reactions between the 
ninhydrin and the terminal free amino group (Scheme 89). 
 
Schema 89 The Kaiser test 
The Kaiser test works well with all natural amino acids with the only exception of 
proline, with which´s secondary amino group, ninhydrin could not undergo the 
same process to form the blue dye molecule. The Kaiser test is extremely 
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sensitive and is applicable even when extremely low concentrations of free amino 
groups (5 µmol / mg) are present. 
With the help of the Kaiser test (test procedure see experimental section), the 
loading of latent thioester linker 4 was determined and the color test was strongly 
positive. Both resin beads and the solution were intense blue and this proved that 
the coupling was totally failed. The loading of the linker 4 onto the resin with only 
an equimolar amount was ineffective thus the coupling did not proceed properly. 
Thereafter, the concentration of the linker 4 should be necessarily increased to 
achieve the proper loading, but the high concentration of the activated latent 
thioester linker 4 may also lead to the esterification between the linkers. In order 
to avoid this undesired esterification, the secondary hydroxyl group of latent 
thioester linker 4 should be masked before it can be used for the synthesis again. 
The protected secondary alcohol will allow the deployment of the high excess 
amount of the linker at the coupling step, moreover the capping will become 
feasible due to the absence of the free hydroxyl group. 
 
3.1.4 Modification of the linker 4 and repeating of the Fmoc-SPPS 
The protection of the hydroxyl group of the linker 4 was achieved through a one-
step protection / deprotection procedure (scheme 90).[129] 
 
Scheme 90. The protection of 4 to generate the new linker 12 
The first step was the general protection of the latent thioester linker 4 with tert-
butyldimethylsilyl chloride in the presence of the imidazole, in this step the free 
hydroxyl group was protected with TBDMS as well as the carboxylic acid. The 
determination of the completion of this reaction is difficult, because after the 
overall protection there were no UV active functionalities left and even worse was 
that the TLC plate could not be stained to become visible. Finally, the completion 
of the reaction was determined through the LC-MS analysis. The fully protected 
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intermediate was then treated with a weak base (K2CO3) to saponificate the silyl 
carboxylic ester and left the primary silyl ether unaffected. The purification was 
easily performed through the flash chromatography and the final product 12 was 
obtained in 73% yield. 
 
 
Scheme 91. Loading of the new linker 12 and the Fmoc-Ile-OH 
The latent thioester linker 12 was unfortunately highly unstable, it can undergo 
decomposition at RT in a very short period (max. 3 hours) even under inert gas. 
At –70 °C this linker could only be kept no longer than one day. Each time this 
new latent thioester linker 12 had to be utilized immediately after the purification.  
The new investigations started with the latent thioester linker 12 and the quality of 
the loading was controlled by Kaiser color test. At the beginning, an equimolar 
amount (1.1 eq.) of the latent thioester linker 12 was coupled onto the resin, but 
the color test failed and an intense blue color was shown both in the solution and 
on the resin beads. Then the introduced amount of the latent thioester linker 12 
was deliberately increased ranged from 2 to 5 equivalents and separately 
coupled onto the resin. After each coupling, the shade of the blue color changed: 
the more the latent thioester linker 12 was charged at the beginning, the lighter 
the blue color became. From 3 equivalents onwards the blue color of the resin 
beads disappeared and the solution only showed a slight green grey color, which 
suggested that the coupling quality was improved. Then the TBDMS group was 
removed overnight on the resin by TBAF and Fmoc-Ile-OH was coupled (10 eq.) 
two times onto the linker 12 through the esterification by using the standard 
HBTU / DMAP activation protocol The coupling quality of the first two steps was 
then quantitatively determined by Fmoc release UV assay.  
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Coupling of latent thioester linker 12 onto the resin with 1.1 equivalent amount 
only achieved a loading of 53% (Table 12, entry 3) and this reflected why an 
intense blue color was seen in both resin bead and the solution. With increasing 
amount of the latent thioester linker 12, the loading of the first two steps 
increased accordingly. When doubling the initial charge of the latent thioester 
linker 14 (2 eq.), the loading increased by 30% and reached 82% (entry 4). With 
increasing amount over 2 eq. the loading increased only insignificantly and 
reached 93% when 3.5 equivalent amounts of the latent thioester linker 12 (entry 
7) was utilized, beyond this point, further addition of latent thioester linker 12 has 
no substantial influence on the loading. 
Table 12. The efficiency of the loading through various charges of linker 12 
entry equivalent of the charged linker 12 loading after first two steps 
3 1.1 53% 
4 2 82% 
5 2.5 85% 
6 3 90% 
7 3.5 93% 
8 4 93% 
9 5 94% 
 
In all further studies, 3.5 eq. amounts of latent thioester linker 12 were uniformly 
applied at the beginning to achieve efficient coupling without unnecessary waste.  
After Fmoc-Ile-OH was successfully anchored onto the linker, the rest amino 
acids (valine, leucine, leucine, tryptophan and cysteine) were consecutively 
assembled by the automated SPPS synthesizer. The linear peptide 14 was then 
cleaved and precipitated with MTB ether. The raw product 14 in a relatively clean 
condition was clearly characterized by the LC-MS analysis. No purification 
through HPLC was performed due to the high sensitivity of the ester bond to the 
water / ACN HPLC eluent. 
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3.2 Investigation of solution phase NCL cyclization 
3.2.1 Investigation of solution phase NCL cyclization of 14 
The NCL cyclization of the linear precursor 14 was initially performed under the 
same conditions described by George et.al.[109] 
 
Scheme 92. Two reactions compete against each other during the NCL 
cyclization 
Table 13. The results of cyclization at various concentrations 
entry buffer mixture used conc. of 
14 
denaturant 
 (6 M GdmCl) 
pH product detected 
10 20% ACN 
80% phosphate buffer 
0.2 mM yes      6.79 hydrolyzed by-
product  
11 20% ACN 
80% phosphate buffer 
0.2 mM yes      6.32 hydrolyzed by-
product 
12 20% ACN 
80% phosphate buffer 
1 mM yes     7.0 hydrolyzed by-
product 
13 20% ACN 
80% phosphate buffer 
2 mM yes       6.68 hydrolyzed by-
product 
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The raw product 14 was at first dissolved in a small portion of ligation buffer 
solution mixture (20% ACN / 80% 0.1 M phosphate buffer containing 6 M 
guanidium chloride (GdmCl)) and was then diluted with a large amount of buffer 
mixture to a final concentration of 0.2 mM in order to avoid the dimerization or 
polymerization. The buffer mixture contained 350 folds of TCEP (70 mM), which 
allowed the rapid deprotection of the disulfide bonds. The pH value was adjusted 
to 6.79, which is common for the NCL reaction (Table 13, entry 10). The 
progression of the cyclization was monitored by analytical HPLC. The linear 
precursor 14 completely disappeared after four hours whereas a new peak 
constantly grew in the analytical HPLC. According to the LC-MS analysis, the 
new formed large peak was not the desired cyclic peptide 15 but the hydrolyzed 
by-product 15´ (Figure 16).  
 
Figure 16. The hydrolyzed by-product was identified as the main product  
Then the pH value was lowered to 6.3 (entry 11) in order to slow down the 
hydrolysis rate based on the statement of the literature,[109] which claimed that the 
high pH value benefits the hydrolysis. The cyclization, which was repeated in this 
way, didn´t change the outcome, the hydrolyzed by-product remained the sole 
detectable main peak in the LC-MS analysis. Then the concentration of the linear 
precursor 14 was intentionally increased to 1 mM and 2 mM (entry 12 and 13) to 
improve the chance of the head-to-tail contact (this may also lead to dimerisation 
or oligomerisation of the linear precursor). Again these attempts were 
unsuccessful, no cyclic products (monomer, dimer, or oligomer) was detected by 
LC-MS. 
The failure of initial experiments indicated that the ester bond linkage is sensitive 
to the nucleophilic buffer solution. If the NCL cyclization could be performed in 
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pure aprotic polar organic solvent, without the disturbance of the nucleophile the 
cyclization might be working.[130] 
 
Scheme 93. The solution phase NCL of 14 in the modified buffer mixtures. 
Table 14. The results of reactions in an organic solvent 
entry buffer mixture  pH value concentration of TCEP product detected 
14 
(RT → 40 °C) 
70% DMF 
30% phosphate buffer 
5.13 50 mM no reaction 
15 90% DMF 
10% phosphate buffer 
/ 50 mM no reaction 
16 95% DMF 
5% phosphate buffer 
/ slightly soluble no reaction 
17 99% DMF 
1% phosphate buffer 
/ slightly soluble no reaction 
18 100% DMF / insoluble no reaction 
 
A series of organic solvent mixtures, which contain different ratios of the aqueous 
phosphate buffer solution were prepared and NCL cyclization of 14 was then 
performed in these mixtures. During these experiments, the presence of water in 
the model study was found very crucial, because the TCEP is only soluble in 
aqueous medium. When there was no or little water in the ligation mixture (Table 
14, entry 16, 17 and 18), the TCEP was very limited dissolved. No reaction took 
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place in pure DMF after 24 hours (entry 18), the linear precursor 14 was intact 
judged by LC-MS. In experiments 16 and 17, after 24 hours, a small amount of 
TCEP was eventually dissolved and reduced one of two disulfide bonds or both 
of them. In these mixtures the linear precursor 14 existed in three different 
reduced forms: fully reduced and two partially reduced forms, no sign of the cyclic 
product was identified though (Figure 17).  
 
Figure 17. Three reduced forms detected by LC-MS 
 
Figure 18. LC-MS analysis (UV: 190 – 600 nm) of entry 16 and 17 
In the experiment 14 and 15, with higher percentage of water in the buffer mixture, 
the TCEP was easily soluble in the buffer mixture and in both cases, after 24 
hours the linear precursor 14 was found existed in fully reduced form (entry 14 
and 15). No ligation took place neither did the hydrolysis. The reaction mixture of 
the experiment 14 was then heated at 40 °C for 12 hours but the linear precursor 
14 could still not be cyclized in organic solvent through NCL. 
Results and discussion  107 
 
3.2.2 Modification of the sequence 14 and investigation of the new 
sequence 16 
The model sequence CWLLVI 14 was comprised of over 80% hydrophobic amino 
acids thus it presented a strong hydrophobic character and in the previous 
experiments it was found to be poor soluble in the aqueous medium. Each time, 
the model sequence 14 could not be directly dissolved in the 20% ACN / 80% 
phosphate buffer mixture but rather firstly dissolved in a small amount of DMF (30 
µL), then the aqueous buffer mixture was carefully added. The poor solubility of 
14 in water might decelerate or even hinder the ligation and thus only the 
hydrolysis by-product was formed 
With the purpose of verifying this speculation, the original model sequence 
CWLLVI 14 underwent some slight changes to increase its water solubility, 
thereby the leucines were deliberately replaced by two serines (Scheme 94).  
Scheme 94 The modification of 14 into 16 
The modified sequence CWSSVI 16 was synthesized through the same 
procedure on the resin and after the synthesis it was cleaved and found to be 
very soluble in the aqueous buffer mixture. Then the NCL cyclization of the 
modified sequence 16 was investigated again under the previous conditions (20% 
ACN / 80% 0.1 M phosphate buffer, 6 M guanidium chloride, 50 mM TCEP, 
concentration: ca 1 mM in buffer mixture). 
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Table 15. Results of cyclization at different pH values 
entry pH value product detected 
19 6.32 by-product 
20 6.55 by-product 
21 6.71 by-product 
22 6.95 by-product 
23 7.08 by-product 
 
In the beginning, a row of buffer mixtures of the pH values ranged between 6.32 
and 7.08 (Table 15) were prepared and the NCL was performed in these mixtures. 
Surprisingly the NCL cyclization did not happen in none of these experiments. 
The hydrolyzed by-product remained the main detectable substance at LC-MS 
analysis, therefore, the pH value was determined not to be a crucial factor for the 
NCL cyclization, at least not in this model study. The problem remained and one 
question still needed to be answered, what is utmost essential factor for the NCL 
cyclization. 
Camellio´s previous investigation of the on-resin NCL cyclization[111] has 
determined that the denaturant 6 M guandium chloride considerably reduced the 
ligation rate, but in most cases the proteins and large peptides are ligated, the 
presence of denaturant is necessary. In this model study, the sequence 16 is a 
small peptide, which theoretically does not possess the secondary structure yet 
and thus the presence of the denaturant is redundant.  
Table 16. Results of cyclization in the denaturant-free buffer mixture 
experiment pH value product detected 
24 6.8 by-product 
25 7.0 by-product 
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Thereafter the solution phase NCL cyclization of 16 was carried out twice in the 
denaturant-free buffer mixtures and the previous problem remained (Table 16). 
As usual the linear precursor 16 was completely hydrolyzed. The denaturant 
might reduce the ligation rate, but in this case study there must be a more 
important fact, which obstructs the NCL cyclization of 16.  
3.2.3 Investigation of CWSSLI 16with alternating stereochemistry 
So far only the L-amino acids were used to construct the model sequence 14, as 
a result there could be a possibility, that the side chains, which all situate on the 
same side of the sequence, caused a large steric blockade when the NCL 
cyclization progresses and under such circumstance the NCL cyclization might 
progress not fast enough to surpass the hydrolysis. In order to reduce the ring 
strain during the cyclization, half of the L-amino acids were thereafter replaced by 
D-amino acids and the resulted optimal geometrical configuration was expected 
to possess less steric hindrance and formation of the cyclic product should be 
eased. The NCL cyclization of 14´ was performed twice under the previous 
conditions (RT, standard buffer mixture).  
 
Scheme 95. The cyclization of linear sequence CWSSLI 16 with alternating 
configurations 
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Table 17. Results of cyclization of the CWSSLI 15 with alternating 
stereochemistry 
experiment buffer mixture used pH value product detected 
26 20% ACN 
80% phosphate buffer 
6.87 by-product 
27 20% ACN 
80% phosphate buffer 
6.68 by-product 
Unfortunately the NCL cyclization of linear CWSSLI 14´ with alternating 
configurations failed again (Table 17), the hydrolyzed by-product was still 
identified as the main product by LC-MS analysis.  
3.2.5 Investigation of solution phase NCL cyclization of 16 with thiol 
additive 
In the buffer mixture, upon reduction of the disulfide bond, the peptide-α-thioalkyl 
ester was formed in situ through the O to S acyl transfer and followed by the 
transthioesterification, which in the case of sequence 16 might be very slow and 
consequentially the cyclization was suppressed by the hydrolysis. According to 
the common knowledge, the transthioesterification rate can be improved by using 
promoters, thereby the influence of promoters (1% v/v benzly mercaptan with 3% 
v/v thiophenol and MESNa) on the NCL cyclization of 16 was investigated. 
Table 18. Results of cyclization with thiol additives 
entry promoter product detected 
28 1% v/v benzy 
mercaptan and 3% 
v/v thiophenol 
no 
29 MESNa no 
 
The cyclization was performed under previous conditions but with additional thiol 
additives (Table 18). The cyclization did not take place in the buffer solution 
containing promoters, no sign of the product was detected after the reaction. 
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3.2.6 Reinvestigation of the solution phase NCL cyclization of 14 at low 
temperatures 
The NCL cyclization of the initial model sequence CWLLVI 14 could be 
accomplished under no circumstances. Inspired by the research reports,[104] 
which suggested that in the NCL reaction, the hydrolysis is the thermodynamic 
product and the NCL is the kinetically controlled product, the NCL cyclization of 
the sequence CWLLVI 14 was reexamined at low temperature. 
Table 19. Results of cyclization at low temperature 
entry tempeature product detected 
30  10 - 13 °C by-product 
31 0 °C by-product 
The new experiments were carried out under the same previous conditions but 
the temperature was lowered down to 10 – 13 °C and 0 °C (Table 19, enty 30 
and 31) respectively. Disappointingly, even at the low temperature the ligation of 
the sequence 14 could still not surpass the hydrolysis to generate the correct 
cyclic product, after 16 hours the hydrolyzed by-product was again identified by 
LC-MS as the single main product in both cases, no trace of the cyclic product 
was found.  
 
Scheme 96. The unsuccessful attempt of cyclization of linear sequence CWLLVI 
14 and CWSSVI 16 
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All attempts of the NCL cyclization with both model sequences CWLLVI 14 and 
CWSSVI 16 failed. None of them could be converted into the desired cyclic 
products due to vast steric hindrance of the C-terminal isoleucine. These results 
were in consistence with Dawson´s publication[78] and verified that the isoleucine 
is not suitable to be used as the ligation partner in the NCL reaction to generate 
the amide linkage. In the case of the NCL cyclization, the geometrical influence of 
the side chain of the C-terminal isoleucine is so high, that the ligation was 
severely hindered by the bulky side chain and consequentially the NCL 
cyclization progressed extremely slowly. Even with the promoters, neither of 
linear precursors 14 and 15 could be cyclized. The NCL cyclization could not be 
accomplished under previous conditions as long as isoleucine situates at the 
junction site.  
3.2.6 Shift of the investigation subject to the sequence 19 
Since the further investigation of the model sequences CWLLVI 14 and CWSSVI 
16 was pointless, a new model sequence CSSLG 19, which was inspired by 
Muir´s work,[105] was constructed. Instead of the bulky isoleucine, glycine was in 
this case placed at the junction site. Formation of a Gly-Cys junction should 
confront the least steric barrier due to the absence of the side chain and the 
ligation rate should be predictably easier.[78] 
The new sequence 19 has the idea geometry at the junction site and is good 
soluble in water and thus it supposed to be a perfect model for the NCL 
cyclization study. The sequence 19 was generated by using the established 
synthetic route and was investigated under various conditions (Scheme 97). 
 
Scheme 97. The cyclization of the new sequence 19 under previous conditions 
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Table 20. Initial results of the cyclization of the sequence19 
entry promoter product detected 
31 none by-product 
32 60 mM MESNa strong MESNa peak 
 
Initially, the investigation was carried under the original conditions (1mM in buffer 
solution, RT, neutral pH, 6 M Gdm∙Cl and 70 mM TCEP) (Table 20, entry 31), 
after four hours the linear precursor 19 disappeared in the analytical HPLC, but 
unfortunately even with minimal steric hindrance at the ligation site, the NCL 
cyclization could not be accomplished. The hydrolyzed by-product emerged as 
the main product judged by the LC-MS analysis. Then the experiment was 
repeated with additional 60 mM MESNa (entry 32) in the buffer mixture and after 
16 hours there was still no sign of the cyclic product 19´.  
In previous experiments, the model sequence CWSSIV 14 was once cyclized at 
low temperatures. The linear precursor 19 was again investigated at low 
temperature, although the previous experiment was unsuccessful. Additionally, in 
order to achieve a higher ligation rate, the denaturant 6 M guanidium chloride 
was excluded from the buffer mixture and would not be used for the further 
investigations.[111] 
Table 21. Results of cyclization of 19 at low temperature 
entry temperature product detected 
33 10 - 13 °C by-product and product co-existed 
34 0 °C yes 
35 (50 mM MPAA) 0 °C yes 
 
The reactions at lower temperature progressed slower than at RT, after four 
hours the starting material 19 still existed in a large amount (analytical HPLC) 
and thus the sequence 19 was allowed to react overnight and after 16 hours the 
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starting material 19 was found completely consumed by LC-MS. After the 
reaction performed at 10 – 13 °C for 16 hours the desired cyclic product 19´ was 
finally detected by LC-MS (Table 21, entry 33), despite the majority of the linear 
precursor 19 was still hydrolyzed in a ratio of approximately 5:1 (LC-MS, 
calculated through integration of the UV chromatogram, Figure 19) to the cyclic 
product 19´. At this temperature, formation of the by-product was still more 
favored. 
 
Figure 19. LC-MS analysis (UV: 190 – 600 nm) of the solution phase NCL 
cyclization of 19 at 10 °C  
Finally, at 0 °C (entry 34) no more hydrolyzed by-product could be observed by 
LC-MS and the cyclic product 19 existed as the sole main product. Furthermore, 
the influence of the promoter MPAA (50 mM) was also investigated at 0 °C and it 
was found that at 0 °C with or without promoter the cyclic product 19´ could be 
cleanly formed. Besides, utilization of a large amount of MPAA was 
disadvantageous, because its high UV absorption created a significant signal in 
the UV spectrum, which overlaps many small peaks including the cyclic product 
19´ (Figure 20). Consequently, all further experiments were carried out without 
promoter.  
 
 
Figure 20. UV spectrum of LC-MC analysis (UV: 190 – 600 nm) of the reaction 
mixture using a large amount of MPAA additive 
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3.2.7 Determination of the ideal TCEP concentration in the buffer mixture 
Theoretically the concentration of TCEP in the buffer mixture does not participate 
in the NCL cyclization, because its only function is to reduce the disulfide bonds. 
However in practice, after the reaction, the solvent will be removed and the cyclic 
product will be directly isolated from the reaction mixture through HPLC. High 
concentrations of TCEP in the buffer mixture resulted in a large amount of TCEP 
residue in the solid mixture. The isolation of the product from the large amount of 
leftover TCEP requires multiple HPLC runs because of the limited loading 
capacity of the HPLC column, as a result this cause considerable handling loss of 
the cyclic product.  
For this particular reason, the amount of TCEP in the buffer solution should be 
reduced to a proper level for the convenient purification and the reduction of the 
handling loss, meanwhile this lower TCEP concentration must be still capable of 
efficient reducing the disulfide bonds.  
Table 22. Cyclization of 19 in buffer mixture with different TCEP concentrations 
entry conc. of TCEP 
36 50 mM 
37 30 mM 
38 10 mM 
 
In order to determine the ideal TCEP concentration in the buffer mixture, the 
linear precursor 19 was allowed to be cyclized in the buffer mixtures containing 
different amount of TCEP (Table 22). The cyclization in these buffer mixtures 
showed that at 0 °C the cyclization in the buffer solution containing 10 mM TCEP 
(entry 38) was accomplished qualitatively as good as in the buffer solution 
containing 50 mM TCEP (entry 36) and no by-product was identified by LC-MS in 
all three cases. This means, efficient reduction of the disulfide bond required no 
more than 10 mM TCEP in the buffer mixture, it is unnecessary to utilize a large 
amount of the TCEP in this case study. The investigation of the cyclization in 
buffer solution containing lower than 10 mM TCEP was not carried out, although 
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in some publications the deprotection in solution phase was performed with mere 
two equivalent amount of TCEP (in this case equals 2 mM TCEP in buffer 
solution). Maintaining of such relatively high concentration of TCEP in buffer 
solution is based on the following basis, because in the further on-resin 
experiments, the immobilized disulfide bond are much less reactive and 
reachable and thus the rapid reduction of the disulfide bond in solid phase should  
require a relatively high level of TCEP concentration. 
The initial investigation of solution phase NCL cyclization of the model sequence 
19 was concluded. The preliminary optimal conditions, which were determined 
through the previous experiments, were summarized here: 
Table 23. The optimal conditions for the solution phase NCL cyclization 
conc. of the linear precursor 1 mM 
temperature  0 – 5 °C 
denaturant  none 
promoter none 
conc. of TCEP 10 mM 
buffer mixture solution  20% ACN / 80% 0.1 M  
phosphate buffer 
pH value  6.8 – 7.0 
 
3.2.8 Investigation of solution phase NCL cyclization of 20 
 
Scheme 98. Cyclization of the linear sequence 20 in the solution phase 
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In order to validate that the established conditions are not specifically applicable 
for the cyclization of the sequence 19, the NCL cyclization of the new sequence 
CWLLF 20 was investigated under the same conditions as well (Scheme 98). 
The linear precursor 20, which contains a C-terminal phenylalanine, was 
prepared through the previous established route and cyclized. While cyclizing 
sequence 20, large steric blockade was expected due to the benzyl residue of the 
C-terminal phenylalanine. But in fact in solution phase and at 0 °C the benzyl 
residue did not have influence on the NCL cyclization, and like its predecessor 19 
the cyclization of sequence 20 resulted in the clean cyclic product 20´.  
Through this experiment the established reaction conditions were proven 
applicable and the NCL cyclization of linear peptide by applying this latent 
thioester linker strategy was feasible at least in these cases.  
Based on these conditions, which were developed for the solution phase NCL 
cyclization, the following work is going to investigate the NCL cyclization of 
various peptides in solid phase. 
3.3 Investigation of on-resin NCL cyclization 
3.3.1 On-resin NCL cyclization of fully protected sequence 21 
At the beginning of the investigation, the model sequence 21, which is the fully 
protected sequence 19, was generated on the TentaGel S RAM resin and directly 
cyclized on the resin under the established conditions. The reason, why a fully 
protected peptide sequence was used, was that under the deprotection condition 
(concentrated TFA treatment), the immobilized peptide sequence will be 
concomitantly cleaved due to the acidic sensitive Rink linker thus no on-resin 
investigations could be conducted (Scheme 99). 
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Scheme 99. The on-resin cyclization of fully protected 21 
Table 24. Results of on-resin cyclization of 21 at various temperatures 
entry temperature product detected 
39 0 - 5 °C no reaction 
40 10 – 15 °C no reaction 
41 RT trace, mostly 
hydrolyzed 
42 40 °C hydrolyzed 
 
Not so surprisingly, the immobilized linear precursor 21 was much less reactive 
than in solution phase, hence the low temperature was inappropriate for the on-
resin NCL cyclization. At low temperature (Table 15, entry 39 and 40), after 16 
hours neither the hydrolyzed by-product nor the NCL cyclic product was observed 
by LC-MS. At RT the cyclization progressed very slowly, after 16 hours the cyclic 
product 21´existed only as trace while the majority of the linear precursor was 
hydrolyzed (entry 41). The higher temperature was not beneficial for the 
cyclization either, because the test at 40 °C showed that after 4 hours only the 
hydrolyzed by-product was detected in the buffer mixture (entry 42). These facts 
indicated that the cyclization on the resin didn´t take place until the temperature 
reached RT and the side chain protecting groups must be removed prior to the 
cyclization, otherwise the NCL cyclization confronts the large steric barrier and 
the hydrolyzed by-product was preferentially formed. 
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3.3.2 Investigation of on-resin NCL cyclization of sequence 19 
In order to deprotect the side chains with concentrated TFA without from the resin, 
the same sequence was generated on the TentaGel NH2 resin instead of the 
previously used TentaGel S RAM resin. The TentaGel NH2 resin is similar to the 
TentaGel Rink S RAM resin in terms of the core copolymer but it does not carry 
the cleavable Rink linker (Figure 21).  
 
Figure 21. Difference between two resins 
The linkage between the latent thioester linker 12 and the TentaGel NH2 resin is 
achieved through an amide bond, which is highly stable upon treatment with 
concentrated TFA thus it allows the attached sequence 19 to be deprotected with 
concentrate TFA without the risk of cleavage of the linear sequence. By following 
the established route, the linear precursor 19 was generated on the TentaGel 
NH2 resin and after the synthesis, the sequence was deprotected with cleavage 
cocktail (concentrate TFA:triisopropylsilane:water = 95%:2.%:2.5%) on the resin 
(in this case all side chain protecting groups except the tert-butyl mercapto 
groups were cleaved). No linear sequence was prematurely released as peptide 
amide during the TFA treatment judged by the LC-MS analysis of the cleavage 
cocktail. After the resin was washed and dried, it was allowed to be swollen in the 
buffer mixture at RT for 16 hours (Scheme 100).  
 
Scheme 100. The on-resin cyclization of 19 
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After 16 hours the cyclic product 19´ was detected as the main product (LC-MS), 
furthermore the solution after the NCL cyclization was relatively clean and none 
of these small peaks were identified as the hydrolyzed by-product (Figure 22).  
 
Figure 22. LC-MS analysis (UV: 190 – 600 nm) of successful on-resin NCL 
cyclization of sequence 19 
This successful experiment indicated that the previously established conditions, 
except the low temperature, were fully adoptable for the on-resin NCL cyclization. 
The purification of product 19´ was performed through semi-prep HPLC in 10% 
overall yield. The overall yield was calculated through comparison of the amount 
of the substance between deployed resin at the beginning of the SPPS and the 
isolated cyclic product at the end.  
The cyclic product 19´ was only isolated in modest overall yield (10%) but it was 
relatively clean and could be easily purified. However, the yield might be 
improved by using modified buffer mixture based on the following consideration: 
The TentaGel NH2 resin, which was used in the model study, only has moderate 
swelling property in water, therefore, the resin may not be properly swollen in the 
20% ACN / 80% phosphate buffer mixture. In this case, a large number of linear 
precursors may still be wrapped underneath the resin and could not participate in 
the NCL cyclization. With higher percentage of the polar, aprotic organic solvent 
in the buffer solution, the swelling ability of the TentaGel might be improved and 
possibly result in higher yield. Thereafter the buffer mixture was adjusted to 
contain more acetonitrile (50%) and the NCL cyclization of the sequence 19 was 
investigated in this mixture again. After 16 hours the cyclic product 19´ was 
isolated through HPLC but the overall yield showed no improvement. 
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3.3.3 Investigation of on-resin NCL cyclization of further model sequences 
3.3.3.1 Investigation on-resin NCL cyclization of further 5 membered 
peptides 
3.3.3.1a On-resin NCL cyclization of sequence 20 
In order to check the general feasibility of the on-resin NCL cyclization, a few 
further sequences were examined under the established conditions (Scheme 
101).  
 
Scheme 101. The on-resin cyclization of 20 
Table 25. Results of on-resin cyclization of 20 at two temperatures 
entry temperature product detected 
42 RT yes 
43 15 °C no reaction after 16 h 
 
The TentaGel NH2 resin loaded with the linear precursor 20 was allowed to be 
swollen at RT for 16 hours and was then examined by LC-MS. 
 
Figure 23. LC-MS analysis (UV: 190 – 600 nm) of on-resin NCL cyclization of 
sequence 20 
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Due to the bulky benzyl moiety of the C-terminal phenylalanine, the ligation 
progressed slower than the cyclization of CSSLG 19. The ligation was unable to 
completely suppress the hydrolysis, a small portion (29% of the cyclic product, 
LC-MS analysis calculated through integration of the UV chromatogram, Table 16, 
entry 42) of the linear precursor 20 was hydrolyzed (Figure 19). The isolated 
overall yield of CSSLF 20´ was 6%, which dropped around 40% in contrast to the 
cyclic product 19´. 
In order to eliminate the hydrolyzed by-product, the cyclization of 20 was carried 
out at 15 °C (Table 25, entry 43), despite the previous unsuccessful attempts at 
low temperature. With no exception, the on-resin NCL cyclization did not take 
place at 15 °C after 16 hours. Lowering of the pH value may not be a right 
solution either, because the low pH value only slows down the cyclization.[105] 
The promoters (MPAA or MESNa) were not considered to be used in the model 
studies for the particular reason, which was described before (section 3.2.6). All 
further on-resin studies were uniformly carried out under the exact conditions, 
which were applied for the on-resin cyclization of sequence 19 without any 
modification.  
3.3.3.1b On-resin NCL cyclization of sequence 22 
In the previous investigations, the consumption of the linear precursor on the 
resin was not monitored due to the immobilized nature of the starting material, so 
when the on-resin cyclization concludes was still unknown. In order to determine 
the real reaction duration, the formation of the cyclic product must be 
quantitatively tracked. Tryptophan has specific UV absorption because of the 
indole residue. When the tryptophan moiety is incorporated into the linear peptide 
precursor and after the formation of the cyclic product, the UV absorbance of the 
tryptophan in the solution could be measured by spectrophotometer thus the 
concentration change of the cyclic product could be monitored this way. 
In order to determine kinetic progression of the on-resin NCL cyclization, the 
sequence CSWLG 22 was prepared on the TentaGel NH2 resin.  
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3.3.3.1b (a) Quantitative quality assessment of the linear sequence 22 prior 
to the cyclization 
Scheme 102. The hydrolysis of the ester bond during Fmoc-SPPS 
After the SPPS, the loading of the sequence 22 on the resin was determined 
through Fmoc release UV assay and this was calculated as 48% overall yield of 
the linear precursor 22 prior to cyclization. This calculated overall yield indicated 
that the C-terminal peptide ester was not completely stable to the piperidine 
treatment (Scheme 35). A substantial amount of the ester bond was hydrolyzed 
for each coupling and the halfway finished linear peptide precursor was 
prematurely released in its peptide caboxylic acid form from the resin after each 
coupling. Fortunately, the freed hydroxyl group of the latent linker could unlikely 
form the new amide bond with any preceding amino acid under the TBTU / 
DIPEA activation and avoid the formation of a large number of products. Later on 
a test reaction was carried out, in which a random Fmoc protected amino acid 
was coupled twice to the linker through the TBTU / DIPEA activation (without 
DMAP). After the coupling the Fmoc release UV assay showed that only very few 
of the amino acids were successfully linked to the linker and this result validated 
the previous hypothesis. 
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3.3.3.1b (b) The on-resin NCL cyclization of 22 under the monitor of the 
spectrophotometer 
 
Scheme 103. The on-resin cyclization of 22 
After the pre-cyclization investigation, the resin bearing the linear precursor 22 
was swollen in the buffer mixture under the previous conditions. The UV 
absorbance of the formed cyclic product 22´ in the solution was recorded for 32 
hours by spectrophotometer at wavelength of 280 nm. After the recording, 
according to the Lambert-Beer law the concentration of the cyclic product 22´ 
was calculated from the recorded UV absorbance: 
         
               
        -1   -1                                 
                       
                                       
The ε of the tryptophan is 5500 L·mol-1·cm-1 at 280 nm.  
With the calculated dates, the kinetic diagram of the on-resin NCL cyclization was 
hereby created. 
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Figure 24. The kinetic diagram of the NCL cyclization 
The kinetic diagram (Figure 24) showed that the on-resin cyclization of 22 
progressed erratically within the first 10 hours, then the concentration elevation 
slowed down and after approximately 24 hours the cyclization completely ceased. 
In the old buffer mixture the reductant TECP after 36 hours might be wore out 
due to the oxidization and lost its reactivity, after the reaction the old buffer 
mixture containing the cyclic product 22´ was drained and the freshly prepared 
buffer mixture containing 10 mM TCEP was then added to the reaction vessel to 
ensure no unreacted linear precursor remains on the resin. In the fresh prepared 
buffer solution, the resin was swollen for additional 16 hours and after the 
reaction only very weak UV absorbance of the solution was measured by the 
spectrophotometer. This indicated that in the fresh buffer solution no more cyclic 
product was formed and the on-resin cyclization of the sequence 22 has already 
concluded within the first 24 hours thus the prolonged reaction time was 
unnecessary. The LC-MS analysis showed that under previous conditions the on-
resin cyclization of 22 has achieved a very similar result as the sequence 20, 
again a small part of the linear precursor was hydrolyzed (29% of the cyclic 
product, LC-MS, calculated through integration of the UV chromatogram, Figure 
25). 
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Figure 25. LC-MS analysis (UV: 190 – 600 nm) of the on-resin NCL cyclization of 
the sequence 22 
After the cyclization of 22, the concentration of the cyclic product 22´ regardless 
of the existence of the hydrolyzed by-product was calculated from the UV 
absorbance and resulted in a concentration of 0.1787 mmol L-1. In 5 mL buffer 
mixture, the theoretic amount of the cyclic product 22´ contained in the buffer 
mixture was: 
          
    
 
              
 
   
           
After the isolation, 0.33 mg cyclic product 22´ was recovered. This figure 
indicated that roughly 34% of the cyclic product 22´ was lost during the HPLC 
purification. The final isolated overall yield was 6%, which suggested that out of 8 
linear precursors on the resin only one has been successfully cyclized and 
isolated. (Comparison of the overall yields before and after the cyclization. 48%:6% 
≈ 8:1)  
3.3.3.1b (c) The attempt to improve the yield on ultrasound bath 
As described in the previous chapter, the TentaGel resin could be only limited 
swollen in the aqueous medium and this is presumably the reason, why in the 
previous experiments all products were isolated in poor yields. When this resin 
was insufficient swollen, the surface of the polymer might still entangle with each 
other and a large amount of linear precursors loaded on the resin was not 
allowed to react. If the entangled polymer surface could be unscrewed by 
ultrasound, the chained linear precursor might be liberated and will participate in 
NCL cyclization. The linear sequence 22 was again allowed to be cyclized on the 
resin but this time the reaction vessel was placed in an ultrasound bath. The 
reaction vessel was kept in the ultrasound bath for eight hours and the warm 
water in the ultrasound bath, which was caused by the ultrasound effect, was 
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replaced by cold water each 20 min. The UV absorbance of the buffer mixture 
was monitored by spectrophotometer: under the effect of ultrasound, the UV 
absorbance rose erratically in the first two hours and after 8 hours the reaction 
concluded Sadly the LC-MS analysis of the buffer mixture showed that the linear 
sequence 22 or the resin was completely destroyed by ultrasound and resulted in 
a large number of fragments, therefore, no cyclic product 22´ was isolated 
afterwards. The UV absorption of the buffer solution was not caused by the cyclic 
product 22´ but by these fragments, which contain tryptophan moiety.  
3.3.3.1b (d) The attempt to improve the yield on the PEGA resin 
 
Scheme 104. The failed Fmoc-SPPS on the PEGA resin  
Since the NCL cyclization on the TentaGel NH2 resin always results in the poor 
yield, the PEGA resin, which has excellent water swelling ability,[113][118] was 
chosen as the solid phase for the on-resin NCL cyclization investigation. In this 
case study, the PEGA NH2 resin was used to synthesize the sequence 22. The 
PEGA NH2 resin is basically the PEGA backbone polymer with the NH2 handle, 
the latent thioester linker 12 was anchored onto the PEGA resin through a stabile 
amide bond. The loading of the linker 12 onto the PEGA resin was as good as on 
the TentaGel NH2 resin judged by the Kaiser test and the TBDMS group was 
then removed overnight by TBAF solution followed by the coupling of Fmoc-Gly-
OH. The Fmoc release UV assay showed that in comparison with previous 
experiments the coupling of Fmoc-Gly-OH on the PEGA NH2 resin achieved a 
comparable loading. Unfortunately the PEGA polymer was too fragile to resist the 
external mechanical force, when the coupling was carried out with slightest 
stirring, only after first two steps the resin beads were completely “grinded” thus 
became very muddy and jammed the filter of the syringe. Under this 
circumstance, assemble of the further amino acids through the batch–flow 
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through process was no more possible. This plan was thereafter abandoned and 
no further experiments on this basis were attempted.  
3.3.3.1c On-resin NCL cyclization of sequence CAALG 24 
Since none of these previous experiments had successfully improved the yield, 
no more efforts to improve the yield would be made, instead the further 
experiments focused on the investigation of the NCL cyclization of the different 
model sequences. So far the model sequences CSSLG 19, CSSLF 20 and 
CSWLG 22 have been investigated and based on these initial studies the NCL 
cyclization was determined to be strongly affected by ligation partner and side 
chains. Among three sequences only the sequence CSSLG 19 could achieve a 
satisfactory NCL cyclization, otherwise the cyclization of both CSSLF 20 and 
CSWLG 22 led to the hydrolyzed product in different degrees. In the case of the 
sequence 20, the additional benzyl residue at the ligation site disturbed the NCL 
cyclization and resulted in a 30% yield decline in contrast to the CSSLG 19. In 
the case of the sequence CSWLG 22, a serine in the middle of the sequence 19 
was replaced by tryptophan and this modification also caused around 30% 
reduction of the isolated yield. According to these preliminary results, the 
outcome of the on-resin NCL cyclization might be forecasted like follows: the NCL 
cyclization of the slim linear peptides may progress faster and results in better 
yield than the bulky peptide sequences. In order to validate this prediction, the 
on-resin NCL cyclization of the sequence CAALG 24 was tested. Serines of the 
previous sequence CSSLG 19 were replaced by alanines and thus the resulted 
sequence 24 is more slim than 19. Therefore, this new sequence was expected 
to achieve the same or even better yield than the sequence CSSLG 19 did. 
The resin loaded with sequence CAALG 24 was allowed to be cyclized for 24 
hours under the established conditions, but after the reaction, the isolated overall 
yield was only 5%. 
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Scheme 105. The on-resin cyclization of CAALG 24 
In order to ensure that this result was not caused by accident, the same 
experiment was carried again and it resulted in a similar isolated yield. Opposite 
to the prediction, the sequence 24 merely achieved the half of the isolated yield 
of the cyclic CSSLG 19´. This result could be rationalized by this: based on the 
theoretically estimation, the sequence CAALG 19 is highly hydrophobic. In this 
study, despite the NCL was conducted on the resin, the actual NCL cyclization 
takes place only in solution phase. The linear peptide precursor immobilized on 
the resin should possess proper water affinity, otherwise in the case of the 
sequence 24, the linear sequence could not be “dissolved” in the buffer solution 
and certainly the NCL cyclization could not progress properly. In order to increase 
the solubility of the sequence CAALG 24 in the buffer mixture, the cyclization was 
then carried out in the buffer mixture containing 50% DMF. After isolation, the 
yield of the recovered cyclic product from this buffer mixture was indifferent from 
the early attempt.  
Based on this fact, aside from the bulky peptide sequences, the highly 
hydrophobic sequences are considered to be less favorable for the on-resin NCL 
cyclization as well. 
3.3.3.2 Investigation of the on-resin NCL cyclization of six-membered 
peptides 
After the studies of the on-resin cyclization of the five-membered peptides, the 
investigations of two hexapeptides, one heptapeptide and one octapeptide, from 
which the model sequences CSLLFG 25, CSWLFG 26 and CAASSLG 27 were 
designed by simple elongation of the previous model sequences, were conducted 
(Scheme 106).  
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Scheme 106. The on-resin cyclization of the 25 and 26 
The sequence 25, 26 and 27 all carry the C-terminal glycine, which is ideal for the 
NCL cyclization according to the previous results, besides the six-membered 
sequence 25 and 26 theoretically might cause less ring strain during the ring 
closure thus they were ideal models for the on-resin NCL cyclization study. 
However with an additional phenylalanine, the cyclization quality of the sequence 
CSSLFG 25 could not catch up with the CSSLG 19, though 5% overall yield was 
still comparable with the sequence CSSLF 20. The additional benzyl moiety 
slowed down the cyclization and allowed the formation of the hydrolyzed by-
product (32% of the cyclic product, LC-MS, calculated through integration of the 
UV chromatogram, Figure 26). In the case of sequence CSWLFG 26, with 
increasing number of the bulky side chain, the NCL cyclization was further 
obstructed, as a result more linear precursor was hydrolyzed (52% of the cyclic 
product, LC-MS calculated through integration of the UV chromatogram, Figure 
21) and the overall yield (3%) has dropped by around 40% in comparison with 
CSLLFG 25.  
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Figure 26. LC-MS analysis (UV: 190 – 600 nm) of on-resin NCL cyclization of 
sequence 25 and 26  
3.3.3.3 Investigation of the on-resin NCL cyclization of seven-membered 
peptide 27 
 
Scheme 107. The on-resin cyclization of CAASSLG 27 
The heptapeptide CAASSLG 27 carries no bulky side chains and it is predictably 
hydrophilic, so it was expected to achieve good result. However, the NCL 
cyclization of 27 achieved the worst yield (1%) so far. This poor yield might not be 
caused only by NCL cyclization itself but also by Fmoc-SPPS. In the previous 
experiment (section 3.3.2) the ester bond, which links the main sequence and the 
linker 12, was found not highly stable upon the piperidine treatment, the ester 
bond was partially hydrolyzed when each time piperidine was introduced, the 
synthesis of sequence CAASSLG 27 needed two additional coupling steps than 
the synthesis of pentapeptide 19, 20 and 22, thus the ester bond was longer 
exposed to piperdine and consequentially more ester bond was hydrolyzed. This 
led to a larger loss of the linear precursor prior to the cyclization and thus the final 
yield was worse. Besides with increasing size of the peptide sequence, the head-
to-tail NCL cyclization became more difficult to be achieved than previous 
experiments.  
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3.3.3.4 Investigation of the on-resin NCL cyclization of eight-membered 
peptide 28 
At the end of this work, the feasibility of NCL cyclization of the octapeptide 28 
was examined. 
Scheme 108. The on-resin cyclization of CWWG(Abu)SGA 28 
The octapepeide CWWG(Abu)SGA 28 was an argyrin B linear precursor 
analogous , which carries some features of the argyrin B linear precursor. After 
24 hours the cyclic product 28´ was clearly identified by LC-MS (Figure 27), but 
after HPLC purification no considerable amount of the cyclic product 28´ was 
obtained. The overall yield was below 1%, the cyclic product 28´ was only 
obtainable as the trace. The poor result might be explained by the same reasons, 
which caused the poor yield of the cyclic CAASSLG 27´. 
 
Figure 27. LC-MS identification of cyclic product 28´ 
In order to verify this explanation, the linear precursor 28 was synthesized on the 
TentaGel S RAM resin and. after cleavage, the desired linear sequence 
CWWG(Abu)SGA 28 was identified only as a minor product by LC-MS (Table 26, 
entry 44). This means that after eight coupling steps, a large number of the ester 
bonds were hydrolyzed and thus only few linear precursor CWWG(Abu)SGA 28 
was still attached to the resin. For comparison the backbone sequence 
CWWG(Abu)SGA without the latent thioester linker 29 (Figure 23) was generated 
through the standard Fmoc-SPPS on the TentaGel S RAM resin. Surprisingly 
Results and discussion  133 
 
after the cleavage, the backbone sequence CWWG(Abu)SGA without the latent 
thioester linker 29 was identified as the main product in LC-MS analysis (Table 
26, entry 45). 
Table 26.  
entry compound result after cleavage 
44 28 minor product 
45 29 main product 
 
This comparison reflected the fact that the backbone model sequences were fully 
compatible with the Fmoc-SPPS, however with the additional latent thioester 
linker the immobilized sequence did not well survive the Fmoc-SPPS. 
Nonetheless the NCL cyclization of the sequence CWWG(Abu)SGA 28 was 
proven feasible, except the very low isolated yield. 
 
Figure 28. Sequence CWWG(Abu)SGA with linker 28 and the sequence 
CWWG(Abu)SGA without linker 29 
Summary and outlook  134 
 
4. Summary and outlook 
In this work, the on-resin NCL cyclization of a few model sequences has been 
investigated in every respect. By using the latent thioester linker strategy the 
linear precursor was generated through the standard Fmoc-SPPS protocol and 
the NCL cyclization was directly carried out on the resin. 
In the beginning, the designed latent thioester linker 4 was synthesized 
straightforward, but the initial idea of the formation of the depsipeptide building 
block 6 in solution phase from the latent thioester linker 4 and Fmoc-Ile-OH failed. 
Alternatively the latent thioester linker 4 was directly immobilized to the resin and 
the first amino acid was linked onto it via an ester bond. The preliminary test 
showed that the coupling of the latent thioester linker 4 onto the resin was not 
successful by charging equimolar amount of the linker 4, however utilization of 
large amount of the linker 4 might potentially cause the esterification between 
themselves. So the free hydroxyl group of the linker 4 was then protected by 
TBDMS silyl ether to construct the new latent thioester linker 12. The coupling of 
the linker 12 was proven efficient, when 3.5 equivalent amount of the linker 12 
was charged.  
The latent thioester linker 12 can be readily synthesized form bromopyruvat 1 in 
four steps in 32% overall yield. The synthetic route could be up-scaled trouble-
free, but the linker 12 was its highly sensitive. It is vulnerable under almost all 
conditions, so it could not be synthesized in a large amount and stored, but rather 
be freshly generated from its stable precursor prior to the coupling. After the 
latent thioester linker 12 was successfully synthesized and coupled onto the resin, 
the model sequence 14 and 16 was generated on the resin through the Fmoc-
SPPS and cleaved. The NCL cyclization was firstly examined in solution phase to 
determine the optimal conditions, which could be applied directly or with slight 
modification for the on-resin NCL cyclization. All attempts with 14 and 16 were 
failed, despite all relevant factors (temperature, pH, prompter and buffer mixture) 
have been changed, modified and tested. Due to the bulky geometry of the C-
terminal isoleucine at the junction point, the NCL cyclization was hardly 
applicable on these model sequences. This result was also found to be in 
consistence with Dawson´s report.[75] 
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Nevertheless when two simpler model sequences 19 and 20 were tested in the 
solution and at low temperature (0 – 5°C), the NCL cyclization was found well 
applicable. By testing these two sequences in solution phase the initial ideal 
conditions were determined. 
Based on these established conditions, the on-resin NCL cyclization of these 
model sequences was then performed. The sequences immobilized on the resin 
were less reactive, therefore the NCL cyclization could only take place at RT in 
contrast to the cyclization in solution phase. The ligation rate on the resin was 
slower than in the solution, so the hydrolysis could not be suppressed entirely in 
most of the cases. Eight model sequences (CSSLG 19, CSSLF 20, CSWLG 24, 
CAALG 22, CSLLFG 25, CSWLFG 26, CAASSLG 27 and CWWG(Abu)SGA) 28 
were investigated. During the experiments the ester bond linkage was found to 
be unstable during the Fmoc-SPPS, after each coupling step, a considerable 
amount of linear sequence went lost. The longer the sequence is, the bigger the 
loss will be. The general poor yield reflects this problem. Aside from the 
substance loss, which was caused by Fmoc-SPPS, the on-resin NCL cyclization 
itself was affected by various factors (Table 27).  
Table 27. Importance of the different factors 
factor importance 
ligation partner decisive 
side-chain essential  
sequence size essential 
temperature semi-essential 
reaction duration semi-essential 
buffer mixture non-essential 
pH value non-essential 
resin not confirmed 
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The decisive factor, which dominates the ligation, is the geometry of the ligation 
partner. The more bulky the ligation partner is, the slower the ligation progresses. 
Second to the ligation partner the side-chain geometry as well as the sequence 
size also significantly affected NCL cyclization. The bulky side chains could block 
the head-to-tail interaction and slow down the ligation rate. The cyclization of the 
large sequences met stronger ring-strain resistance than the shorter sequence. 
Temperature is an important factor, it should be kept at ambient temperature at 
all times, below or above RT only leads the reaction to the wrong way. The 
preliminary experiment confirmed that the complete on-resin cyclization required 
up to 24 hours, prolonged reaction time is unnecessary The NCL ligation could 
be performed in a relatively wide range of pH values (6.5 – 7.5), some slight 
alternation didn´t change the outcome of the NCL cyclization and the composition 
of the buffer mixture only played a subordinate roll throughout the entire NCL 
cyclization study.  
The model studies showed that the rapid establishment of a library of the cyclic 
peptides by using this new on-resin strategy was possible but with some 
limitations. The isolated overall yield of all these model sequences were generally 
poor, but as the prove-of-concept experiments, further optimization are 
definitively required.  
So far, no promoter (MPAA, MESNa) has been used in large excess for the on-
resin studies in order to avoid complexity at the HPLC purification, but maybe 
equimolar amount or slight excess amount of promoter already has the ability to 
accelerate the NCL without disturbing the HPLC purification. This should be 
tested in the further investigation. The denaturant 6 M guanidium chloride was 
generally not used because of its side effect, which reduces the ligation rate, but 
in the case of cyclization of the longer sequence (heptamer, octamer), which 
might begin to construct the secondary structure and hinder the cyclization, the 
influence of additional denaturant on the cyclization should be tested. Moreover 
the on-resin study was only performed on the TentaGel resin, which is a PS-POE 
polymer and has moderate swelling properties in the aqueous medium. The 
investigation of the sequence CSWLG 22 has showed that only around 12% of all 
immobilized linear precursors were cyclized from the TentaGel resin.  
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The PEGA resin with excellent swelling properties was also test, but the 
synthesis of the linear precursor on the PEGA resin was unsuccessful because of 
high fragility of the PEGA resin, if the PEGA resin could be stirred by nitrogen 
vortex instead of the magnetic stirrer bar, the practical problems may be 
overcome and the on-resin NCL cyclization on the PEGA resin might be 
examined. The CLEAR resin was reported to have an excellent performance for 
the on-resin NCL, so this resin should be tested as well.  
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Experimental section 
Part I. Development of synthetic strategies for libraries of    
heterocyclic and bicyclic inhibitors of Cdc25A 
 
1. General details 
 
Reactions and materials 
All reactions were carried out at RT (unless otherwise specified) without inert gas 
atmosphere 
All solvent and reagents used were obtained from Sigma-Aldrich, Acros, Fluka, 
TCI (Tokyo Chemical industry Co.,Ltd), or J.T Baker and were used as received 
without further purification. 
Thin layer and flash chromatography 
Analytic TLC was run on aluminium sheets coated with silica gel 60 F254 (Merck 
KGaA). The analysis of the TLC plate was conducted under ultraviolet lamp (λ = 
254 nm) and consecutively the TLC plate was dipped into color reagents 
(potassium permanganate or Cer(IV) reagent) to visualize the spots.  
The flash chromatography was carried out under slight pressure on the flash 
chromatography column loaded with silica gel 60 (Merck, 40–60 μm, 60 Å). 
Nuclear magnetic resonance and mass spectrometry 
Proton nuclear magnetic resonances (1H NMR) and carbon nuclear magnetic 
resonances (13C NMR) were recorded on a 300 Hz Brucker DPX300 at 298 K, 
and the chemical shifts are reported in parts per million (δ) from an internal 
standard of residual chloroform (7.26 ppm, 77.2 ppm), or methanol (3.31 ppm, 
4.78 ppm, 49.0 ppm).  
Proton NMR signals multiplicity is reported as follows: s = singlet, d = doublet, t = 
triplet, q = quartett, m = multiplet, b = broad. Carbon NMR signals multiplicity is 
reported as: s = singlet, d = doublet, t = triplet, q = quartett.  
Experimental section  139 
 
High-resolution mass spectra (HRMS) were measured on a Brucker maXis HD by 
using the electron spray ionization (ESI) mode, from the department of the 
chemical biology, Helmholtz Centre for Infection Research, Braunschweig, 
Germany. 
 
Most of the synthesis has only been performed once thus all yields reported are 
not optimized. 
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2. Synthesis of the lead structure 13 and its amide derivatives 20 and 21 
through Hantzsch method 
2.1. 1,4-dibromobutane-2,3-dione (10) 
 
2.58 g 2,3-Butanedione (0.03 mmoL) was dissolved in 5.2 mL chloroform in a 
round flask, 3.2 mL bromine (10 g, 0.06 mmoL) was dissolved in 5.2 mL 
chloroform and added dropwise at RT over 2.5 hours to the round flask. After the 
introduction, the reaction was heated at 45 °C until no more gas emerged. Then 
the mixture was cooled to the RT and the round flask was cooled in the 
refrigerator overnight. The precipitation was filtered and washed 3 times with 
chloroform (3 × 10 mL). Finally, the raw product was subject to the 
recrystallization from toluene to yield a pale yellow solid. (776 mg, 11%) 
Rf = 0.7 (PE:EtOAc = 8 :1) 
1H NMR (300 MHz, CDCl3): δH 4.32 (s, 4H, CH2) 
13C NMR (75 MHz, CDCl3): δC 188.0 (q, 2C, CO), 28.4 (d, 2C, CH2). 
The NMR data is in consistence with that reported in literature.[46] 
 
2.2 Thiophene-2-carbothioamide (6) 
 
500 mg thiophene (5.94 mmoL) was charged into a brown round flask and 
dissolved carefully at 0 °C with 9 mL methanesulfonic acid. Then this solution 
was slowly added into a second round flask, which was already loaded with 662 
mg potassium thiocyanate (6.83 mmoL) at 0 °C. After the addition the mixture 
was stirred at RT for 4.5 hours. After the starting material was completely 
consumed (TLC, DCM:MeOH = 20:1), the mixture was poured in ice water and 
the precipitation was then filtered. The precipitation was washed with ice water a 
few times afterwards and the aqueous layer was then extracted three times with 
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DCM (3 × 20 mL), then the organic layer was dried over sodium sulfate and the 
DCM was remove through rotation evaporator and resulted in a brown crystal. 
This brown crystal was then combined with other precipitation and purified 
through the flash chromatography (DCM:MeOH = 40:1) and yield a pale brown 
crystal. (409 mg, 48%)  
Rf = 0.57 (DCM:MeOH = 20 :1). 
1H NMR (300 MHz, CDCl3): δH 7.52 (d, J = 3.83 Hz, 1H, thiophene), 7.49 (d, J = 
3.83 Hz , 1H, thiophene), 7.07 (dd, J = 4.23, 5.24, 1H, thiophene). 
13C NMR (75 MHz, CDCl3): δC 192.1 (q, SC), 144.7 (q, thiophene), 133.9 (t, 
thiophene), 128.3 (t, thiophene), 126.9 (t, thiophene). 
The 13C NMR was identical with that reported in literature.[44] 
 
2.3. 2-bromo-1-(2-(thiophen-2-yl)thiazol-4-yl)ethanone (2) 
 
100 mg thiophene-2-carbothioamide (2) (0.7 mmoL) was dissolved in a flash with 
2.2 mL abs. ethanol. 510 mg 1,4-dibromobutane-2,3-dione (10) was dissolved in 
10 mL abs. ethanol and slowly added to the flask charged with the thiophene-2-
carbothioamide (2). The mixture was then allowed to be stirred at first for 1 hour 
at RT and followed by 3 hours stir under reflux. The reaction was monitored by 
the TLC (DCM :PE = 3 :1) and after the starting materials were completely gone 
the solvent was simply removed by evaporation. The solid was then added to 30 
mL saturated sodium hydrogen carbonate solution and extracted 3 times with 
chloroform (3 × 20 mL). The organic layer was dried over sodium sulfate and 
concentrated. The raw product was then subject to the flash chromatography 
(PE:EtOAc = 20 :1) to yield a pale white crystal. (99 mg, 49%) 
Rf = 0.16 (PE:EtOAc = 20 :1). 
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1H NMR (300 MHz, CDCl3): δH 8.17 (s, 1H, thiazole), 7.56 (d, J = 3.7 Hz, 1H, 
thiophene), 7.46 (d, J = 4.78 Hz, 1H, thiophene), 7.10 (dd, J = 3.78, 5.43 Hz, 1H, 
thiophene), 4.72 (s, 2H, CH2).  
13C NMR (75 MHz, CDCl3): δC 185.9 (q, CO), 162.2 (q, thiazole), 152.3 (q, 
thiazole), 136.1 (q, thiophene), 129.0 (t, thiophene), 128.1 (t, thiophene), 127.8 (t, 
thiophene), 125.9 (t, thiazole), 33.7 (d, CH2). 
2.4 (Z)-ethyl 3-(((tetrahydrofuran-2-yl)methyl)amino)but-2-enoate (12) 
 
1 g ethyl 3-oxobutanoate (11) (3.8 mmoL) and 931.5 mg (tetrahydrofuran-2-
yl)methanamine (4) (4.6 mmoL) were mixed in a round flask and was allowed to 
react for 3 hours at RT and was monitored by the TLC (PE:EE = 4 :1). After the 
reaction, the raw product was purified by the flash chromatography (PE:EtOAc = 
8 :1) to yield 667 mg clear oily substance (82%) 
Rf = 0.44 (PE:EtOAc = 8:1). 
1H NMR (300 MHz, CDCl3): δH 4.44 (s, 1H, enamine), 4.08 (q, J = 7.49 Hz, 2H, 
CH2, COOEt), 3,98 (m, 1H, THF), 3.88 (q, J = 7.49 Hz, 1H, THF), 3.76 (q, J = 
7.93 Hz, 1H, CH2), 3.38 -3.20 (m, 2H, CH2 and THF), 2.05 – 1.98 (m, 2H, THF), 
1.92 (s, 3H, CH3, COOEt), 1.94 -1,85 (m, 1H, THF), 1.67 – 1.57 (m, 1H, THF). 
13C NMR (75 MHz, CDCl3): δC 170.5 (q, CO), 161.7 (q, alkene), 82.6 (t, alkene), 
78.0 (t, THF), 68.4 (d, THF), 58.2 (d, CH2, OEt), 46.9 (d, CH2), 28.8 (d, THF), 
25.8 (d, THF), 19.5 (s, CH3, Me), 14.6 (s, CH3, OEt). 
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2.5 Ethyl 2-methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-
yl)thiazol-4-yl)-1H-pyrrole-3-carboxylate (13) 
 
 
46.4 mg 2-bromo-1-(2-(thiophen-2-yl)thiazol-4-yl)ethanone (2) (0.16 mmoL) was 
dissolve with 0.75 mL dimethoxyethane (DME) in a round flask. 58.4 mg (Z)-ethyl 
3-(((tetrahydrofuran-2-yl)methyl)amino)but-2-enoate (12) (0.26 mmoL) was 
dissolved in 0.75 mL DME and slowly added to the round flask. The mixture was 
allowed to react overnight under reflux (85 °C). After 12 hours, the 2-bromo-1-(2-
(thiophen-2-yl)thiazol-4-yl)ethanone (2) was completely consumed as judged by 
the TLC (PE:EtOAc = 8:1) and the mixture was poured into 30 mL saturated 
sodium hydrogen carbonate solution. The aqueous layer was then extracted 3 
times with ethyl acetate (3 × 15 mL) and the combined organic layer was washed 
3 times with saturated brine solution (3 × 30 mL) and dried over sodium sulfate. 
Finally, the solvent was removed and the raw product was then subjected to the 
flash chromatography (PE:EE = 15 :1) to yield a withe crystal. (26.5 mg, 43%) 
Rf = 0.25 (PE:EtOAc = 15:1). 
1H NMR (300 MHz, CDCl3): δH 7.5 (d, J = .3.2 Hz, thiophene 1H), 7.37 (d, J = 
5.42 Hz, thiophene, 1H), 7.2 (s, thiazole,1H), 7.07 (t, thiophene 1H), 6.85 (s, 
pyrrole,1H), 4.63 (dd, J = 2.46 Hz, 13.3 Hz, 1H, THF), 4.27 (q, J = 7,20 Hz, 2H, 
CH2, OEt), 4.32 – 4.21 (m, 2H, CH2), 3.81 – 3.62 (m, THF 2H), 2.65 (s, CH3 3H), 
2.02 – 1.92 (m, THF, 1H), 1.86 – 1.75 (m, THF, 2H), 1.59 – 1.48 (m, THF,1H) 
1.34 (t, J = 7.20 Hz, 3H, CH3, OEt).  
13C NMR (75 MHz, CDCl3): δC 165.4 (q, CO), 160.9 (q, thiazole), 149.0 (q, 
thiazole), 138.6 (q, thiophene), 137.5 (q, pyrrole), 128.9 (t, thiophene), 126.6 (t, 
thiophene), 126.4 (t, thiophene), 126.3 (q, pyrrole), 113.2 (t, thiazole), 112.1 (q, 
pyrrole), 111.1 (t, pyrrole), 79.4 (t, THF), 68.4 (d, THF), 59.7 (d, CH2, OEt), 49.1 
(d, CH2), 29.4 (d, THF), 26.0 (d, THF), 15.0 (s, CH3, OEt), 12.2 (s, CH3).  
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2.6 2-methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-
yl)-1H-pyrrole-3-carboxylic acid (18) 
 
95.9 mg ethyl 2-methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-
yl)thiazol-4-yl)-1H-pyrrole-3-carboxylate (13) (0.24 mmoL) was dissolved in 0.7 
mL ethanol and 776 μL 10% KOH ethanol solution (1.2 mmoL) was introduced to 
this solution. The mixture was allowed to react under reflux overnight. After 12 
hours, the starting material was gone as judged by the TLC (DCM:EtOAc = 20:1 
with 0.2% acetic acid), then the mixture was neutralized with saturated 
ammonium chloride solution. The aqueous layer was then extracted 3 times with 
chloroform (3 × 10 mL) and the combined organic layer was dried over sodium 
sulfate. The solvent was subsequently removed and the raw product was then 
deployed without purification for the next conversion.  
Rf = 0.39 (DCM:EtOAc = 20:1 with 0.2% acetic acid). 
2.7 2-methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-
yl)-1H-pyrrole-3-carboxamide (19) 
 
44.1 mg raw starting material 2-methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-
(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-3-carboxylic acid (18) (0.12 mmoL), 90.3 
mg EDC·HCl (0.48 mmoL) and 28.8 mg DMAP (0.24 mmoL) were loaded in a 
round flask and dissolved under inert gas in 1.6 mL anhydrous DCM. 700 μL NH3 
solution 0.5 M in dioxane (1.4 mmoL) was then introduced to the flask and the 
mixture was stirred at RT for 6 hours. After the starting material was completely 
consumed (TLC, (DCM:EtOAc = 20 :1 with 0.1% acetic acid) the mixture was 
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diluted with 3 mL DCM. The organic layer was washed by the 1 M HCl solution 
twice (2 × 5 mL) and followed by 10 mL saturated sodium hydrogen carbonate 
solution. Afterwards, the organic layer was dried over sodium sulfate and 
concentrated in vacuo. The raw product was purified by the flash chromatography 
(DCM:EtOAc = 15:1) to yield a white crystal. (11.5 mg, 26% over two steps) 
Rf = 0.42 (DCM:EtOAc = 15 :1). 
1H NMR (300 MHz, CDCl3): δH 7.50 (d, J = 3.55 Hz, 1H, thiophene), 7.38 (d, J = 
4.98 Hz, 1H, thiophene), 7.23 (s, 1H, thiazole), 7.08 (t, 1H, thiophene), 6.90 (s, 
1H, pyrrole), 4.64 (d, J = 11.37 Hz, 2.46 Hz, 1H, THF), 4.33 – 4.20 (m, 2H, CH2), 
3.80 -3.68 (m, 2H, THF), 2.69 (s, 3H, Me), 2.03 – 1.95 (m, 1H, THF), 1..89 – 1.75 
(m, 2H, THF), 1.61 – 1.47 (m, 1H, THF). 
13C NMR (75 MHz, CDCl3): δC 161.2 (q, CO), 161.0 (q, thiazole), 148.6 (q, 
thiazole), 141.4 (q, thiophene), 137.5 (q, pyrrole), 128.0 (t, thiophene), 127.7 (t, 
thiophene) 126.8 (q, pyrrole), 126.5 (t, thiophene), 113.9 (t, thiazole), 111.7 (t, 
pyrrole), 111.3 (q, pyrrole), 78.9 (t, THF), 68.0 (d, THF), 49.0 (d, CH2), 29.1 (d, 
THF), 25.6 (d, THF), 12.1 (s, Me). 
HRMS m/z calcd for C18H20N3O2S2 [M + H]
+, 374.0991; found, 374.0988. 
2.8 N,2-dimethyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-
4-yl)-1H-pyrrole-3-carboxamide (20) 
 
53.3 mg raw starting material 2-methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-
(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-3-carboxylic acid (18) (0.14 mmoL), 109.1 
mg EDC·HCl (0.57 mmoL) and 35.5 mg DMAP (0.28 mmoL) were loaded in a 
round flask and dissolved under inert gas in 2 mL anhydrous DCM. 30.5 mg 
methylamine hydrogenchloride (0.21 mmoL) was then added to the flask and the 
mixure was allowed to be stirred at RT and monitored by the TLC (DCM:EtOAc = 
8 :1 with 0.1% acetic acid). After 24 hours the reaction was completed and the 
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mixture was diuted with 3 mL DCM. Then the organic layer was washed twice 
with 1 M HCl solution (2 × 5 mL) and followed by 10 mL saturated sodium 
hydrogen carbonate solution. The combined organic layer was dried over sodium 
sulfate and the solvent was removed The raw product was then subject to the 
flash chromatography (DCM:MeOH = 30 :1) to yield a white crystal. (14.5 mg, 
26.3% over two steps) 
Rf = 0.31 (DCM:MeOH = 30:1). 
1H NMR (300 MHz, CDCl3): δH 7.50 (d, J = 3.83 Hz, 1H, thiophene), 7.38 (d, J = 
5.03 Hz, 1H, thiophene,), 7.14 (s, 1H, thiazole,), 7.07 (dd, J = 3.87, 5.3, 1H, 
thiophene), 6.52 (s, 1H, pyrrole),5.76 (b, 1H, NH), 4.54 (dd, J = 3.23, 13.99 Hz, 
1H, CH, THF), 4.30 – 4.14 (m, 2H, CH2), 3.77 – 3.59 (m,, 2H, THF), 2.92 (d, J = 
4.78, 3H, NHCH3), 2.65 (s, 3H, Me), 2.03 – 1.89 (m,. 1H, THF), 1.87 – 1.74 (m, 
2H, THF), 1.59 – 1.45 (m, 1H, THF). 
13C NMR (75 MHz, CDCl3): δC 166.3 (q, CO), 160.7 (q, thiazole), 148.8 (q, 
thiazole), 137.3 (t, thiophene), 135.5 (t, thiophene), 126.2 (t, thiophene), 125.9 (q, 
pyrrole), 114.9 (q, pyrrole), 112.7 (t, thiazole), 107.4 (t, pyrrole), 78.7 (t, THF), 
67.7 (d, THF), 48.3 (d, CH2), 28.8 (d, THF), 25.9 (s, NHCH3), 25.3 (d, THF), 11.4 
(s, Me).  
HRMS m/z calcd for C19H22N3O2S2 [M + H]
+, 388.1148; found, 388.1149. 
 
2.9 N,N,2-trimethyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-
yl)thiazol-4-yl)-1H-pyrrole-3-carboxamide (21) 
 
This compound was prepared by using the same precedure of synthesis of the 
compound 20. 
Isolated substance: 12 mg, 21% over two steps. 
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Rf = 0.35 (DCM:MeOH = 20:1). 
1H NMR (300 MHz, CDCl3): δH 7.50 (d, J = 3.77 Hz, 1H, thiophene), 7.37 (d, J = 
5.09 Hz, 1H, thiophene), 7.13 (s, 1H, thiazole), 7.07 (dd, J = 3.77, 5.92 Hz, 1H, 
thiophene), 6.41 (s, 1H, pyrrole), 4.62 – 4.48 (m, 1H, CH, THF), 4.29 – 4.15 (m, 
2H, CH2), 3.80 – 3.61 (m, 2H, THF), 3.07 (s, 6H, CH3, Me2NH), 2.41 (s, 3h, Me), 
2.05 – 1.90 (m, 1H, THF), 1.87 – 1.72 (m, 2H, THF), 1.59 - 1,45 (m, 1H, THF).  
13C NMR (75 MHz, CDCl3): δC 168.8 (q, CO), 16.8 (q, thiazole), 149.3 (q, 
thiazole), 137.6 (q, thiophen), 133.2 (q, pyrrole), 127.9 (t, thiophene), 127.5 (t, 
thiophene), 126.3 (t, thiophene), 125.7 (q, pyrrole), 115.8 (q, pyrrole), 112.7 (t, 
thiazole), 109.3 (t, pyrrole), 79.2 (t, THF), 67.9 (d, THF), 48.7 (d, CH2), 29.1 (d, 
THF), 25.5 (d, THF), 11.7 (s, Me). 
HRMS m/z calcd for C20H24N3O2S2 [M + H]
+, 402.1304; found, 398.1308. 
3 Syntheses of N-substituted pyrrole derivatives through the Paar-Knorr 
pyrrole synthesis route 
3.1 Ethyl 2-acetyl-4-oxo-4-(2-(thiophen-2-yl)thiazol-4-yl)butanoate (14) 
 
22.5 mg sodium hydrid (60% dispersed in mineral oil) (0.56 mmoL) was washed 
twice under inert gas by pentane and dried in in vacuo. Dried sodium hydrid was 
then dispersed in 0.7 mL absolute THF. 90 μL ethyl 3-oxobutanoate (11) (0.47 
mmoL) was introduced to the sodium hydrid suspension at 0 °C and after 5 min., 
150 mg 2-bromo-1-(2-(thiophen-2-yl)thiazol-4-yl)ethanone (2) (0.52 mmoL in 1 
mL absolute THF) was added to this mixture. The mixture was then allowed to 
react at 0 °C for 10 min. and the reaction concluded as judged by the TLC 
(DCM:PE = 3:1). After the reaction, the mixture was poured to the phosphate 
buffer solution (pH = 7.4) and the aqueous layer was extracted 3 times with DCM 
(3 × 5 mL). Then the combined organic layer was wash twice with saturated brine 
solution (2 × 10 mL) and dried over sodium sulfate. The solvent was then 
removed and the raw product was then purified by the flash chromatography 
(DCM → DCM:EtOAc = 20 :1) to yield a white crystal. (66.8 mg, 42%) 
Experimental section  148 
 
Rf = 0.19 (DCM). 
1H NMR (300 MHz, CDCl3): δH 8.03 (s, 1H, thiazole), 8.03 (s, 1H, thiazole), 7.55 
(d, J = 3.42 Hz, 1H, thiophene), 7.44 (d, J = 4.79, 1H, thiophene), 7.09 (d, J = 
5.48 Hz, 1H, thiophene), 4.22 (q, J = 7.24 Hz, 2H, CH2, COOEt), 4.20 – 4.14, (m, 
1H, CH), 3.75 (dq, J = 50.44, 8.24 Hz, 2H, CH2), 2.41 (s, 3H, Me), 1.29 (t, J = 
7.49 Hz, 3H, CH3, COOEt). 
13C NMR (75 MHz, CDCl3): δC 202.3 (q, COMe), 192.1 (q, CO), 169.0 (q. CO, 
COOEt), 162.0 (q, thiazole), 154.2 (q, thiazole), 136.4 (q, thiophene), 128.7 (t, 
thiophene), 128.0 (t, thiophene), 127.6 (t, thiophene), 124.6 (t, thiazole), 61.7 (d, 
CH2, OEt), 53.9 (t, CH), 39.0 (d, CH2), 30.0 (s, CH3, Me), 14.1 (s, CH3, Oet).  
General procedure of generation of N-substituted pyrrole derivatives 
3.2 Ethyl 2-methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-
yl)thiazol-4-yl)-1H-pyrrole-3-carboxylate (13) 
 
29.6 mg ethyl 2-acetyl-4-oxo-4-(2-(thiophen-2-yl)thiazol-4-yl)butanoate (14) 
(0.088 mmoL) was dissolved in 0.8 mL absolute ethanol. 9 μL (tetrahydrofuran-2-
yl)methanamine (4) (0.088 mmoL) was added to this solution and followed by 1 
drop of acetic acid. The mixture was then stirred under reflux for 2 hours and 
monitored by the TLC (DCM:EEtOAc = 20:1). After the starting material was 
completely gone, the mixture was diluted with 5 mL ethyl acetate, and the organic 
layer was sequentially washed 10 mL with saturated sodium hydrogen carbonate 
solution and 10 mL water. Afterwards, the organic layer was dried over sodium 
sulfate and concentrated. The raw product was then subjected to the flash 
chromatography (DCM:EtOAc = 20 :1) to yield a white crystal. (13.7 mg, 38.9%) 
All analytic data of 13 made from Paar-Knorr method are identical to 13, which 
was made from previous method. 
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The compounds 15, 16, 51 – 58 were prepared by following the same procedure 
of synthesis of the compound 13. 
3.3 Ethyl 1-benzyl-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-3-
carboxylate (15) 
 
Isolated yield 54% 
Rf = 0.45 (DCM) 
1H NMR (300 MHz, CDCl3): δH 7.43 (d, J = 4.05 Hz, 1H, thiophene), 7.33 (d, J = 
5.39 Hz, 1H, thiophene), 7.29 – 7.18 (m, 3H, HAr), 7.09 (s, 1H, thiazole), 7.03 (dd, 
J = 4.05, 5.06 Hz, 1H, thiophene), 7.00 – 6.95 (m, 2H, HAr), 6.94 (s, 1H, pyrrole), 
5.59 (s, 2H, CH2), 4.30 (q, J = 6.38 Hz, 2H, CH2, OEt), 2.52 (s, 3H, Me), 1.37 (t, J 
= 8.10 Hz, 3H, CH3, OEt). 
13C NMR (75 MHz, CDCl3): δC 165.7 (q, CO), 161.3 (q, thiazole). 148.6 (q, 
thiazole), 138.3 (q, thiophene), 138.3 (q, CAr), 137.1 (q, pyrrole), 128.9 (t, 2C, CAr), 
128.0 (t, 2C, thiophene), 127.3 (q, pyrrole), 126.7 (t, thiophene), 126.4 (t, 2C, CAr), 
113.7 (t, thiazole), 112.8 (q, pyrrole), 111.3 (t, pyrrole), 59.8 (d, CH2, OEt), 48.6 
(d, CH2), 14.8 (s, CH3, OEt), 11.7 (s, Me). 
3.4 Ethyl 1-(3-fluoro-4-methylphenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-
yl)-1H-pyrrole-3-carboxylate (16) 
 
Isolated yield 70% 
Rf = 0.5 (DCM) 
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1H NMR (300 MHz, CDCl3): δH 7.40 (d, J = 3.52 Hz, 1H, thiophene), 7.33 (d, J = 
5.46 Hz, 1H, thiophene), 7.28 (t, J = 8.10 Hz, 1H, HAr), 7.18 (s, 1H, thiazole), 7.01 
(dd,J = 3.88, 5.29 Hz, 1H, thiophene), 6.99 – 6.93 (m, 2H, HAr), 6.24 (s, 1H, 
pyrrole), 4.32 (q, J = 7.05 Hz, 2H, CH2, OEt), 2.36 (s, 6H, Ar-Me and Me), 1.37 (t, 
J = 6.87 3H, CH3, OEt). 
13C NMR (75 MHz, CDCl3): δC 165.7 (q, CO), 162.6 (q, CAr), 160.6 (q, thiazole), 
160.1 (q, CAr), 147.7 (q, thiazole) 138.9 (q, thiophene), 137.6 (q, pyrrole), 137.4 
(q, d, J = 10.53 Hz, CAr, F coupling), 132.2 (t, d, J = 6.70 Hz, CAr, F coupling), 
128.6 (q, pyrrole), 128.0 (t, thiophene), 128.0 (t, thiophene), 126.7 (t, thiophene), 
126.5 (q, CAr), 126.3 (q, CAr), 124.5 (t, CAr), 116.2 (t, CAr), 116.0 (t, CAr), 113.2 (q, 
Pyrrole), 111.8 (t, thiazole), 111.2 (t. pyrrole), 59.9 (d, CH2, OEt), 14.8 (s, CH3, 
OEt), 14.8 (s, CH3, Ar-Me), 12.1 (s, Me).  
3.5 Ethyl 1-(2-fluorophenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxylate (51) 
 
Isolated yield 82% 
Rf = 0.93 (DCM). 
1H NMR (300 MHz, CDCl3): δH 7.57 – 7.51 (m, 1H, HAr), 7.43 (d, J = 2.54 Hz, 1H, 
thiophene), 7.38 (d, J = 3.56 Hz, 1H, thiophene), 7.37 – 7.28 (m , 3H, HAr), 7.25 
(s, 1H, thiazole), 7.06 (dd, J = 3.56, 5.11 Hz, 1H, thiophene), 6.55 (s, 1H, pyrrole), 
4.40 (q, J = 7.12 Hz, 2H, CH2, OEt), 2.44 (s, 3H, Me), 1.46 (t, J = 7.12 Hz, CH3, 
OEt). 
13C NMR (75 MHz, CDCl3): δC 165.7 (q, CO), 160.8 (q, thiazole), 160.6 (q, CAr), 
157.3 (q, CAr), 147.8 (q, thiazole), 139.3 (q, thiophene), 137.7 (q, CAr), 131.3 (t, d, 
J = 7.86 Hz, CAr, F coupling), 131.1 (t, CAr), 128.6 (q, pyrrole), 128.1 (t, thiophene), 
128.0 (t, thiophene), 126.8 (t, thiophene), 126.6 (q, pyrrole), 125.0 (t, d, J = 4.05 
Hz, CAr, F coupling), 117.2 (t, d, J = 19.70 Hz, CAr, F coupling), 113.6 (q, pyrrole), 
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111.8 (t, thiazole), 111.3 (t, pyrrole), 60.0 (d, CH2, OEt), 15.0 (s, CH3, OEt), 12.2 
(s, Me).  
 
3.6 Ethyl 1-(3-fluorophenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxylate (52) 
 
Isolated yield 86% 
Rf = 0.67 (DCM). 
1H NMR (300 MHz, CDCl3): δH 7.54 (q, J = 7.74 Hz, 1H, HAr), 7.48 (d, J = 5.24 Hz, 
1H, Thiophene), 7.42 (d, J = 5.24 Hz, 1H, Thiophene), 7.28 (td, J = 8.73, 2.25 Hz, 
1H, HAr), 7.18 – 7.16 (m, 1H, HAr), 7.16 – 7.13 (m, 1H, HAr), 7.11 (s, 1H, Thiazole), 
7.10 (dd, J = 4.24, 5.24 Hz, 1H, Thiophene), 6.43 (s, 1H, Pyrrole), 4.41 (q, J = 
7.24 Hz, 2H, CH2, OEt), 2.46 (s, 3H, Me), 1.47 (t, J = 6.99 Hz, 3H, CH3, OEt). 
13C NMR (75 MHz, CDCl3): δC 165.3 (q, CO), 164.4 (q, CAr), 161.1 (q, CAr), 160.4 
(q, thiazole), 147.3 (q, thiazole), 139.7 (q. CAr), 138.4 (q, thiophene), 137.1 (q, 
pyrrole), 130.4 (t, d, J = 8.73 Hz, CAr, F coupling), 128.1 (q, pyrrole), 127.7 (q, 
thiophene), 127.6 (q, thiophene), 126.4 (t, thiophene), 124.6 (t, d, J = 3.54 Hz, CAr, 
F coupling), 116.5 (t, CAr), 116.2 (t, CAr), 113.1 (q, pyrrole), 111.5 (t, thiazole), 
111.2 (t, pyrrole), 59.6 (d, CH2, OEt), 14.5 (s, CH3, OEt), 12.2 (s, Me).
Experimental section  152 
 
3.7 Ethyl 1-(4-fluorophenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxylate (53) 
 
Isolated yield 96%  
Rf = 0.49 (DCM). 
1H NMR (300 MHz, CDCl3): δH 7.46 (d, J = 3.51, 1H, thiophene), 7.41 (d, J = 5.41, 
1H, thiophene), 7.36 – 7.29 (m, 2H, HAr), 7.27 (s, 1H, thiazole), 7.09 (dd, J = 3.51, 
5.40, 1H, thiophene), 6.91 (t, J = 8.83 Hz, 1H, HAr), 6.67 (q, J = 4.53 Hz, 1H, HAr), 
6.35 (s, 1H, pyrrole), 4.40 (q, J = 6.97 Hz, 2H, CH2, OEt), 2.43 (s, 3H, Me), 1.45 (t, 
J = 7.21 Hz, 3H, CH3, OEt). 
13C NMR (75 MHz, CDCl3): δC 165.3 (q. CO), 164.1 (q, CAr), 160.8 (q, thiazole), 
160.3 (q, CAr), 147.4 (q, thiazole), 138.6 (q, thiophene), 137.1 (q, pyrrole), 134.3 
(q, d, J = 3,67 Hz, CAr, F coupling), 130.4 (q, pyrrole), 130.4 (t, d, J = 8.43 Hz, 2C, 
CAr F coupling), 128.3 (q, pyrrole), 127.7 (t, thiophene), 127.6 (t, thiophene), 
126.4 (t, thiophene), 116.4 (t, d, J = 22.58 Hz, 2C, CAr, F coupling) , 112.9 (q, 
pyrrole), 111.4 (t, thiazole), 111.0 (t, pyrrole), 59.5 (d, CH2, OEt), 14.5 (s, CH3, 
OEt), 12.2 (s, Me). 
 
3.8 Ethyl 1-(2-methoxyphenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxylate (54) 
 
Isolated yield 49% 
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Rf = 0,55 (DCM). 
1H NMR (300 MHz, CDCl3): δH 7.46 (t, J = 7.97 Hz, 1H, HAr), 7.38 (d, J = 3.45 Hz, 
1H, thiophene,), 7.32 (d, J = 4.47 Hz, 1H, thiophene,), 7.24 (s, 1H, thiazole,), 7.19 
(dd, J = 7.72, 1.22 Hz, 1H, HAr), 7.07 (d, J = 2.23 Hz, 1H, HAr), 7.04 (dd, J = 5.89, 
8.53 Hz, 1H HAr), 7.00 (dd, J = 3.66, 4.27 Hz, 1H, thiophene), 6.13 (s, 1H, 
pyrrole), 4.32 (q, J = 6.90 Hz, 2H, OEt), 3.72 (s, 3H, OMe), 2.31 (s, 3H, Me), 1.37 
(t, J = 6.90 Hz, 3H, OEt). 
13C NMR (75 MHz, CDCl3): δC 165.6 (q, CO), 160.0 (q, thiazole), 156.0 (q, CAr), 
147.9 (q, thiazole), 139.3 (q, thiophene), 137.4 (q, pyrrole), 130.6 (t, CAr), 130.1 (t, 
CAr), 128.2 (q, pyrrole), 127.6 (t, thiazole), 127.6 (t, thiazole), 127.0 (q, CAr), 126.3 
(t, thiophene), 120.9 (t, CAr), 112.5 (q, pyrrole), 112.3 (t, CAr), 111.2 (t, thiophene), 
109.7 (t, pyrrole), 59.4 (d, CH2, OEt), 55.8 (s, OMe), 14.6 (s, CH3, OEt), 11.8 (s, 
Me). 
3.9 Ethyl 1-(3-methoxyphenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxylate (55) 
 
Isolated yield 69% 
Rf = 0,53 (DCM) 
1H NMR (300 MHz, CDCl3): δH 7.47 (d, J = 2.89 Hz, 1H, thiophene), 7.39 (t, J = 
8.02 Hz, 1H, HAr), 7.34 (d, J = 5.13 Hz, 1H, thiophene), 7.04 (dd, J = 1.21, 2.65 
Hz, thiophene), 7.03 – 7-00 (m, 1H, HAr), 6.87 (dq, J = 7.96, 0.72 Hz, 1H, HAr), 
6.80 (t, J = 2.29 Hz, 1H, HAr), 6.08 (s, 1H, pyrrole), 4.32 (q, J = 7.47 Hz, 2H, CH2, 
OEt), 3.79 (s, CH3, OMe), 2.37 (s, CH3, Me), 1.37 (t, J = 7.23 Hz, 3H, CH3, OEt). 
13C NMR (75 MHz, CDCl3): δC 165.4 (q, CO), 160.4 (q, thiazole),160.2 (q, CAr), 
147.4 (q. thiazole), 139.3 (q, thiophene), 138.7 (q, CAr), 137.2 (q, pyrrole), 130.11 
(t, CAr), 128.3 (q. pyrrole), 127.6 (t, 2C, thiophene), 126.5 (t, thiophene), 120.8 (t, 
Experimental section  154 
 
CAr), 115.0 (t, CAr), 114.2 (t, CAr), 112.7 (q, pyrrole), 111.5 (t, thiazole), 110.4 (t, 
pyrrole), 59.5 (d, CH2, OEt), 55.5 (s, CH3, OMe), 14.6 (s, CH3, OEt), 12.2 (s, Me). 
 
3.11 Ethyl 1-(3-fluorobenzyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxylate (57) 
 
Isolated yield 80% 
Rf = 0,63 (DCM).
  
1H NMR (300 MHz, CDCl3): δH 7.42 (d, J = 3.63 Hz, 1H, thiophene), 7.33 (d, J = 
4.98 Hz, 1H, thiophene), 7.20 (t, J = 7.72 Hz, 1H, HAr), 7.02 (t, J = 3.96 Hz, 1H, 
thiophene), 6.93 (s, 1H, pyrrole), 6.88 (t, J = 10.74 Hz, 1H, HAr), 6.77 (d, J = 7.72 
Hz, 1H, HAr), 6.69 (d, J = 9.8 Hz, 1H, HAr), 5.59 (s, 2H, CH2), 4.30 (q, J = 6.97 Hz, 
2H, CH2, OEt), 2.51 (s, 3H, Me), 1.36 (t, J = 7.16 Hz, 3H, CH3, OEt). 
13C NMR (75 MHz, CDCl3): δC 165.3 (q, CO), 164.7 (q, CAr), 161.4 (q, CAr), 161.1 
(q, phiazole), 148.1 (q, thiazole), 140.6 (q, thiophene), 137.8 (q, pyrrole), 137.3 (q, 
CAr), 130.1 (t, d, J = 8.06 Hz, CAr F coupling), 127.8 (t, 2C, thiophene), 126.8 (q, 
pyrrole), 126.4 (t, thiophene), 121.6 (t, d, J = 2.46 Hz, CAr, F coupling), 113.9 (t, d, 
J = 20.74 Hz, CAr, F, coupling), 113.4 (t, thiazole), 113.0 (t, d, J = 22.16 Hz, CAr, F 
coupling), 112.7 (q, pyrrole), 111.0 (t, pyrrole), 59.5 (d, CH2, OEt), 47.9 (d, CH2), 
14.5 (s, CH3, OEt), 11.4 (s, Me). 
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3.12 Ethyl 1-(4-fluorobenzyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxylate (58) 
 
Isolated yield 41% 
Rf = 0,63 (DCM). 
1H NMR (300 MHz, CDCl3): δH 7.43 (d, J = 3.77 Hz, 1H, thiophene), 7.34 (d, J = 
5.09 Hz, 1H, thiophene), 7.12 (s, 1H, thiazole), 7.03 (dd, J = 3.58, 5.39 Hz, 1H, 
thiophene), 6.98- 6.92 (m, 4H, HAr), 6.91 (s, 1H, pyrrole), 5.54 (s, 2H, CH2), 4.29 
(q, J = 7.16 Hz, CH2, OEt), 2.51 (s, 3H, Me), 1.36 (t, J = 6.97 Hz, 3H, CH3, OEt). 
13C NMR (75 MHz, CDCl3): δC 165.3 (q, CO), 163.5 (q, CAr), 161.1 (q, thiazole), 
160.2 (q, CAr), 148.2 (q, thiazole), 137.8 (q. thiophene), 137.3 (q, pyrrole), 133.5 
(q, d, J = 6.38 Hz, CAr, F coupling), 127.8 (t, d, J = 6.75 Hz, 2C, CAr, F coupling), 
127.7 (t, 2C, thiophene), , 126.8 (q, pyrrole), 126.5 (t, thiohene), 115.5 (t, d, J = 
21.01 Hz, 2C, CAr, F coupling), 113.5 (t, thiazole), 112.6 (q, pyrrole), 111.0 (t, 
pyrrole), 59.5 (d, CH2, OEt), 47.7 (d, CH2), 14.5 (s, CH3, OEt), 11.4 (s, Me).  
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Compounds 15, 16, 51 – 58 were hydrolyzed according to the same procedure of 
generation of 18 to their respective carboxylic acid intermediate without 
purification. 
3.13 1-benzyl-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-3-
carboxylic acid (15´) 
 
Rf = 0,26 (DCM:EtOAc = 20:1 with 0.2% acetic acid). 
 
3.14 1-(3-fluoro-4-methylphenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-
1H-pyrrole-3-carboxylic acid (16´) 
 
Rf = 0,21 (DCM:EtOAc = 20:1 with 0.2% acetic acid). 
 
3.15 1-(2-fluorophenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-
3-carboxylic acid (51´) 
 
Rf = 0,28 (DCM:EE = 40:1 with 0.1% acetic acid). 
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3.16 1-(3-fluorophenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-
3-carboxylic acid (52´) 
 
Rf = 0.26 (DCM:EtOAc = 40:1 with 0.1% acetic acid). 
 
3.17 1-(4-fluorophenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-
3-carboxylic acid (53´) 
 
Rf = 0.22 (DCM:EtOAc = 40:1 with 0.1% acetic acid). 
 
3.18 1-(2-methoxyphenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxylic acid (54´) 
 
Rf = 0.26 (DCM:EtOAc = 40:1 with 0.1% acetic acid). 
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3.19 1-(3-methoxyphenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxylic acid (55´) 
 
Rf = 0.27 (DCM:EtOAc = 40:1 with 0.1% acetic acid). 
 
3.20 1-(4-methoxyphenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxylic acid (56´) 
 
Rf = 0.23 (DCM:EtOAc = 40:1 with 0.1% acetic acid). 
 
3.21 1-(3-fluorobenzyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-
3-carboxylic acid (57´) 
 
Rf = 0.30 (DCM:EtOAc = 40:1 with 0.1% acetic acid). 
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3.22 1-(4-fluorobenzyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-
3-carboxylic acid (58´) 
 
Rf = 0.34 (DCM:EtOAc = 40:1 with 0.1% acetic acid). 
 
Compounds 15´, 16´, 51´ – 58´ were then converted into the primary or 
secondary amides according to the same procedures of generation of 19 and 20. 
 
3.23 1-benzyl-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-3-
carboxamide (23) 
 
Isolated yield 28% over two steps 
Rf = 0.25 (DCM) 
1H NMR (300 MHz, CDCl3): δH 7.44 (d, J = 3.81 Hz, 1H, thiophene), 7.35 (d, J = 
4.57 Hz, 1H, thiophene), 7.30 -7.20 (m, 3H, HAr),), 7.13(s, 1H, thiazole), 7.04 (dd, 
J = 3.55, 5.33 Hz,1H, thiophene), 7.00 (d, J = 1.62 Hz, 1H, HAr), 6.99 (s, 1H, 
pyrrole), 6.99 – 6.97 (m, 1H, HAr), 5.86 (b, 2H, NH2), 5.61 (s, 2H, CH2), 2.59 (s, 
3H, Me). 
13C NMR (75 MHz, CDCl3): δC 161.6 (q, CO), 161.5 (q, thiazole), 148.2 (q, 
thiazole), 141.3 (q, thiophene), 137.7 (q. pyrrole), 137.7 (q. CAr), 129.1 (t, 2C, CAr), 
128.3 (t, thiophen), 128.2 (t, thiophene), 127.9 (q, pyrrole), 127.6 (t, thiophene), 
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127.0 (t, CAr), 126.5 (t, 2C, CAr), 114.6 (t, thiazole), 112.1(t, pyrrole), 48.9 (d, CH2), 
12.1 (s, Me). 
HRMS m/z calcd for C20H18N3OS2 [M + H]
+, 380.0886; found, 380.0874. 
3.24 1-(3-fluoro-4-methylphenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-
1H-pyrrole-3-carboxamide (24) 
 
Isolated yield 21% over two steps  
Rf = 0.27 (DCM:PE = 10:1). 
1H NMR (300 MHz, CDCl3): δH 7.41 (d, J = 3.30 Hz, 1H, thiophene), 7.33 (d, J = 
4.76 Hz, 1H, thiophene), 7.31 (t, J = 8.42 Hz, 1H, HAr), 7.04 – 6.98 (m, 1H, 
thiophene and 2H, HAr), 6.35 (s, 1H, pyrrole), 5.78 (b, 2H, NH2), 2.45 (s, 3H, Ar-
Me), 2.37 (s, Me). 
13C NMR (75 MHz, CDCl3): δC 162.3 (q, CO), 161.2 (q, CAr), 160.5 (q, thiazole), 
159.8 (q, CAr), 147.1 (q, thiazole), 141.5 (q, thiophene), 137.2 (q, pyrrole), 136.7 
(q, d, J = 10.46 Hz, CAr F coupling), 132.0 (q, d, J = 5.78 Hz, CAr F coupling), 
128.8 (t, CAr), 127.8 (t, thiophene), 127.7 (t, thiophene), 126.5 (t, thiophene), 
126.3 (q, pyrrole), 124.1 (t, d, J = 4.07 Hz, CAr, F coupling), 115.8 (t, d, J = 17.62 
Hz, CAr, F coupling), 112.1 (q, pyrrole), 111.9 (t, thiazole), 111.7 (t, pyrrole), 14.5 
(s, Me-Ar), 12.5 (s, Me). 
HRMS m/z calcd for C20H17FN3OS2 [M + H]
+, 398.0792; found, 380.0782. 
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3.25 1-(2-fluorophenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-
3-carboxamide (59) 
 
Isolated yield 52% over two steps 
Rf = 0.55 (DCM). 
1H NMR (300 MHz, CDCl3): δH 7.49 (q, 1H, HAr), 7.36 (d, J = 3.94, 1H, thiophene), 
7.33 (t, 1H, HAr), 7.31 (s, 1H, thiazole), 7.30 – 7.25 (m, 2H, HAr; 1H, thiophene), 
6.99 (t, 1H, thiophene), 6.60 (s, 1H, pyrrole), 5.89 (b, 2H, NH2), 2.45 (s, 3H, Me). 
13C NMR (75 MHz, CDCl3): δC 161.0 (q, CO), 160.6 (q, thiazole), 159.7 (q, CAr), 
157.2 (q. CAr), 147.1 (q. thiazole), 141.9 (q. thiophene), 137.2 (q. pyrrole), 131.1 
(t, d, J = 8.35 Hz, CAr, F coupling), 130.6 (t, CAr), 128.7 (q, pyrrole), 127.7 (t, 
thiophene), 127.6 (t, thiophene), 126.4 (t, thiophene), 126.1 (q, d, J = 12.77 Hz, 
CAr, F coupling), 124.7 (t, d, J = 3.94 Hz, CAr, F coupling), 116.8 (t. CAr), 116.6 (t, 
thiazole), 112.4 (q, pyrrole), 111.7 (t, pyrrole), 12.1 (s, Me). 
HRMS m/z calcd for C19H15FN3OS2 [M + H]
+, 384.0635; found, 384.0640. 
 
3.26 1-(3-fluorophenyl)-N,2-dimethyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxamide (60) 
 
Isolated yield 45% over two steps  
Rf = 0.19 (DCM:MeOH = 40 :1). 
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1H NMR (300 MHz, CDCl3): δH 7.46 (dd, J = 1.6, 8.31, 1H, HAr), 7.43 (d, J = 3.52, 
1H, thiophene), 7.36 (d, J = 4.79, 1H, thiophene), 7.21 (t, ,1H, HAr), 7.08 (d, J = 
7.67, 1H, HAr), 7.03 (t, 1H, HAr), 7.02 (dd, J = 3.84, 8.95, 1H, thiophene), 6.94 (s, 
1H, thiazole), 6.07 (s, 1H, pyrrole), 5.96 (b, 1H, NH), 2.97 (s, 3H, NHCH3), 2.38 (s, 
3H, Me). 
13C NMR (75 MHz, CDCl3): δC 166.5 (q, CO), 164.4 (q, CAr), 161.9 (q, CAr), 160.9 
(q, thiazole), 147.5 (q, thiazole), 140.1 (q, pyrrole), 139.8 (q, d, J = 10.13 Hz, CAr, 
F coupling), 137.3 (q, thiophene), 136.9 (q, pyrrole), 130.7 (t, d, J = 9.49 Hz, CAr, 
F coupling), 128.3 (q, pyrrole), 128.2 (t, thiophene), 128.1 (t, thiophene), 127.0 (t, 
thiophene), 124.7 (t, d, J = 22.76 HZ, CAr, F coupling CAr), 116.3 (t, d, J = 21.77 
Hz, CAr, F coupling), 116.1 (t, d, J = 21.26 Hz, CAr, F coupling), 116.1 (q, pyrrole), 
110.8 (t, thiazole), 108.0 (t, pyrrole), 25.5 (s, NHCH3), 12.3 (s, Me).  
HRMS m/z calcd for C20H17FN3OS2 [M + H]
+, 398.0792; found, 398.0760. 
 
3.27 1-(4-fluorophenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-
3-carboxamide (63) 
 
Isolated yield 29% over two steps 
Rf = 0.75 (DCM:EE = 40:1 with 0.1% AcOH). 
1H NMR (300 MHz, CDCl3): δH 7.40 (d, J = 3.90 Hz, 1H, thiophene), 7.33 (d, J = 
4.48 Hz, 1H, thiophene), 7.31 – 7.26 (m, 2H, HAr), 7.25 (s, 1H, thiazole), 7.23 – 
7.16 (m, 2H, HAr), 7.07 (dd, J = 3.7, 5.07, 1H, thiophene), 6.38 (s, 1H, Pyrrole), 
2.44 (s, 1H, Me). 
13C NMR (75 MHz, CDCl3): δC 164.3 (q, CO), 161.1 (q, Thiazole), 161.0 (q, CAr), 
160.6 (q, CAr), 147.1 (q, thiazole), 141.5 (q. thiophene), 137.1 (q, pyrrole), 134.0 
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(q, d, J = 3.05 Hz, CAr, F coupling), 130.4 (t, d, J = 7.74 Hz, 2C, CAr, F coupling), 
128.9 (q, pyrrole), 127.9 (t, thiophene), 127.7 (t, Tthiophene), 126.5 (t, thiophene), 
116.6 (t, d, J = 17.40 Hz, 2C, CAr, F coupling), 112.1 (q. pyrrole), 111.9 (t. 
thiazole), 111.8 (t, pyrrole), 12.5 (s, Me). 
HRMS m/z calcd for C19H15FN3OS2 [M + H]
+, 384.0635; found, 384.0635. 
 
3.28 1-(4-fluorophenyl)-N,2-dimethyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxamide (64) 
 
Isolated yield 59% over two steps 
Rf = 0.26 (DCM:MeOH = 40 :1). 
1H NMR (300 MHz, CDCl3): δH 7.43 (d, J = 3.87 Hz, 1H, thiophene), 7.36 (d, J = 
5.09 Hz, 1H, thiophene), 7.29 – 7.14 (m, 4H, HAr), 7.03 (dd, J = 3.67, 5.09 Hz, 1H, 
thiophene), 6.94 (s, 1H, thiazole), 6.02 (s, 1H, pyrrole), 5.94 (b, 1H, NH), 2.97 (d, 
J = 1.47 Hz, 3H, NHCH3), 2.36 (s, 3H, Me). 
13C NMR (75 MHz, CDCl3): δC 166.7 (q, CO), 161.6 (q, thiazole), 161.3 (q, CAr), 
160.9 (q, CAr), 147.7 (q, thiazole), 137.4 (q, thiophene), 137.2 (q, pyrrole), 134.7 
(q, d, J = 2.89 HZ, CAr, F coupling), 130.9 (t, d, J = 8.09 Hz, 2C, CAr, F coupling 
CAr), 128.6 (q, pyrrole), 128.3 (t, thiophene), 128.2 (t, thiophene), 127.1 (t, 
thiophene), 116.9 (t, d, J = 22.42 Hz, 2C, CAr, F coupling), 116.1 (q, pyrrole), 
110.7 (t, thiazole), 108.7 (t, pyrrole), 26.6 (s, CH3, NHCH3), 12.4 (s, Me). 
HRMS m/z calcd for C20H17FN3OS2 [M + H]
+, 398.0792; found, 398.0768. 
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3.29 (1-(2-methoxyphenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxamide (65) 
 
Isolated yield 22% over two steps 
Rf = 0.50 (DCM). 
1H NMR (300 MHz, CDCl3): δH 7.48 (t, 1H, HAr), 7.39 (d, J = 3.78 Hz, 1H, 
thiophene), 7.33 (s, 1H, thioazole), 7.30 (d, J = 5.11 Hz, 1H, thiophene), 7.23 (d, 
J = 7.95, 1H, HAr), 7.09 (d, J = 3.22, HAr), 7.06 (t, 1H, HAr), 7.00 (dd, J = 3.78, 5.3 
Hz, thiophene), 6.25 (s, 1H, pyrrole), 5.78 (b, 2H, NH2), 3.76 (s, 3H, OMe), 2.40 
(s, 3H, Me). 
13C NMR (75 MHz, CDCl3): δC 161.4 (q, CO), 160.1 (q, thiazole), 155.9 (q, CAr), 
147.6 (q, thiazole), 142.2 (q, thiophene), 137.4 (q, CAr), 130.8 (t, CAr), 130.0 (t, 
CAr), 128.6 (q, pyrrole), 127.6 (t, 2C, thiophene), 126.8 (q, pyrrole), 126.4 (t, 
thiophene), 120.9 (t, CAr), 112.3 (t, CAr), 111.9 (q, pyrrole), 111.7 (t, thiazole), 
110.5 (t, pyrrole), 55.9 (s, OMe), 12.1 (s, Me). 
HRMS m/z calcd for C20H18N3O2S2 [M + H]
+, 396.0835; found, 396.0838. 
3.30 1-(2-methoxyphenyl)-N,2-dimethyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxamide (66) 
 
Isolated yield 35% over two steps  
Rf = 0.19 (DCM:MeOH = 40:1). 
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1H NMR (300 MHz, CDCl3): δH 7.47 (t, J = 8.14 Hz, 1H, HAr), 7.43 (d, J = 3.56 Hz, 
1H, thiophene), 7.35 (d, J = 5.09 Hz, 1H, thiophene), 7.20 (d, J = 7.63 Hz, 1H, 
HAr), 7.09 – 7.03 (m, 2H, HAr), 7.03 (dd, J = 3.56, 5.14 Hz, 1H, thiophene), 7.00 (s, 
1H, thiazole), 5.94 (b, 1H, NH), 5.93 (s, 1H, pyrrole), 3.72 (s, 3H, CH3, OMe), 
2.97 (d, J = 3.56 Hz, 3H, NHCH3), 2.32 (s, 3H, Me). 
13C NMR (75 MHz, CDCl3): δC 166.5 (q, CO), 160.2 (q, thiazole), 156.0 (q, CAr), 
147.7 (q, thiazole), 137.3 (q, thiophene), 137.2 (q, pyrrole), 130.7 (t, CAr), 130.3 (t, 
CAr), 128.0 (q, CAr), 127.7 (t, thiophene), 127.7 (t, thiophene), 127. 0 (q, pyrrole), 
126.6 (t, thiophene), 121.0 (t, CAr), 115.2 (q, pyrrole), 108.9 (t, Tthiazole), 180.0 (t, 
pyrrole), 55.8 (s, CH3, OMe), 26.1 (s, CH3, NHCH3), 11.6 (s, Me). 
HRMS m/z calcd for C21H20N3O2S2 [M + H]
+, 410.0991; found, 410.0968. 
3.31 1-(3-methoxyphenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxamide (67) 
 
Isolated yield 21% over two steps  
Rf = 0.24 (DCM:PE = 3 .1). 
1H NMR (300 MHz, CDCl3): δH 7.45 – 7.38 (m, 1H, thiophene, 1H, HAr), 7.34 -
7.30 (m, 1H, thiophene, 1H,thiazole), 7.05 (dd, J = 2.63, 8.46 Hz, 1H, HAr), 7.01 
(dd, J = 3.76, 4.70 Hz, 1H, thiophene), 6.91 (d, J = 7.71, 1H, HAr), 6.84 (t, 1H, 
HAr), 6.78 (s, 1H, pyrrole), 5.76 (b, 2H, NH2), 3.81 (s, 3H, OMe), 2.46 (s, 3H, Me). 
13C NMR (75 MHz, CDCl3): δC 161.3 (q, CO), 160.5 (q, thiazole), 160.3 (q,CAr), 
147.1 (q, thiazole), 141.5 (q, thiophene), 139.0 (q, CAr), 137.2 (q, pyrrole), 130.2 
(t, CAr), 128.8 (q, pyrrole), 127.8 (t, thiophene), 127.7 (t, thiophene), 126.5 (t, 
thiophene), 120.8 (t, CAr), 115.3 (t, CAr), 114. 0 (t, CAr), 112.0 (t, thiazole), 112.0 
(q, pyrrole), 111.2 (t, pyrrole), 55.8 (s, OMe), 12.5 (s, Me). 
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HRMS m/z calcd for C20H18N3O2S2 [M + H]
+, 396.0835; found, 396.0830. 
3.32 1-(3-methoxyphenyl)-N,2-dimethyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxamide (68) 
 
Isolated yield 59% over two steps  
0.25 (DCM:MeOH = 40 :1). 
1H NMR (300 MHz, CDCl3): δH 7.44 (d, J = 3.68, 1H, thiophene), 7.40 (t, 1H, HAr), 
7.36 (d, J = 5.14, 1H, thiphene), 7.04 (dq, J = 7.61, 1H, thiophene), 7.04 (dd, J = 
3.79, 5.29, 1H, HAr), 6.99 (s, 1H, thiazole), 6.87 (dq, J = 7.59, 1H, HAr), 6.80 (t, 1H, 
HAr), 5.96 (b, 1H, NH), 5.92 (s, 1H, pyrrole), 3.80 (s, 3H, OMe), 2.97 (d, J = 3.92, 
3H, NHCH3), 2.39 (s, 3H, Me). 
13C NMR (75 MHz, CDCl3): δC 166.8 (q. CO), 160.9 (q, thiazole), 160.7 (q, CAr), 
147.7 (q. thiazole), 139.8 (q, CAr), 137.5 (q. thiophene), 137.2 (q, pyrrole), 130.7 
(t, CAr), 128.5 (q. pyrrole), 128.2 (t, 2C, thiophene), 127.1 (t, Thiophene), 121.3 (t, 
CAr), 115. 9 (q. pyrrole), 115.5 (t, CAr), 114.6 (t, CAr), 110.3 (t, thiazole), 108.3 (t, 
pyrrole), 56.0 (s, OMe), 26.6 (s, NHCH3), 12.4 (s, Me). 
HRMS m/z calcd for C21H20N3O2S2 [M + H]
+, 410.0991; found, 410.0968. 
3.33 1-(4-methoxyphenyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxamide (69) 
 
Isolated yield 49% over two steps 
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Rf = 0.63 (DCM:EE = 40 .1). 
1H NMR (300 MHz, CDCl3): δH 7.43 (d, J = 3.86 Hz, 1H, thiophene), 7.32 (d, J = 
4.54, 1H, thiophene), 7.32 (s, 1H, thiazole), 7.23 (d, J = 9.07, 2H, HAr), 7.02 (d, J 
= 9.53, 2H, HAr), 7.01 (dd, J = 3.86, 4.99, 1H, thiophene), 6.12 (s, 1H, pyrrole), 
5.77 (b, 2H, NH2,), 3.88 (s, 3H, OMe), 2.43 (s, 3H, Me). 
13C NMR (75 MHz, CDCl3): δC 161.4 (q, CO), 160.3 (q, thiazole), 160.0 (q, CAr), 
147.3 (q, thiazole), 141.9 (q, thiophene), 137.3 (q, CAr), 130.6 (q, pyrrole), 129.6 
(t, 2C, CAr), 129.1, (q, pyrrole), 127.7 (t, thiophene), 127.6 (t, thiophene), 126.5 (t, 
thiophene), 114.7 (t, 2C, CAr), 111.9 (t, thiazole), 111.8 (q, pyrrole), 111.1 (t, 
pyrrole), 55.6 (s, OMe), 12.5 (s, Me). 
HRMS m/z calcd for C20H18N3O2S2 [M + H]
+, 396.0835; found, 396.0807. 
 
3.3.4 1-(4-methoxyphenyl)-N,2-dimethyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxamide (70) 
 
Isolated yield 68% over two steps. 
Rf = 0.25 (DCM:MeOH = 40 :1). 
1H NMR (300 MHz, CDCl3): δH 7.43 (d, J = 3.60, 1H, thiphene), 7.35 (d, J = 4.98, 
1H, thiophene), 7.17 (d, J = 6.37, 2H, HAr), 7.03 (dd, J = 3.60, 4.71, 1H, 
thiophene), 6.99 (d, J = 6.65, 2H, HAr), 6.98 (s, 1H, thiazole), 5.99 (b, 1H, NH), 
5.84 (s, 1H, pyrrole), 3.87 (s, 3H, OMe), 2.96 (d, J = 4.15, 3H, NHCH3), 2.35 (s, 
3H, Me). 
13C NMR (75 MHz, CDCl3): δC 166.8 (q, CO), 160.6 (q, thiazole), 160.2 (q, CAr), 
147.9 (q thazole), 137.5 (q, thiophene), 137.5 (q, pyrrole), 131.3 (q. CAr), 130.1 (t, 
2C, CAr), 128.8 (q. pyrrole), 128.1 (t, 2C, thiophene), 127.0 (t, thiophene), 115.7 
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(q. pyrrole), 115.1 (t, 2C, CAr), 110.1 (t, thiazole), 108.5 (t, pyrrole), 56.0 (s. CH3, 
OMe), 26.5 (s, CH3. NHCH3), 12.4 (s, Me). 
HRMS m/z calcd for C21H20N3O2S2 [M + H]
+, 410.0991; found, 410.0970. 
3.3.5 1-(3-fluorobenzyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-
3-carboxamide (71) 
 
Isolated yield 45% over two steps 
Rf = 0.25 (DCM). 
1H NMR (300 MHz, CDCl3): δH 7.43 (d, J = 3.77, 1H, thiophene),7.35 (d, J = 4.80, 
1H, thiophene), 7,23 (q, 1H, HAr), 7.17(s, 1H, thiazole), 7.04 (dd, J = 3.74, 5.18, 
1H, thiophene), 6.98 (s, 1H, pyrrole), 6.91 (t, 1H, HAr), 6.78 (d, J = 8.25, 1H, HAr), 
6.73 (d, J = 9.06, 1H, HAr), 5.88 (b, 2H, NH2), 5.61 (s, 2H, CH2), 2.58 (s, 3H, Me). 
13C NMR (75 MHz, CDCl3): δC 164.3 (q, CO), 161.9 (q, CAr), 161.3 (q, thiazole), 
161.0 (q, CAr), 147.6 (q, thiazole), 140.7 (q, thiophene), 140.0 (q, d, J = 7.29 Hz, 
CAr, F coupling), 137.2 (q, pyrrole), 130.2 (t, d, J = 8.06 Hz, CAr, F coupling), 
127.9 (t, thiophene), 127.9 (t, thiophene), 127.4 (q, pyrrole), 126.6 (t, thiophene), 
121.7 (t, d, J = 3.04 HZ, CAr, F coupling), 114.2 (t, thiophene), 114.1 (t, d, J = 
21.09 HZ, CAr, F coupling), 113.2 (t, d, J = 22.76 HZ, CAr, F coupling), 111.8 (q, 
pyrrole), 111.6 (t, pyrrole), 48.1 (d, CH2), 11.6 (s, Me). 
HRMS m/z calcd for C20H17FN3OS2 [M + H]
+, 398.0792; found, 398.0800. 
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3.3.6 1-(4-fluorobenzyl)-2-methyl-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-
3-carboxamide (72) 
 
Isolated yield 37% over two steps 
Rf = 0.29 (DCM). 
1H NMR (300 MHz, CDCl3): δH 7.44 (d, J = 3.56 Hz, 1H, thiophene), 7.35 (d, J = 
4.07 Hz, 1H, thiophene), 7.14 (s, 1H, thiazole), 7.04 (dd, J = 3.56, 5.22 Hz, 1H, 
thiophene), 7.00 – 6.93 (m, 3H, HAr), 6.96 (s, 1H, pyrrole), 6,96 – 6.93 (m, 1H, 
HAr), 5.79 (b, 2H,. NH2), 5.56 (s, 2H, CH2), 2.58 (s, 3H, Me). 
13C NMR (75 MHz, CDCl3): δC 163.5 (q, CO), 161.6 (q, CAr), 161.4 (q, CAr), 161.1 
(q, thiazole), 148.0 (q, thiazole), 141.0 (q, thiophen), 137.5 (q, pyrrole), 133.3 (q, 
d, J = 3.01 HZ, CAr, F coupling, 128.2 (t, d, J = 8.02 HZ, 2C CAr, F couplingr), 
128.2 (t, 2C, thiophene), 127.7 (q, pyrrole), 126.9 (t, thiophen), , 115.8 (t, d, J = 
21.67 Hz, 2C, CAr, F coupling), 114.6 (t, thiazole), 112.1 (q, pyrrole), 111.9 (t, 
pyrrole), 48.2 (d, CH2), 12.0 (s, Me). 
HRMS m/z calcd for C20H17FN3OS2 [M + H]
+, 398.0792; found, 398.0799. 
 
4 Synthesis of the derivative with N-methyl pyrrole on the right side. 
4.1 1-methyl-1H-pyrrole-2-carbothioamide (26) 
 
This compound was prepared by the same synthetic method of generation of 
thiophene-2-carbothioamide (6). 
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The raw product was clean judged by TLC hence no purification: collected yield 
59%. 
Rf = 0.76 (DCM:MeOH = 20 :1). 
1H NMR (300 MHz, MeOD): δH 6.93 (t, 1H, pyrrole), 6.73 (dd, J = 1.75, 4.02, 1H, 
pyrrole), 6.10 (dd, J = 2.63, 4.16, 1H, pyrrole), 4.05 (s, 3H, Me). 
13C NMR (75 MHz, MeOD): δC 192.0 (q, CS), 133.8 (q. pyrrole), 131.9 (t, pyrrole), 
113.6 (t, pyrrole), 108.2 (t, pyrrole), 37.9 (s, Me). 
 
4.2 2-bromo-1-(2-(1-methyl-1H-pyrrol-2-yl)thiazol-4-yl)ethanone (29) 
 
1.2 g 1,4-dibromobutane-2,3-dione (10) (4.96 mmoL) was dissolved in 9 mL 
anhydrous THF, 312.8 mg 1-methyl-1H-pyrrole-2-carbothioamide (26) was also 
dissolved in 9 mL anhydrous THF and this solution was slowly introduced to 1,4-
dibromobutane-2,3-dione (10) THF solution and followed by 0.4 mL DIPEA (2.48 
mmoL). This mixture was allowed to be stirred at RT for 15 min. and the starting 
material is completely consumed (TLC, DCM:PE = 5:1). After the reaction, the 
mixture was poured into 30 mL saturated sodium hydrogen carbonate solution, 
and the aqueous layer was extracted 3 times with chloroform (3 × 20 mL). The 
combined organic layer was then dried over sodium sulfate and the solvent was 
removed. The raw material was then subject to the flash chromatography 
(DCM:PE = 2 :1) to yield a slight red crystal. (287.6 mg, 41%) 
Rf = 0.63 (DCM:PE = 5:1). 
1H NMR (300 MHz, CDCl3): δH 8.06 (s, 1H, thiazole), 6.78 (t, J = 1.88 Hz, 1H, 
pyrrole), 6.71 (t, J = 3.96 Hz, 1H, pyrrole), 6.16 (dd, J = 2.64, 3.88 Hz, 1H, 
pyrrole), 4.61 (s, 2H, CH2), 4.05 (s, 3H, Me). 
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13C NMR (75 MHz, MeOD): δC 185.8 (q, CO), 161.4 (q, thiazole), 151.8 (q, 
thiazole), 127.6 (t, thiazole), 125.5 (q, pyrrole), 124.6 (t, pyrrole), 113.7 (t, pyrrole), 
108.7 (t, pyrrole), 36.9 (s, Me), 33.1 (d, CH2). 
4.3 Ethyl 2-methyl-5-(2-(1-methyl-1H-pyrrol-2-yl)thiazol-4-yl)-1-
((tetrahydrofuran-2-yl)methyl)-1H-pyrrole-3-carboxylate (31) 
 
This compound was prepared through the same method of generation ethyl 2-
methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxylate (13) and was isolated in 37% yield as a pink solid. 
Rf = 0.56 (DCM:EtOAc = 40 :1). 
1H NMR (300 MHz, CDCl3): δH 7.39 (s, 1H, thiazole), 6.96 (s, 1H, pyrrole), 6.87 (t, 
J = 2.03 Hz, 1H, N-methyl pyrrole), 6.83 (dd, J = 3.05, 4.07 Hz, 1H, N-methyl 
pyrroel), 6.30 (dd, J = 3.05, 3.56 Hz, 1H, pyrrole), 4.69 (dd, J = 4.58, 14.50 Hz, 
1H, CH, THF), 4.50 (dd, J = 7.12, 14.54 Hz, 1H, CH2), 4.41 (q, J = 7.12 Hz, 2H, 
CH2, OEt), 4.21 – 4.15 (m, 1H, CH2), 4.14 (s, 3H, CH3, N-methyl pyrrole), 3.89 – 
3.73 (m, 2H, THF), 2.78 (s, 3H, Me). 1.97 – 1.84 (m, 3H, THF), 1.62 – 1.52 (m, 
1H, THF), 1.48 (t, J = 7.12 Hz, 3H, CH3, OEt). 
13C NMR (75 MHz, MeOD): δC 164.6 (q, CO), 58.7 (q, thiazole), 148.4 (q, 
thiazole), 138.1 (q, pyrrole), 126.9 (q, pyrrole), 126.7 (q. N-methyl pyrrole), 126.6 
(t, N-methyl pyrrole), 126.6 (t, thiazole), 112.3 (t, N-methyl pyrrole), 112.0 (q, 
pyrrole), 111.1 (t, N-methyl pyrrole), 108.3 (t, pyrrole), 78.4 (t, THF), 67.9 (d, 
THF), 59.3 (d, CH2, OEt), 48.1 (d, CH2), 36.8 (s, CH3, N-methyl pyrrole), 28.9 (d, 
THF), 25.4 (d, THF), 14.5 (s, CH3, OEt), 11.7 (s, Me).  
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4.4 2-methyl-5-(2-(1-methyl-1H-pyrrol-2-yl)thiazol-4-yl)-1-((tetrahydrofuran-2-
yl)methyl)-1H-pyrrole-3-carboxylic acid (33) 
 
37.8 mg ethyl 2-methyl-5-(2-(1-methyl-1H-pyrrol-2-yl)thiazol-4-yl)-1-
((tetrahydrofuran-2-yl)methyl)-1H-pyrrole-3-carboxylate (31) (0.095 mmoL) was 
dissolven in a flask with 0.3 mL ethanol. 0.6 mL 10% KOH ethanol solution (0.93 
mmoL).was then added to the flask then the mixture was allowed to react under 
reflux for 48 hours and monitored by the TLC. (TLC, DCM :EtOAc = 20 . 1 with 
0.1% acetic acid). After the reaction, the mixture was neutralized by 10 mL 1 M 
HCl solution and the aqueous layer was extracted 3 times with chloroform (3 × 
5mL). The combined organic layer was then dried over sodium sulfate and 
concentrated to give the pink raw product. The raw product was then utilized for 
the amide formation without purification.  
Rf = 0.42 (DCM:EtOAc = 20 :1 :1 with 0.1% AcOH) 
 
4.5 2-methyl-5-(2-(1-methyl-1H-pyrrol-2-yl)thiazol-4-yl)-1-((tetrahydrofuran-2-
yl)methyl)-1H-pyrrole-3-carboxamide (35) 
 
This compound was prepared by following the same procedure of generation of 
2-methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxamide (19) in 39% yield over 2 steps as the pale red crystal. 
Rf = 0.3 (DCM:EtOAc = 40 :1).  
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1H NMR (300 MHz, CDCl3): δH 7.13 (s, 1H, thiazole), 6.86 (s, 1H, pyrrole), 6.74 (t, 
J = 2.03 Hz, 1H, N-methyl pyrrole), 6.70 (dd, J = 1.53, 5.59 Hz, 1H, N-methyl 
pyrrole), 6.16 (dd, J = 2.54, 4.07 Hz, 1H, N-methyl pyrrole), 5.92 (b, 2H, NH2), 
4.56 (dd, J = 4.58, 14.24 Hz, 1H, CH, THF), 4.38 (dd, J = 7.63, 14.24 Hz, 1H, 
CH2), 4.08 – 4.02 (m, 1H, CH2), 4.00 (s, CH3, N-methyl pyrrole), 3.75 – 3-61 (m, 
2H, THF), 2.69 (s, 3H, Me), 1.86 – 1.72 (m, 3H, THF), 1.49 – 1.39 (m, 1H, THF). 
13C NMR (75 MHz, CDCl3): δC 161.0 (q, CO), 160.5 (q, thiazole), 147.8 (q, 
Thiazole), 140.8 (q, pyrrole), 127.2 (q, N-methyl pyrrole), 126.5 (t, N-methyl 
pyrrole), 126.5 (q, pyrrole), 112.8 (t, N-methyl pyrrole), 112.5 (t, N-methyl pyrrole), 
111.5 (t, thiazole), 111.1 (q, pyrrole), 108.2 (t, pyrrole), 78.2 (t, THF), 67.8 (t, 
THF), 48.2 (d, CH2), 36.7 (d, THF), 28.8 (d, THF), 25.3 (d, THF), 11.8 (s, Me). 
HRMS m/z calcd for C19H25N4O2S [M + H]
+, 371.1536; found, 371.1614. 
 
4.6 N,2-dimethyl-5-(2-(1-methyl-1H-pyrrol-2-yl)thiazol-4-yl)-1-
((tetrahydrofuran-2-yl)methyl)-1H-pyrrole-3-carboxamide (36) 
 
This compound was prepared by following the same procedure of generation of 
N,2-dimethyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxamide (20) in 52% yield over 2 steps as the pale red crystal. 
Rf = 0.21 (DCM:MeOH = 30:1). 
1H NMR (300 MHz, MeOD): δH 7.05 (s, 1H, thiazole), 6.73 (t, J = 2.07 Hz, 1H, N-
methyl pyrrole), 6.69 (dd, J = 1.70, 3.77 Hz, 1H, N-methyl pyrrrole), 6.48 (s, 1H, 
pyrrole), 6.16 (dd, J = 2.64, 3.77 Hz, 1H, pyrrole), 5.77 (b, 1H, NH), 4.48 (dd, J = 
5.09, 14.06 Hz, 1H, CH, THF), 4.34 (dd, J = 6.97, 14.65 Hz, 1H, CH2), 4.07 – 
4.02 (m, 1H, CH2), 4.00 (s, 3H, Me, N-methyl pyrrole), 3.78 – 3.56 (m, 2H, THF), 
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2.92 (s, 3H, CH3, NHCH3), 2.65 (s, 3H, Me), 1.81 – 1.71 (m, 3H, THF), 1.50 – 
1.35 (m, 1H, THF). 
13C NMR (75 MHz, CDCl3): δC 166.5 (q, CO), 160.5 (q. thiazole), 148.4 (q, 
Thiazole), 135.7 (q, pyrrole), 126.8 (q. pyrrole), 126.6 (t, N-methyl pyrrole), 126.6 
(q, N-methyl pyrrole), 112.6 (t, N-methyl pyrrole), 111.9 (t, N-methyl pyrrole), 
108.4 (t, thiazole), 107.6 (t, pyrrole), 78.3 (t, THF), 67.9 (d, THF), 48.0 (d, CH2), 
36.9 (s, CH3, N-methyl pyrrole), 29.0 (d, THF), 26.1 (s, CH3, NHCH3), 11.5 (s, 
Me). 
HRMS m/z calcd for C20H25N4O2S [M + H]
+, 385.1693; found, 371.1694. 
5 Synthesis of derivative with N-methyl indole on the right side. 
5.1 1-methyl-1H-indole (27) 
 
3.02 g sodium hydride (60% dispersed in mineral oil) (75 mmoL) was loaded in a 
flask and washed twice under inert gas with pentane and then dried in vacuo. 
The dry sodium hydride was dispersed in 5 mL anhydrous THF. 5.82 g Indole (50 
mmoL) was dissolved at 0 °C in 15 mL anhydrous THF and slowly introduced into 
the flask loaded with sodium hydride. The mixture was allowed to be stirred at 
0 °C for 10 min. then 4.2 mL methyl iodide (67 mmoL) was slowly added. The 
temperature was warmed to RT and the mixture was stirred at this temperature 
for 2 hours. After the starting material was consumed as judged by the TLC 
(PE:EtOAc = 10 :1), the mixture was again cooled to the 0 °C and 30 mL 
saturated ammonium chloride solution was added. The aqueous layer was then 
extracted 3 times with ethyl acetate (3 × 20 mL) and the combined organic layer 
was washed sequentially with 20 mL 1 M HCl solution, 20 mL saturated 
ammonium chloride solution and 20 mL saturated brine. Then the organic layer 
was dried over sodium sulfate and the solvent was completely removed. The 
resulted raw product (colorless liquid) was utilized without further purification for 
the next step.  
Rf = 0.78 (PE:EtOAc = 10 :1).  
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5.2 1-methyl-1H-indole-3-carbothioamide (28) 
 
1.5 g unpurified 1-methyl-1H-indole (27) (11.4 mmoL) was carefully dissolved at 
0 °C in 17 mL methyl sulfonic acid (263 mmoL) and 2.56 g potassium thiocyanate 
(26.3 mmoL) was added to this mixture. The mixture was stirred at RT for 30 
hours and monitored by the TLC (DCM:EtOAc = 15 :1). After the reaction, the 
reaction mixture was poured into the ice water and the red precipitation was then 
filtered and washed with very little amount of ethyl acetate. The precipitation was 
then dried in vacuo and subject to the flash chromatography to yield the pale red 
solid. (685.9 mg, 32%) 
Rf = 0.3 (DCM:EE = 15 :1) 
mp: 136 °C  
The melting point is in consistence with the reference.[44] 
 
5.3 2-bromo-1-(2-(1-methyl-1H-indol-3-yl)thiazol-4-yl)ethanone (30) 
 
100 mg 1-methyl-1H-indole-3-carbothioamide (28) (0.57 mmoL) was dissolved in 
9 mL absolute ethanol and 281.3 mg 1,4-dibromobutane-2,3-dione (10) (1.14 
mmoL dissolved in 9 mL absolute ethanol) was slowly introduced to this solution. 
The mixture was stirred at RT for 30 min. and the reaction was concluded as 
judged by the TLC (TLC, DCM:EtOAc = 30 :1). After the reaction, the ethanol was 
evaporated and 15 mL saturated sodium hydrogen carbonate solution was added. 
The aqueous layer was then extracted 3 times with chloroform (3 × 10 mL) and 
the combined organic layer was dried over sodium sulfate. After evaporation of 
the solvent, the raw product was subject to the flash chromatography 
(DCM:EtOAc = 30:1) to yield the pale red crystal. (54.5 mg, 29%) 
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Rf = 0.35 (DCM:EtOAc 30:1). 
1H NMR (300 MHz, MeOD): δH 8.30 – 8.24 (m ,1H, HAr), 8.09 (s, 1H, thiazole), 
7.69 (s, 1H, pyrrole (indole)), 7.38 – 7.30 (m, 3H, HAr), 4.78 (s, 2H, CH2), 3.84 (s, 
3H, Me).  
13C NMR (75 MHz, MeOD): δC 168.5 (q, CO), 163.9 (q, thiazole), 152.2 (q, 
thiazole), 137.7 (q. CAr), 130.0 (t, pyrrole), 125.5 (q, CAr), 124.0 (t, thiazole), 123.6 
(t. CAr), 122.0 (t. CAr), 121.3 (t, CAr), 110.4 (q.pyrrole), 110.3 (t, CAr), 34.3 (s, CH3, 
N-methyl), 33.7 (d, CH2). 
 
5.4 Ethyl 2-methyl-5-(2-(1-methyl-3a,7a-dihydro-1H-indol-3-yl)thiazol-4-yl)-1-
((tetrahydrofuran-2-yl)methyl)-1H-pyrrole-3-carboxylate (32) 
 
This compound was prepared through the same procedure of generation of ethyl 
2-methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxylate (13) in 41 % yield as the pale red solid. 
Rf = 0.2 (DCM:EtOAc = 30 :1). 
1H NMR (300 MHz, CDCl3): δH 8.24 (d, J = 7.99, 1H, HAr), 7.70 (s, 1H, thiazole), 
7.36 (t, 1H, HAr), 7.34 – 7.26 (m, 2H, HAr), 7.15 (s, 1H, pyrrole (indole)), 6.86 (s, 
1H, HAr), 4.72 (dd, J = 3.73, 12.25, 1H, THF), 4.41 (q, 1H, THF), 4.28 (q, 2H, CH2, 
OEt), 4.21 – 4.11 (m, 1H, THF), 3.85 (s, 3H, N – methyl), 3.67 (dq, J = 31.97, 2H, 
THF), 2.67 (s, 3H, Me), 1.86 – 1.75 (m, 1H, THF), 1.75 – 1.69 (m, 2H, THF), 1.52 
– 1.41 (m, 1H, THF), 1.35 (t, 3H, CH3, OEt).  
13C NMR (75 MHz, CDCl3): δC 165.5 (q, CO), 162.3 (q. thiazole), 148.3 (q. 
thiazole), 138.2 (q, CAr), 137.3 (q, pyrrole), 129.1 (t, pyrroel (indole)), 127.1 (q, 
pyrrole), 125.1 (q, CAr,), 122.8 (t, CAr), 121.1 (t, CAr), 120.9 (t, CAr), 112.0 (q. 
pyrrole), 111.3 (t, thiazole), 111.1 (q, pyrrole (indole)), 110.9 (t, CAr), 109.8 (t, 
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pyrrole), 78.7 (t, THF), 67.9 (d, THF), 59.2 (d, CH2, OEt), 48.4 (d, CH2), 33.2 (s, 
CH3, N-methyl), 28.9 (d, THF), 25.4 (d, THF), 14.6 (s, CH3, OEt), 11.8 (s, Me). 
5.5 2-methyl-5-(2-(1-methyl-3a,7a-dihydro-1H-indol-3-yl)thiazol-4-yl)-1-
((tetrahydrofuran-2-yl)methyl)-1H-pyrrole-3-carboxylic acid (34) 
 
20.6 mg ethyl 2-methyl-5-(2-(1-methyl-3a,7a-dihydro-1H-indol-3-yl)thiazol-4-yl)-1-
((tetrahydrofuran-2-yl)methyl)-1H-pyrrole-3-carboxylate (32) (0.05 mmoL) was 
dissolved in a t-Butyl alcohol / methanol mixture (2 mL:2 mL). Under inert gas 1 
mL 10% KOH ethanol solution (1.6 mmoL) was introduced to this solution. The 
mixture was then stirred at 60 °C and monitored by the TLC (DCM:EtOAc:MeOH 
= 20 :1:1 with 0.1% acetic acid). After 36 hours the reaction concluded, then the 
mixture was acidified with 1M HCL solution and the aqueous layer was extracted 
3 times with chloroform (3 × 10 mL). The combined organic layer was dried over 
sodium sulfate and concentrated in vacuo. The raw product was used for the 
amide formation without further purification. 
Rf = 0.38 (DCM:EtOAc: MeOH = 20 :1 :1 with 0.1% AcOH) 
5.6 2-methyl-5-(2-(1-methyl-3a,7a-dihydro-1H-indol-3-yl)thiazol-4-yl)-1-
((tetrahydrofuran-2-yl)methyl)-1H-pyrrole-3-carboxamide (37) 
 
This compound was prepared through the same procedure of generation of 2-
methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-yl)-1H-
pyrrole-3-carboxamide (19) in 62% yield over 2 steps as the pale red solid. 
Rf = 0.21 (DCM:EE = 8 :1). 
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1H NMR (300 MHz, CDCl3): δH 8.24 (d, J = 7.93, 1H, HAr), 7.71 (s, 1H,thiazole), 
7.32 (t, 2H, HAr), 7.18 (s, 1H, pyrrole (indole)), 6.92 (s, 1H, pyrrole), 5.77 (b, 2H, 
NH2), 4.73 (dd, J = 4.20, 15.11, 1H, THF), 4.44 (q, 1H, THF), 4.23 – 4.14 (m, 1H, 
THF), 3.86 (s, 3H, CH3, N-methyl), 3.76 – 3.60 (m, 2H, THF), 3.73 (s, Me), 1.88 – 
1.79 (m, 1H, THF), 1.79 – 1.68 (m, 2H, THF), 1.53 – 1.44 (m, 1H, THF).  
13C NMR (75 MHz, CDCl3): δC 162.5 (q, CO), 161.3 (q, thiazole), 147.9 (q, 
thiazole), 141.0 (q, CAr), 137.3 (q, pyrrole), 129.1 (t, pyrrole (indole)), 127.6 (q, 
pyrole), 125.2 (q, CAr), 122.8 (t, CAr), 121.2 (t, CAr), 120.9 (t, CAr), 111.9 (t, 
Thiazole), 111.6 (t, CAr), 111.3 (q. pyrrole), 111.1 (q, pyrrole (indole)), 109.8 (t, 
pyrrole), 78.6 (t. THF), 68.0 (d, THF), 48.6 (d, THF), 33.2 (s, CH3; N-methyl), 29.0 
(d, THF), 25.5 (d, THF), 12.0 (s, Me). 
HRMS m/z calcd for C23H25N4O2S [M + H]
+, 421.1693; found, 421.1663. 
6 Synthesis of 2-trifluoromethyl pyrrole derivative. 
6.1 Ethyl 4,4,4-trifluoro-3-oxo-2-(2-oxo-2-(2-(thiophen-2-yl)thiazol-4-
yl)ethyl)butanoate (41) 
 
30.4 mg sodium hydride (60% dispersed in mineral oil, 0.72 mmoL) was washed 
twice under inert gas with pentane and then dried in vacuo. Dry sodium hydride 
was dispersed in 1.4 mL dimethoxyethane afterwards and 102 μL ethyl 4,4,4-
trifluoro-3-oxobutanoate (38) (0.34 mmoL) was dropwise added to the dispersion 
at 0 °C. The mixture was stirred at 0 °C for 10 min. and 100 mg 2-bromo-1-(2-
(thiophen-2-yl)thiazol-4-yl)ethanone (2) (0.34 mmoL in 2 mL dimethoxyethane) 
was slowly introduecd at the same temperature. The temperature was then 
warmed to the RT and the mixture was then stirred under reflux overnight. After 
the starting material was completely consumed (TLC, DCM:PE = 3 :1), the 
mixture was poured to 4 mL water and the aqueous layer was adjusted to about 
pH = 2 with 2M HCl solution. The aqueous layer was then extracted 3 times with 
ethyl acetate (3 × 10 mL) and the combined organic layer was dried over sodium 
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sulfate and concentrated in vacuo. The resulted raw product (162 mg) was used 
without purification for the next step. 
Rf = 0.25 (DCM:PE = 3 :1). 
 
6.2 Ethyl 1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-yl)-2-
(trifluoromethyl)-1H-pyrrole-3-carboxylate (40) 
 
The raw starting material 4,4,4-trifluoro-3-oxo-2-(2-oxo-2-(2-(thiophen-2-
yl)thiazol-4-yl)ethyl)butanoate (41) (162 mg 0.41 mmoL) was dissolved in 4 mL 
absolute ethanol, to this solution 40 μL furan-2-ylmethanamine (4) (0.41 mmoL) 
was then slowly introduced and followed by 4 drops of acetic acid. The mixture 
was stirred under reflux for 3 hours until the starting material was completely 
consumed. (TLC, DCM:PE = 3:1 → DCM). After the reaction the mixture was 
diluted with 5 mL ethyl acetate and washed sequentially with 10 mL saturated 
sodium hydrogen carbonate solution and 10 mL water. The organic layer was 
then dried over sodium sulfate and the solvent was removed. The raw product 
was then subject to the flash chromatography (DCM → DCM:EtOAc = 40:1) to 
yield the white crystal. (29.9 mg, 16% over 2 steps) 
Rf = 0.28 (DCM). 
1H NMR (300 MHz, CDCl3): δH 7.54 (d, J = 3.66, 1H, thiophene), 7.41 (d, J = 4.97, 
1H , thiophene), 7.35 (s, 1H, thiazole), 7.09 (dd, J = 3.79, 4.97, 1H, THF), 6.86 (s, 
1H, pyrrole), 4.70 (q, 1H, THF), 4.58 (dd, J = 3.93, 14.92 , 1H, THF), 4.30 (q, J = 
7.03 Hz, 2H, CH2, OEt), 4.19 – 4-13 (m, 1H, THF), 3.64 – 3.56 (m, 1H, THF), 
3.53 – 3.44 (m, 1H, THF), 1.97 – 1.87 (m, 1H, THF), 1.80 – 1.71 (m, 2H, THF), 
1.56, 1.46 (m, 1H, THF), 1.34 (t, J = 7.32 Hz, 3H, CH3, OEt). 
13C NMR (75 MHz, CDCl3): δC 163.5 (q, CO), 161.9 (q, thiazole), 148.0 (q, 
thiazole), 137.4 (q, thiophene), 131.1 (q, pyrrole), 128.5 (t, thiophene), 128.4 (t, 
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thiophene), 127.3 (t, thiophene), 123.2 (q. pyrrole), 119.1 (q, pyrrole), 117.1 (t, 
thiazole), 113.6 (t, pyrrole), 78.7 (t, THF), 68.4 (d, THF), 51.2 (d, CH2), 29.5 (d, 
THF), 25.9 (d, THF), 14.6 (s, Me). 
CF3 is invisible in 
13C spectrum 
 
6.3 1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-yl)-2-
(trifluoromethyl)-1H-pyrrole-3-carboxylic acid (42) 
 
21.2 mg ethyl 1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-yl)-2-
(trifluoromethyl)-1H-pyrrole-3-carboxylate (40) (0.05 mmoL) was dissolved in 0.4 
mL ethanol and 0.4 mL 10% KOH ethanol solution (0.62 mmoL) was also added. 
The mixture was stirred under reflux for 2 hours until the starting material was 
completely consumed (TLC, DCM:EtOAc = 40:1 with 0.1% acetic acid). After the 
reaction, the mixture was neutralized with 1 M HCl solution. The aqueous layer 
was then extracted 3 times with chloroform (3 × 10 mL). The combined organic 
layer was then dried over sodium sulfate and the solvent was removed. The raw 
product was then deployed for the next step without purification.  
Rf = 0.28 (DCM:EtOAc = 40 :1 with 0.1% AcOH). 
6.4 1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-yl)-2-
(trifluoromethyl)-1H-pyrrole-3-carboxamide (43) 
 
28.9 mg unpurified raw product 1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-
yl)thiazol-4-yl)-2-(trifluoromethyl)-1H-pyrrole-3-carboxylic acid (42) (0.07 mmoL), 
20.9 mg HOBt·H2O (0.14 mmoL) and 26.1 mg EDC·HCl (0.14 mmoL) were 
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loaded in a round flask and dissolved in 0.8 mL DMF at 0 °C, 3 mL 2 M NH3 
dioxan solution (1.6 mmoL) was then added to the solution and the mixture was 
stirred at 60 °C for 2 hours. After the starting material was completely consumed 
(TLC, DCM:MeOH = 40 :1), the mixture was poured into 30 mL saturated sodium 
hydrogen carbonate solution. The aqueous layer was then extracted 3 times with 
ethyl acetate (3 × 15mL) and the combined organic layer was dried over sodium 
sulfate. Then the solvent was removed and the raw product was then purified by 
the flash chromatography to yield the pale white solid. (7.5 mg, 26% over 2 steps) 
Rf = 0.17 (DCM:MeOH = 40 :1). 
1H NMR (300 MHz, CDCl3): δH 7.54 (d, J = 2.54 Hz, 1H, thiophene), 7.41 (d, J = 
5.09 Hz, 1H, thiophene), 7.34 (s, 1H, thiazole), 7.10 (dd, J = 3.56, 5.09 Hz, 1H, 
thiophene), 6.68 (s, 1H, pyrrole), 5.76 (b, 2H, NH2) 4.67 (dd, J = 8.65, 14.85 Hz, 
1H, THF), 4.53 (dd, J = 3.56, 14.85 Hz, 1H, CH2), 4.20 – 4.13 (m, 1H, CH2), 3.63 
– 3.44 (m, 2H, THF), 2.00 – 1.89 (m, 1H, THF), 1.82 – 1.71 (m, 2H, THF), 1.57 – 
1.47 (m, 1H, THF). 
13C NMR (75 MHz, CDCl3): δC 166.0 (q, CO), 161.6 (q, thiazole), 147.5 (q. 
thiazole), 137.0 (q, thiophene), 131.2 (q, pyrrole), 128.1 (t, thiophene), 128.0 (t, 
thiophene), 126.9 (t, thiophene), 122.5 (q, pyrrole), 119.8 (q, pyrrole), 116.4 (t, 
thiazole), 111.1 (t, pyrrole), 78.3 (t, THF), 68.0 (d, THF), 50.6 (d, CH2), 29.1 (d, 
THF), 25.5 (d, THF). 
CF3 is invisible in 
13C spectrum 
HRMS m/z calcd for C18H17 F3N3O2S2 [M + H]
+, 428.0709; found, 428.0709. 
6.5 N-methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-
yl)-2-(trifluoromethyl)-1H-pyrrole-3-carboxamide (44) 
 
26.4 mg unpurified 1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-
yl)-2-(trifluoromethyl)-1H-pyrrole-3-carboxylic acid (42) (0.06 mmoL), 18.5 mg 
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HOBt·H2O (0.12 mmoL) and 23.6 mg EDC·HCl (0.12 mmoL) were loaded in a 
flask and dissovled at 0 °C in 0.4 mL DMF. 25.6 methylamine hydrochloride (0.37 
mmoL) was then introduced to the flask and the mixture was allowed to react for 
1 hour at RT and then overnight at 60 °C. After the starting material was gone 
(TLC DCM:EE = 40:1 with 0.1% acetic acid), 10 mL saturated sodium hydrogen 
carbonate solution was added. The aqueous layer was then extracted 3 times 
with ethyl actate (3 × 10 mL) and the combined organic layer was dried over 
sodium sulfate and concentrated in vacuo. The raw product was purified by flash 
chromatography (DCM:MeOH = 80 :1 → 40:1) to yield the white crystal. (3.5 mg, 
13% over 2 steps) 
Rf = 0.35 (DCM:EE = 40:1). 
1H NMR (300 MHz, CDCl3): δH 7.54 (d, J = 3.80, 1H, thiophene), 3.41 (d, J = 5.02, 
1H, thiophene), 7.33 (s, 1H, thiazole), 7.10 (dd, J = 3.71, 5.24, 1H, THF), 6.60 (s, 
1H, pyrrole), 5.78 (b, 1H, NH), 4.65 (q, 1H, THF), 4.50 (dd, J = 3.49, 15.07, 1H, 
THF), 4.20 – 4.12 (m 1H, THF), 3.53 (dq, J = 39.75, 2H, THF), 2.95 (d, J = 5.68, 
CH3, NHCH3), 1.98 – 1.88 (m, 1H, THF), 1.82 – 1.71 (m, 2H, THF), 1.56 – 1.47 
(m, 1H, THF). 
13C NMR (75 MHz, CDCl3): δC 165.2 (q, CO), 161.5 (q, thiazole), 147.7. (q, 
thiazole), 137.0 (q, thiophene), 131.2 (q, pyrrole), 128.1 (t, thiophene), 128.0 (t, 
thiophene), 127.0 (q, pyrrole), 126.9 (t, thiophene), 123.5 (q, pyrroel), 116.2. 
(t ,thiazole), 110.6 (t, pyrrole), 78.3 (t, THF), 67.9 (d, THF), 50.5 (d, CH2), 29.1 (d, 
THF), 26.8 (s, CH3, NHCH3), 25.5 (d, THF). 
CF3 and the nearby quartet carbon are invisible in 
13C NMR spectrum. 
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7 Synthesis of 2-methoxymethyl pyrrole derivative 
7.1 Ethyl 4-methoxy-3-oxo-2-(2-oxo-2-(2-(thiophen-2-yl)thiazol-4-
yl)ethyl)butanoate (46) 
 
8.3 mg sodium hydride (60% dispersed in mineral oil, 0.2mmoL) was washed 
under inert gas with pentane and dried in vacuo. Dry sodium hydride was then 
dispersed in 0.4 absolute THF. 22 μL ethyl 4-methoxy-3-oxobutanoate (45) (0.17 
mmoL) was added at 0 °C and the mixture was stirred at the same temperature 
for 10 min. 52.6 mg 2-bromo-1-(2-(thiophen-2-yl)thiazol-4-yl)ethanone (2) was 
dissolved in in 1 mL absolute THF and added at 0 °C, then mixture was warmed 
to RT and stirred for 3.5 hours. After the reaction (TLC DCM:EE = 40:1), the 
mixture was poured to 20 mL saturated ammonium chloride solution and the 
aqueous layer was extracted 3 times with DCM (3 × 10 mL). The combined 
organic layer was then washed by the saturated brine solution and dried over 
sodium sulfate. The solvent was then removed and the raw product was subject 
to the flash chromatography (DCM → DCm:EE = 40 :1) to yield white solid. (21 
mg, 36%) 
Rf = 0.11 (DCM). 
1H NMR (300 MHz, CDCl3): δH 8.02 (s, thiazole), 7.54 (d, J = 4.07 Hz, 1H, 
thiophene), 7.44 (d, J = 5.09 Hz, 1H, thiophene), 7.08 (dd, J = 4.07, 5.09 Hz, 1H, 
thiophene), 4.32 (s, 2H, CH2, COCH2OMe), 4.29 (q, J = 5.09 Hz, CH), 3.90 (dd, J 
= 8.65, 19.33 Hz, 1H, CH2), 3.75 (s, 3H, CH3, COCH2OMe), 3.71 (dd, J = 5.09, 
19.15 Hz, 1H, CH2), 3.46 (s, 3H, COOMe).  
13C NMR (75 MHz, CDCl3): δC 203.1 (q, CO, COCH2OMe), 192.1 (q, CO, 
COOMe), 169.5 (q, CO), 162.3 (q, thaizole), 154.2 (q, thiazole), 136.6 (q, 
thiophene), 129.1 (t, thiophene), 128.2 (t, thiophene), 127.9 (t, thiophene), 125.0 
(t, thiazole), 77.5 (d, CH2, COCH2OMe), 59.7 (s, CH3, COCH2OMe), 53.0 (t, C), 
49.2 (s, CH3, COOMe), 39.1 (d, CH2).  
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7.2 Ethyl 2-(methoxymethyl)-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-
2-yl)thiazol-4-yl)-1H-pyrrole-3-carboxylate (47) 
 
This compound was prepared by following the same procedure of generation of 
ethyl 1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-yl)-2-
(trifluoromethyl)-1H-pyrrole-3-carboxylate (40) in 82% yield.  
Rf = 0.46 (DCM:EE = 40 :1). 
1H NMR (300 MHz, CDCl3): δH 7.51 (d, J = 3.56 Hz, 1H, thiophene), 7.38 (d, J = 
5.09 Hz, 1H, thiophene), 7.25 (s, 1H, thiazole), 7.08 (dd, J = 4.07, 5.09 Hz, 1H, 
thiophene), 6.87 (s, 1H, pyrrole), 5.02 (dd, J = 12.72, 66.12 Hz, 2H, CH2, 
CH2OMe), 4.48 (dd, J = 8.65, 14.24 Hz, 1H, CH2), 4.29 – 4.21 (m, 1H, CH2), 3.81 
(s, CH3, OMe), 3.75 – 3.63 (m, 2H; THF), 3,36 (s, 3H, CH3, CH2OMe), 2.06 – 
1.97 (m, 1H, THF), 1.86 – 1.76 (m, 2H, THF), 1.58 – 1.50 (m, 1H, THF). 
13C NMR (75 MHz, CDCl3): δC 165.6 (q, CO), 161.3 (q, thiazole), 148.9 (q, 
thiazole), 137.7 (q, thiophene), 136.6 (q, pyrrole), 136.6 (q, pyrrole), 128.2 (t, 
thiophene), 128.0 (t, thiophene), 126.8 (t, thiophene), 114.7 (q, pyrrole), 114.3 (t, 
thiazole), 111.4 (t, pyrrole), 79.5 (t, THF), 68.3 (d, THF), 63.3 (d, CH2, CH2OMe), 
57.8 (s, CH3, CH2OMe), 51.2 (s, CH3, OMe), 49.8 (d, CH2), 29.4 (d, THF), 25.9 (d, 
THF). 
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7.3 Ethyl 2-(methoxymethyl)-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-
2-yl)thiazol-4-yl)-1H-pyrrole-3-carboxylate (48) 
 
This compound was prepared through the same procedure of synthesis of 1-
((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-yl)-2-(trifluoromethyl)-
1H-pyrrole-3-carboxylic acid (42). The resulted raw product was used for the next 
step without any purification. 
Rf = 0.2 (DCM:EtOAc = 40 :1 with 0.1% AcOH). 
7.4 2-(methoxymethyl)-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-
yl)thiazol-4-yl)-1H-pyrrole-3-carboxamide (49) 
 
This compound was prepared through the same procedure of generation of 1-
((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-yl)-2-(trifluoromethyl)-
1H-pyrrole-3-carboxamide (43) in 7% yield over two steps.  
1H NMR (300 MHz, CDCl3): δH 7.55 (d, J = 3.72 Hz, 1H, thiophene), 7.42 (d J = 
5.84 Hz, 1H; thiophene), 7.38 (s, 1H, thiazole), 7.22 (s, 1H, pyrrole), 7.11 (dd, J = 
3.72, 5.38 Hz, 1H, thiophene), 5.01 (q, J = 12.66 Hz, 2H, CH2, CH2OMe), 4.81 
(dd, J = 2.81, 14.48 Hz, 1H, CH, THF), 4.54 (dd, J = 8.87, 14.25 Hz, 1H, CH2), 
4.39-4.29 (m, 1H, CH2), 3.81-3.68 (m, 2H, THF), 3.36 (s, 3H, CH3, CH2OMe), 
2.16-2.05 (m, 1H, THF), 1.95-1.81 (m, 2H, THF), 1.65-1.58 (m, 1H, THF).  
HRMS m/z calcd for C19H21N3O3S2Na [M + Na]
+, 426.0917; found, 426.0916. 
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7.5 2-(methoxymethyl)-N-methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-
(thiophen-2-yl)thiazol-4-yl)-1H-pyrrole-3-carboxamide (50) 
 
This compound was prepared through the same procedure of generation of N-
methyl-1-((tetrahydrofuran-2-yl)methyl)-5-(2-(thiophen-2-yl)thiazol-4-yl)-2-
(trifluoromethyl)-1H-pyrrole-3-carboxamide (44) in 61% yield over two steps.  
Rf = 0.14 (DCM:EtOAc = 40 :1 with 0.1% AcOH). 
1H NMR (300 MHz, CDCl3): δH 7.51 (d, J = 4.06 Hz, 1H, thiophene), 7.38 (d, J = 
5.47 Hz, 1H, thiophene), 7.22 (s, 1H, thiazole), 7.08 (dd, J = 3.24, 5.47 Hz, 1H, 
thiophene), 6.71 (s, 1H, pyrrole), 6.51 (b, 1H, NH), 4.87 (dd, J = 13.18, 49.07 Hz, 
2H, CH2, CH2OMe), 4.68 (dd, J = 2.84, 15.00 Hz, 1H, CH, THF), 4.46 (dd, J = 
7.50, 14.60 Hz, 1H, CH2), 4.25 – 4.16 (m, 1H, CH2), 3.74 -3.62 (m, 2H, THF), 
3.40 (s, 3H, CH3, OMe), 2.93 (d, J = 5.07 Hz, 3H, CH3, NHCH3), 2.04 – 1.96 (m, 
1H, THF), 1.83 – 1.75 (m, 2H, THF), 1.55 – 1.48 (m, 1H, THF). 
13C NMR (75 MHz, CDCl3): δC 165.6 (q, CO), 160.7 (q. thiazole), 148.4 (q, 
thiazole), 137.1 (q, thiophene), 132.2 (q, pyrrole), 127.6 (t, thiophene), 127.4 (t, 
thiophene), 127.4 (q, pyrrole), 126.2 (t, thiophene), 119.1 (q, pyrrole), 113.& (t, 
thiazole), 108.9 (t, pyrrole), 78.9 (t, THF), 67.7 (d, THF), 63.3 (d, CH2), 57.1 (s, 
OMe), 48.7 (d, CH2, MeOCH2), 28.6 (d, THF), 26.0 (s, NHCH3), 25.3 (d, THF). 
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8 Synthesis of the lead structure of the bicyclic inhibitor 
8.1 1-(4-acetylphenyl)-1H-pyrrole-2,5-dione (75) 
 
1 g 1-(4-aminophenyl)ethanone (74) (7.4 mmoL) was dissovled in t15 mL dioxane 
and the solution was cooled to 0 °C, at this temperature 2.1 g phosphorus 
pentoxide (14.8 mmoL) was slowly added and followed by 858.8 mg maleic acid 
(73) (7.4 mmoL). The mixture was stirred under reflux for 1 hour and the both 
starting materials were completely consumed (TLC: DCM:EtOAc = 40:1). After 
the reaction, the mixture was poured to 50 mL ice water. Then the aqueous layer 
was extracted 3 times with chloroform (3 × 30 mL). The combined organic layer 
was dried over sodium sulfate and the solvent was then removed. The raw 
product was purified through the flash chromatography (DCM:EtOAc = 40 :1) in 
52% yield (827 mg) as the white solid.  
Rf = 0.25 (DCM:EtOAc = 40 :1) 
1H NMR (300 MHz, CDCl3): δH 8.05 (d, J = 8.38 Hz, 2H, HAr), 7.52 (d, J = 8.69 Hz, 
2H, HAr), 6.88 (s, 2H, alkene), 6.21 (s, 3H, CH3). 
13C NMR (75 MHz, CDCl3): 197.0 (q, CO), 168.9 (q, 2C, CO, imide), 135.9 (q, 
CAr), 135.5 (q, CAr), 134.3 (t, 2C, alkene), 129.2 (t, 2C, CAr), 125.4 (t, 2C, CAr), 
26.6 (s, CH3).  
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8.2 (S,E)-methyl 4-methyl-2-(2-methylbenzylideneamino)pentanoate (78) 
 
1 g L-leucine methyl ester hydrochloride (76) (5.5 mmoL) was dissolved in 9 mL 
absolute DCM, 1.05 g anhydrous sodium sulfate (7.36 mmoL) was then added to 
this solution. 890 µL triethylamine (6.44 mmoL) was then dropwise introduced to 
this mixture and the mixture was stirred at RT for 1 h. After 1 h, 530 µL 2-
methylbenzaldehyde (77) (4.49 mmoL) was added to the mixture and the mixture 
was allowed to react for 3 days. After 3 days, the starting materials were found to 
be completely consumed (TLC: DCM), the sodium sulfate was subsequently 
filtered and the solution was concentrated to yield a white solid. The solid was 
then washed with petroleum ether twice (2 × 30 mL) and followed by 10 mL 
chloroform. Then the white solid was dried in vacuo and used for the next step 
without further purification.  
Rf = 0.21 (DCM) 
 
8.3 (1S)-methyl 5-(4-acetylphenyl)-1-isobutyl-4,6-dioxo-3-o-
tolyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate (79) 
 
320 mg 1-(4-acetylphenyl)-1H-pyrrole-2,5-dione (75) (1.5 mmoL) was dispersed 
in 13 mL toluene. 1.1 g unpurified (S,E)-methyl 4-methyl-2-(2-
methylbenzylideneamino)pentanoate (78) (4.5 mmoL) was then added to the 
suspension and the mixture was stirred under reflux for 3 days. After 3 days, the 
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reaction was accomplished (TLC: DCM), the solvent was removed and the raw 
product was subjected to the flash chromatography (DCM) to yield 312.5 mg 
product (45% yield over two steps) as the white solid.  
Rf = 0.14 (DCM) 
1H NMR (300 MHz, MeOD): δH 7.82 (d, J = 8.12 Hz, 2H, HAr), 7.62-7.57 (m, 1H, 
HAr), 7.34 (d, J = 8.23 Hz, 2H, HAr), 7.15-7.16 (m, 3H, HAr), 4.79 (d, J = 7.06 Hz, 
1H, H3), 3.80 (s, 3H, CH3, COOMe), 3.70 (t, J = 7.64 Hz, 1H, H2), 3.47 (d, J = 
8.23 Hz, 1H, H1), 2.53 (s, 3H, CH3, COMe), 2.44 (s, 3H, CH3, Ar-Me), 2.25-2.15 
(m, 1H, H5), 1.95-1.74 (m, 2H, CH2), 1.04 (d, J = 6.12 Hz, CH3), 0.96 (d, J = 6.59 
Hz, CH3). 
13C NMR (75 MHz, MeOD): δC 199.4 (q, CO, COMe), 177.0 (q, CO, COOMe), 
172.2 (q, 2C, CO, imide), 144.1 (q, CAr), 136.9 (q, CAr), 136.6 (q, CAr), 133.5 (q, 
CAr), 131.3 (t, CAr), 130.3 (t, 2C, CAr), 128.3 (t, CAr), 127.1 (t, CAr), 126.7 (t, CAr), 
120.6 (t, 2C, CAr), 71.6 (q, C4), 62.5 (t, C3), 60.9 (t, C1), 54.0 (t, C2), 52.8 (s, Me, 
COOMe), 48.4 (d, CH2 visible in DEPT), 26.4 (s, CH3), 26.2 (s, CH3), 25.1 (s, CH3, 
COMe), 23.7 (t, C5), 19.8 (s, CH3, Ar-Me) 
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Part II. Development of solid phase synthesis of cyclic peptides 
1 General details 
 
Materials. Sodium hydrogen sulfide, potassium carbonate anhydrous and 
bromopyruvic acid were purchased from Abcr GmbH, 2–(1H–benzotriazol–1–yl)–
1,1,3,3–tetramethyluronium  hexaflurorophosphate (HBTU), N,N-
diisopropylethylamine (DIPEA), triflouroacetic acid (TFA), tris-(2-carboxyethyl)-
phosphine hydrochloride (TCEP), piperidine and dimethylformamide (DMF) were 
obtained from Carl Roth GmbH. Fmoc-Gly-OH, Fmoc-Leu-OH, Fmoc-Val-OH, 
Fmoc-Ser-OH, Fmoc-Trp-OH, Fmoc-Ile-OH, Fmoc-Ala-OH, Fmoc-Phe-OH and 2-
(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate (TBTU) 
were obtained from Fa. Gerhardt (Wolfhagen, DE). Fmoc-Abu-OH and Fmoc- 
Cys(StBu)-OH were obtained from Nova Biochem. TentaGel S RAM resin was 
obtained from Iris Biotech GmbH (Marktredwitz, DE), TentaGel S NH2 resin was 
obtained from RAPP Polymere GmbH (Tübingen, DE). Sodium borohydride 
powder, 2-methyl-2-propanethiol, 4-mercaptophenylacetic acid (MPAA), Ion 
exchange resin Dowex 1×2 (Cl-) form (200-400 mesh), formic acid, 
triisopropylsilane, methanol anhydrous and dichloromethan (DCM) were obtained 
from Sigma Aldrich. Ion exchange resin Dowex 50×2 (H
+
) from (200-400 mesh) 
was obtained from Alfa Aesar. Tetrabutylammonium fluoride trihydrate (TBAF) 
and 4-(dimethylamino)pyridine (DMAP) were obtained from Acros organics. 1-
Methyl-2-pyrrolidinone (NMP) was obtained from Biosolve BV (Valkenswaad, NL). 
1-Butanol was obtained from Th. Geyer (Renningen, DE). Acetonitrile HPLC 
grade, methanol and chloroform were purchased from J.T.Baker (Avantor 
performance materials, Deventer, NL). tert-butyl(chloro)-dimethylsilane was 
obtained from Fluorochem Ltd. (Hadfield, USA). Imidazole was obtained from 
Fluka. 
Thin layer and flash chromatography 
Analytic TLC was run on aluminium sheets coated with silica gel 60 F254. The 
flash chromatography was carried out under slight pressure on the flash 
chromatography column loaded with silica gel 60 (Merck, 40 – 60 μm, 60 Å).  
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Analytic and preparative HPLC 
A Merck Hitachi D-7000 HPLC instrument with a Phenomenex C5 column (5 µm, 
50 × 2.00 mm) at flow rate 0.7 mL / min was used for analytic HPLC. Semi-
preparative HPLC was performed by using a Thermo scientific UltiMate 3000 
instrument with a Phenomenex C18 column (5 µm, 250 × 21 mm) at a flow rate of 
10 mL / min.  
Nuclear magnetic resonance 
All NMR sample were dissolved either in CD3OD (Sigma Aldrich) or DMSO-d6 
(Deutero GmbH, Kastellaun, DE) and spectra were recorded at 298K.  
Proton nuclear magnetic resonances (1H NMR) and carbon nuclear magnetic 
resonances (13C NMR) were recorded on 700 Hz and 500 Hz Brucker NMR 
spectrometers (Ascend 700 / Avance III HD, Ultrashield 500 Plus / Avance III 500) 
at 298 K, and the chemical shifts are reported in parts per million (δ) from an 
internal standard of residual chloroform (7.24 ppm, 77.0 ppm), methanol (3.31 
ppm, 4.78 ppm, 49.0 ppm) and DMSO-d6 (2.49 ppm, 39.7 ppm). Proton NMR 
signals multiplicity is reported as follows: s = singlet, d = doublet, t = triplet, q = 
quartett, m = multiplet, b = broad. 
LC-MS and high-resolution mass spectroscopy 
LC-MS was carried out on an Agilent Technologies 1100 series device. A 
Phenomenex column (2.6 µm, 50 × 2.1 mm) and a flow rate 10 mL / min is used 
for the LC-MS. High-resolution mass spectra (HRMS) were obtained on a 
Brucker MaXis mass spectrometer by using electron spray ionization (ESI) from 
the department of microbial drugs, Helmholtz Centre for Infection Research, 
Braunschweig, Germany. 
Microwave and automated SPPS synthesizer 
The microwave assisted disulfide formation was performed in a CEM Discover S–
class microwave synthesizer with microwave suitable glass vessel.  
The automatic peptide synthesis was carried out on a MultiSyn tech´s Syro 
peptide synthesizer.   
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2 Procedure of preparing ion exchange column  
2.1 Preparation of (H+) exchange column 
15 g commercially purchased Dowex 50×2 (H
+
) form resin was soaked in 4 M 
HCl and swollen for 1Hour. The resin was then loaded in a chromatography 
column (20 × 1 cm), washed slowly with 4 M HCl for 1Hour and followed by the 
deionized water until it was neutral.  
2.2 Preparation of (CH3COO
-) exchange column 
20 g commercially purchased Dowex 1×2 (Cl-) resin was soaked in 1 M NaOH 
and swollen for 1 hour. The resin was then loaded in a chromatography column 
(20 ×1 cm) and washed slowly with 1 M NaOH for 1 additional hour and followed 
by the deionized water until pH was neutral. Afterward the column was slowly 
washed with 3 M sodium acetate solution for 1 hour to load the acetate ion into 
the resin, the rest sodium acetate solution was then washed out by deionized 
water. The column was ready for the ion exchange as soon as the pH value 
reaches 7. 
 
3 Procedure of Kaiser test to determine the free amino groups 
10 mg resin was picked up from the syringe and washed a few times with DMF 
followed by DCM and dried under vacuum. To the resin beads, three drops of 
each reagent A (5 g ninhydrin in 100 ml ethanol), reagent B (80 g phenol in 20 ml 
ethanol) and reagent C (2 ml 0.00 1 M aqueous KCN in 98 ml pyridine) [128] were 
added and this mixture was heated at 120 °C for 3 min. Based on the following 
chart, the progress of reaction could be qualitatively estimated. 
solution bead completeness of reaction 
colorless colorless completed 
light blue to blue colorless nearly completed, capping of 
unreacted amino group 
light blue dark blue Incomplete, recoupling 
required 
dark blue dark blue coupling failed 
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4 Determination of the loading through Fmoc release UV assay  
After coupling of the first amino acid, the resin was washed a few times with DMF 
followed by the DCM and completely dried under vacuum. Between 5 to 10 mg 
resin would be taken into a vial. 1 mL 20% piperidine / DMF solution was then 
added to the vial and shaken for 20 min. Afterwards, two aliquots of each 100 µL 
piperidine / DMF solution from the vial were diluted with 10 mL DMF in the flasks. 
The UV absorbance of the Fmoc group was measured on the UV spectrometer at 
280 nm, while the pure DMF was taken as the blank sample. The final loading 
was then calculated by using the following equation: 
          
     
      
 
A = Fmoc absorbance  
W = weight of the resin 
5 Preparation of the latent thioester linker 12 
5.1 2-hydroxy-3-mercaptopropanoic acid (3) 
 
Anhydrous sodium hydrogen sulfide (1 g, 17.8 mmoL) was dissolved in 5 mL 
anhydrous methanol and this solution was introduced into the reaction vessel 
loaded with bromopyruvic acid (1.5 g, 8.9 mmoL) in 10 mL anhydrous methanol 
over 90 min at 0 °C. During the addition a white precipitation was formed 
gradually. After the addition of the sodium hydrogen sulfide the reaction mixture 
was stirred at RT for further 20 min and the vessel was added with 5 mL ethanol 
afterwards. The precipitation was then filtered and washed three times with 
absolute ethanol and dried under vacuum. The white powder was then dissolved 
in a mixture of 9 mL mL 0.1 M HCl and 15 mL ethanol and recrystallized in the 
fridge overnight. The newly grew white crystal was filtered and washed three 
times with 5 mL absolute ethanol each then followed by two times each of 2 mL 
75% ethanol and the raw product was  dried for one day over phosphorus 
pentaoxide in an evacuated desiccator. 997 mg raw intermediate (5.6 mmoL) was 
dissolved in 7 mL deionized water and 275 mg sodium hydride (7.3 mmoL) was 
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slowly added at RT under stirring. After the introduction of sodium hydride, the 
mixture was stirred for one further hour. After the starting material was completely 
consumed (TLC, n-butanol:formic acid:water = 75%:15%:10%) the solution was 
directly loaded into the cation exchange column, and slowly eluted with 150 mL 
deionized water. The fractions were collected and concentrated to dryness by 
rotation evaporator.  The white powder was again dissolved in 2 mL deionized 
water  and the pH value was adjusted to around 6 by using the 28% ammonium 
hydroxide solution, then the solution was loaded in the anion exchange column 
and eluted firstly with 100 mL deionized water and followed by 200 mL 1 M formic 
acid. The fractions were collected and dried under vacuum to yield a white fine 
powder (489 mg, 45%) 
Rf = 0.79 (n-butanol:formic acid :water = 75%:15%:10%) 
1HNMR (500 MHz, MeOD): δH 4.32 (t, J = 4.68 Hz, 1H), 2.92 (dd, J = 13.45, 4.09 
Hz, 1H), 2.83 (dd, J = 13.74, 5.85 Hz, 1H). 
13CNMR (125 MHz, MeOD): δC 175.75, 72.71, 29.41. 
HRMS m/z:calcd for C3H5O3S [M – H]
-, 120.9959, found 120.9956. 
 
5.2 3-(tert-butyldisulfanyl)-2-hydroxypropanoic acid (4) 
 
150 mg 2-hydroxy-3-mercaptopropanoic acid (3) (1.2 mmoL) was dissolved in 15 
mL buffer solution (10 mM ammonium acetate solution in acetonitrile:water = 3:2) 
in a microwave suitable glass tube (diameter 2.5 cm),1.35 mL 2-methyl-2-
propanethiol (12 mmoL) and 0.85 mL DMSO (12 mmoL) were subsequently 
added into this. The tube was sealed and placed into a CEM microwave and 
stirred under following configurations (power = 150 W, Tmax = 150 °C) for 10 min. 
After all the starting material disappeared (TLC, n-butanol:formic acid:water = 
75%:15%:10%), the mixture was transferred into a round bottomed flask and 
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concentrated to about 5 mL by rotation evaporator. The DMSO and water residue 
was subsequently removed by a centrifugal evaporator (Christ, RVC 2–25 CD 
plus) at 40 °C and the raw product was finally purified through the preparative 
HPLC (water:acetonitrile, gradient 5%–95%, 30 min.) to yield a white fine powder. 
(240 mg, 95%) 
Rf = 0.91 (n-butanol:formic acid:water = 75%:15%:10%) 
1HNMR (500 MHz, MeOD): δH 4.40 (q, J = 3.97 Hz, 1H), 3.19 (dd, J = 13.39, 3.93 
Hz, 1H), 2.98 (dd, J = 13.35, 7.93 Hz, 1H), 1.38 (s, 9H). 
13CNMR (125 MHz, MeOD): δC 175.94, 70.54, 48.57, 46.35, 30.23 (3C). 
HRMS m/z:calcd for C7H13O3S2Na [M – H]
-, 233.0282, found 233.0274. 
5.3 2-(tert-butyldimethylsilyloxy)-3-(tert-butyldisulfanyl)propanoic acid (12) 
 
240 mg 3-(tert-butyldisulfanyl)-2-hydroxypropanoic acid (4) (1.14 mmoL) was 
dissolved in 2.5 mL anhydrous DMF, 372 mg imidazole (5.4 mmoL) and 416 mg 
tert-butyldimethylsilyl chloride (2.7 mmoL) were added too. The mixture was 
stirred at RT overnight and then diluted with 8 mL (ethyl acetate:toluene = 1:1) 
solvent. The organic layer was then sequentially washed with each 15 mL of 10% 
citric acid, saturated sodium hydrogen carbonate solution, water and saturated 
brine solution and dried over sodium sulfate. The solvent was then evaporated to 
give a pale yellow oily substance. All yellow oily substance was dissolved in 22 
mL methanol, 690 mg potassium carbonate (5 mmoL) was then added and 
followed by 7.2 mL water at 0 °C. The mixture was warmed up to RT and stirred 
overnight. After the reaction is finished (TLC: DCM:MeOH = 20:1) the mixture 
was slowly acidified with 10% citric acid. At pH = 3 white solids were precipitated 
and these were extracted 3 times with ethyl acetate (3 × 10 mL). The organic 
layer was then dried over sodium sulfate and the solvent was evaporated. The 
raw product was subjected to the flash chromatography (100 mL fractions DCM 
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followed by 200 mL DCM:MeOH = 40:1) to yield the pale yellow oily substance 
(277 mg, 75%) and this was utilized immediately in the next step due to its high 
instability. 
Rf = 0.18 (DCM:MeOH = 20 :1) 
1HNMR (500 MHz, CDCl3): δH 4.49 (q, J = 3.64 Hz, 1H), 3.15 (dd, J = 13.57, 3.54 
Hz, 1H), 2.95 (dd, J = 13.58, 7.36 Hz, 1H), 1.33 (s. 9H), 0.94 (s, 9H), 0.19 (s, 3H), 
0.15 (s, 3H). 
13CNMR (125 MHz, CDCl3): δC 172.91, 71.32, 48.34, 45.64, 29.89 (3C), 25.72 
(3C), -4.54. 
HRMS m/z:calcd for C13H27O3S2Si [M – H]
-, 323.1171, found 323.1181. 
6 General procedure of loading of the linker 12 onto the Tentalgel NH2 resin 
 
486.7 mg TentaGel S NH2 resin (loading: 0.27 mmoL / g) was swollen in DMF in 
a syringe with filter for 30 min and then drained to dryness. 150 mg linker (0.46 
mmoL) was dissolved under inert gas in 0.5 mL anhydrous DMF and injected into 
a HBTU solution 174.5 mg HBTU (0.46 mmoL) was dissolved under inert gas in 
0.5 mL anhydrous DMF) 156 µL DIPEA (0.92 mmoL) was then added into this 
and the mixture was pre activated for 5 min. before it was injected into the 
syringe loaded with resin. The resin was shaken under inert gas overnight on an 
orbital shaker and 20 mg of the resin was taken and tested with Kaiser reagent. 
Judged by the very pale blue color of the test solution and the colorless beads 
the reaction was nearly completed and the rest solution was drained. The resin 
was washed a few times with DMF followed by DCM and dried in vacuo. The 
unreacted free amino groups were capped twice for each 15 min. with acetylation 
mixture (DMF:acetic anhydride:water = 8:1 :1).  
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7 TBAF deprotection and the coupling of the first amino acid through the 
esterification 
 
The resin was swollen in anhydrous THF for 15 min and then the solvent was 
drained, 5 mL fresh prepared 1 M TBAF THF solution was added. The TBAF 
group was deprotected overnight and the TBAF solution was drained. 10 fold first 
amino acid was dissolved in 0.5 mL DMF and added into the HBTU solution (10 
folds HBTU dissolved in 0.5 mL DMF) the amino acid was pre-activated for 5 min 
with additional 20 folds of DIPEA. After the pre-activation the mixture was 
injected into the syringe loaded with the resin. Additionally 1 fold of DMAP was 
added into this syringe as well. The resin was shaken for 2 hours and washed a 
few times with DMF. Then the coupling of the first amino acid was repeated 
under the same condition for one additional hour. After the coupling was 
completed, the resin was washed with DMF, tested with Fmoc release UV assay 
(loading: 93%) and the following amino acids were allowed to be assembled by 
the automated Fmoc-SPPS. 
 
8 Post SPPS work-up and deprotection of the various protecting groups 
After the automated Fmoc-SPPS was done, the resin was washed a few times 
with DMF followed by the DCM and completely dried under vacuum. The 
deprotecting cocktail (TFA:triisopropylsilane:water = 9.5:0.5:0.5  (in case the 
sequence contains tryptophan, the cocktail mixture was changed to 
TFA:phenol:dimethyl sulfide:water = 8.5:0.5:0.5 :0.5 ) was added then the 
deprotection mixture was covered with aluminum sheet and with occasionally 
shake for two hours. After the deprotection, the deprotecting cocktail was drained 
and the resin was washed a couple of times with DMF and DCM then dried under 
vacuum and the cyclization will be carried out.  
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9 General procedure of the on-resin NCL cyclization 
100 mg resin was swollen in cyclization buffer solution (0.1 M sodium phosphate 
buffer solution: acetonitrile = 4:1, containing 10 mM TCEP, pH = 6.7 ~ 6.8) and 
shaken under inert gas for 24 hours, after the cyclization the buffer solution was 
drained and the resin was wash a few times with mixture water:acetonitrile = 4:1, 
the filtrate was combined with the buffer solution and was directly freeze-dried. 
The raw product was subjected to semi-preparative HPLC to yield the white and 
hydroscopic substance.  
9.1 Cyclo Cys-Ser-Ser-Leu-Gly (19´) 
 
HPLC purification: t
R
 = 20.87 min, UV = 205 nm, gradient: ACN / water = 0% - 
70%, 90 min. 
1HNMR (700 MHz, DSMO): δH 8.74 (t, J = 5.47 Hz, 1H), 8.2 (d, J = 8.62Hz, 1H), 
8.07 (d, J = 6.61Hz, 1H), 7.69 (d, J = 9.02Hz, 1H), 7.5 (d, J = 8.62 Hz, 1H), 
5.32(b, 2H), 4.3 (m, 1H), 4.28 (m, 1H), 4.26 (m, 1H), 4.01 (m, 1H), 3.94 (m, 1H), 
3.67 (m, 2H), 3.65 (m, 2  H), 3.60 (m, 1H), 2.87 (m, 1H), 2.74 (m, 1H), 2.55 (t, J = 
8.43 Hz, 1H), 1.55 (m, 1H), 1.45 (m, 2H),0.88 (d, J = 5.07 Hz, 3H), 0.87 (d, J = 
5.07 Hz, 3H). 
13C NMR (175 MHz, DMSO): δC 172.84, 170.11, 169.93, 169.37, 169.18, 60.47, 
60.28, 56.75, 56.68, 54.64, 50.91, 43.54, 41.10, 25.44, 24.35, 22.83, 21.92.  
HRMS m/z:calcd for C17H30N5O7S [M + H]
+, 448.1866; found 448.1858. 
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9.2 Cyclo Cys-Ser-Ser-Leu-Phe (20´) 
 
HPLC purification: tR = 36.65 min., UV = 220 nm, gradient: ACN / water = 5% - 
95%, 70 min. 
1HNMR (700 MHz, DSMO): δH 8.17 (d, J = 8.28 Hz, 1H), 8.04 (d, J = 8.69 Hz, 1H), 
7.87 (d, J = 8.28 Hz,1H), 7.74 (d, J = 7.86 Hz, 1H), 7.68 (d, J = 8.69 Hz, 1H), 7.28 
(t, J = 7.86 Hz, 2H), 7.22 (d, J = 7.86 Hz, 3H), 5.36 (broad, 1H), 5.24 (b, 1H), 4.36 
(m, 1H), 4.2 (m, 1H), 4.16 (m, 1H), 4.12 (m, 1H), 4.08(m, 1H), 3.70(m, 2  H), 
3.62(m, 2H), 3.08 (m, 1H), 3.02 (m, 1H), 2.4 (t, J= 8.26 Hz, 1H), 1.45 (m, 1H), 
1.32 (m, 2H), 0.80 (d, J = 6.09 Hz, 3H), 0.77(d, J = 6.09 Hz, 3H). 
13CNMR (175 MHz,  DMSO): δC 171.35, 170.70, 169.83, 169.71, 169.18, 137.28, 
129.06 (2C), 128.23 (2C), 126.48, 60.40, 60.35, 57.49, 56.32, 55.95, 55,49, 
52.97, 40.58, 36.73, 24.88, 24.10, 22.39, 21.98. 
HRMS m/z:calcd for C17H30N5O7S [M + H]
+, 538.2335; found 538.2340. 
9.3 Cyclo Cys-Ser-Typ-Leu-Gly (22´) 
 
HPLC purification: tR = 38.78 min., UV = 220 nm, gradient: ACN / water = 5% - 
95%, 70 min. 
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1HNMR (700 MHz, DSMO): δH 10.88 (d, J = 1.83 Hz, 1H), 8.8 (t, J = 5.7 Hz, 1H), 
8.38 (d, J = 8.16 Hz, 1H), 8.12 (d, J = 6.78 Hz, 1H), 7.74 (d, J = 8.50 Hz,  1H), 
7.58 (d, J = 8.62 Hz, 1H), 7.53 (d, J = 7.93 Hz, 1H), 7.33 (d, J = 8.44 Hz,1H), 7.14 
(d; J = 2.07 Hz , 1H), 7.07 (td, J = 7.56, 0.89 Hz, 1H), 6.98 (td, J = 7.34, 0.78 Hz, 
1H), 5.26 (t, J = 4.76 Hz, 1H), 4.27 (m, 1H), 4.23 (m, 2H), 4.14 (m, 1H), 3.90 (m, 
1H), 3.69 (m, 1H), 3.54 (m, 1H), 3.38 (m, 1H), 3.18 (m, 2H), 2.86 (m, 1H), 2.54 (t, 
J = 8.50 Hz, 1H), 2.74 (m, 1H), 1.45 (m, 2H), 1.39 (m, 1H), 0.86 (d, J = 6.54 Hz, 
3H), 0.84 (d, J = 6.54 Hz, 3H). 
13CNMR (175 MHz,  DMSO): δC 173.33, 171.46, 170.00, 169.47, 169.28, 136.10, 
127.01, 123.56, 120.99, 118.37, 118.15, 111.37, 109.58, 60.37, 57.14, 56.66, 
54.70, 50.77, 43.62, 40.97, 26.32, 25.37, 24.38, 22.90, 21.75. 
HRMS m/z:calcd for C25H35N6O6S [M + H]
+, 547.2339; found 547.2336. 
9.4 Cyclo Cys-Ala-Ala-Leu-Gly (24´) 
 
HPLC purification: tR = 26.6 min., UV = 205 nm, gradient: ACN / water = 5% - 
95%, 70 min. 
1HNMR (700 MHz, DSMO): δH  8.89 (t, J =8.03 Hz, 1H), 8.36 (d, J = 7.9 Hz, 1H), 
8.03 (d, J = 6.6 Hz, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.36 (d, J = 8.64 Hz, 1H), 4.27 
(m, 2H), 4.24 (m, 1H), 3.92 (m, 2H), 3.37 (m, 1H), 2.90 (m, 2H), 2.42 (t, J = 8.92 
Hz, 1H), 1.53 (m, 1H), 1.44 (m, 2H), 1.33 (m, 3H), 1.32 (m, 3H), 0.89 (d, J = 7.20 
Hz, 3H), 0.88 (d, J = 7.0 Hz, 3H). 
13CNMR (175 MHz,  DMSO): δC 173.49, 172.77, 171.24, 169.52, 168,94, 56,33, 
51,72, 50.56, 48.87, 43.70, 41.25, 25.29, 24.49, 22.95, 21.77, 16.93, 16.54. 
HRMS m/z:calcd for C17H30N5O5S [M + H]
+, 416.1968, found 416.1962. 
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9.5 Cyclo Cys-Ser-Leu-Leu-Phe-Gly (25´) 
 
HPLC purification: tR = 44.14 min., UV = 220 nm, gradient: ACN / water = 5% - 
95%, 70 min. 
1HNMR (700 MHz, DSMO): δH 8.82 (t, J = 5.36 Hz, 1H), 8.48 (d, J = 8.66 Hz, 1H), 
7.88 (d, J = 5.78 Hz, 1H), 7.83 (d, J = 8.25 Hz, 1H), 7.74 (d, J = 8.25 Hz, 1H), 
7,38 (d, J = 5.78 Hz, 1H), 7.25 (t, J = 7.43 Hz, 2H), 7.20 (t, J = 7.01 Hz, 1H), 
7.12(d, J = 7.01 Hz, 2H), 5.36 (t, J = 6.48 Hz 1H), 4.37 (m, 1H), 4.35 (m, 1H), 
4.31 (m, 1H), 3.98(m, 1H), 3.81(m, 2H), 3.69 (m, 1H), 3.45(m, 1H), 2.97 (m. 2H), 
2.93 (m, 1H), 2.76 (m, 1H), 2.41 (t, J = 8.51 Hz, 1H), 1.62 (m, 1H), 1.49(m, 2H), 
1.44 (m, 1H), 1.43 (m, 1H), 1.36 (m, 1H), 0.89 (d, J = 6.77 Hz, 3H), 0.84 (d, J = 
6.21 Hz, 3H), 0.83 (d,  J = 6.7 Hz, 3H), 0.79 (d, J = 6.21 Hz, 3H). 
13CNMR (175 MHz,  DMSO): δC 171.92, 171.53, 169.90, 169.64, 169.39, 169.20, 
136.99, 129.16 (2C), 128.01 (2C), 126.39, 61.49, 55.66, 54.20, 53.95, 53.20, 
51.89, 43.47, 40.59, 40,15, 37.56, 25.01, 24.19 (2C), 22.86, 22.80, 21.48, 21.28. 
HRMS m/z:calcd for C29H45N6O7S [M + H]
+, 621.3070, found 621.3072. 
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9.6 Cyclo Cys-Ser-Trp-Leu-Phe-Gly (26´) 
 
HPLC purification: tR = 45.43 min., UV = 220 nm, gradient: ACN / water = 5% – 
95%, 70 min. 
1H NMR (700 MHz, DSMO): δH 10,89 (s, 1H), 8.8 (t, J = 5.5.2 Hz, 1H), 8.47 (d, J = 
7.73 Hz, 1H), 7.98 (d, J = 6.35 Hz, 1H), 7.86 (d, J = 8.55 Hz, 1H), 7.71 (d, J = 
7.73 Hz, 1H), 7.5 (d, J = 7.73 Hz, 1H), 7,36 (d, J = 5.93 Hz, 1H), 7.33 (d, J = 8.03 
Hz, 1H), 7.24 (m, 2H), 7.18 (m, 2H), 7.10 (d, J = 8.01 Hz, 2H), 7.07 (t, J = 8.41 
Hz, 1H), 6.98 (t, J = 7.61 Hz, 1H), 5.35 (t, J= 5.91 Hz, 1H), 4.40 (m, 1H), 4.30 (m, 
1H), 4.28 (m, 1H), 4.26 (m, 1H), 4.03 (m, 1H), 3.76 (m, 2H), 3.69 (m, 1H), 3.44 
(m, 1H), 3.10 (m, 2H), 2.93 (m, 2H), 2.75 (m, 1H), 2.42 (t, J = 8.50 Hz, 1H), 1.27 
(m, 2H), 1.23 (m, 1H), 0.76 (d, J = 5.81 Hz, 3H), 0.69 (d, J = 5.81 Hz, 3H). 
13C NMR (175 MHz, DMSO): δC 171.49, 171.44, 171.20, 169.88, 169.52, 169.16, 
137.01, 136.06, 129.12 (2C), 127.96 (2C), 127.10, 126.32, 123.55, 120.95, 
118.34, 118.08, 111.33, 109.36, 61.49, 55.47, 54.18, 53.74, 52.35, 52.14, 43.58, 
40.43, 37.58, 28.97, 26.85, 23.92, 22.53, 21.48. 
HRMS m/z:calcd for C34H44N7O7S [M + H]
+, 694.3022, found 694.3043. 
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9.7 Cyclo Cys-Ala-Ala-Ser-Ser-Leu-Gly (27´) 
 
HPLC purification: tR = 23.56 min., UV = 205 nm, gradient: ACN / water = 5% - 
95%, 70 min. 
1H NMR (700 MHz, DSMO): δH 8.33 (d, J = 5.80 Hz, 1H), 8.13 (t, J = 8.13 Hz, 
1H), 8.08 (d, J = 6.69 Hz, 1H), 8.05 (d, J = 7.14 Hz, 1H), 7.94 (d, J = 7.14 Hz, 1H), 
7.91 (d, J = 7.14 Hz, 1H), 7.78 (d, J = 8.13 Hz, 1H),5.32 (t, J = 5.01 Hz, 2H), 4,35 
(m, 1H), 4.20 (m, 2H), 4.16 (m, 1H), 4.08 (m, 1H), 4.03 (m, 1H), 3.94 (m, 1H), 
3.72 (m, 2H), 3.62 (m, 2  H), 3.55 (m, 1H), 2.86 (m, 1H), 2.81 (m, 1H), 2.29 (t, J = 
8.46 Hz, 1H), 1.58 (m, 1H), 1.53 (m, 2H), 1.27 (t, J = 7.24 Hz, 6H), 0.87 (d, J = 
6.43 Hz, 3H), 0.83 (d, J = 6.43 Hz, 3H). 
13C NMR (175 MHz, DMSO): δC 172.26, 171.99, 171.86, 170.36, 169.70, 169.50, 
168.87, 61.20, 61.08, 56.05, 55.82, 55.01, 51.91, 46.68, 49.07, 42.62, 40.48, 
25.87, 24.11, 22.88, 21.50, 16.98, 16.93. 
HRMS m/z:calcd for C23H40N7O9S [M + H]
+, 590.2608, found 590.2596. 
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MCAZ7599.010.001.1r.esp
7.6 7.5 7.4 7.3 7.2 7.1 7.0 6.9 6.8 6.7 6.6 6.5 6.4 6.3 6.2 6.1
Chemical Shift (ppm)
1
.1
9
1
.0
5
1
.0
0
MCAZ7599.011.001.1r.esp
280 260 240 220 200 180 160 140 120 100 80 60 40 20 0 -20
Chemical Shift (ppm)
1
9
2
.1
1
4
4
.7
1
3
3
.9
1
2
8
.3
1
2
6
.9
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MCAR7653.010.001.1r.esp
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
Chemical Shift (ppm)
2
.2
6
1
.1
9
1
.0
7
1
.1
6
1
.0
0
MCAR7653.011.001.1r.esp
280 260 240 220 200 180 160 140 120 100 80 60 40 20 0 -20 -40
Chemical Shift (ppm)
1
8
5
.9
1
6
2
.2
1
5
2
.3
1
3
6
.1
1
2
9
.0
1
2
8
.1
1
2
7
.8
1
2
5
.9
3
3
.7
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MCAZ7619.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
3
.5
4
1
.1
6
1
.2
8
3
.2
5
1
.7
5
2
.1
3
1
.1
1
1
.0
1
1
.1
5
2
.2
0
1
.0
0
MCAZ7619.011.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
7
0
.5
1
6
1
.7
8
2
.6
7
8
.0
6
8
.4
5
8
.2
4
6
.9
2
8
.8
2
5
.8
1
9
.5
1
4
.6
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MCAZ7693.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
3
.4
3
1
.1
8
2
.2
3
1
.2
2
3
.1
0
2
.2
8
4
.3
5
1
.0
8
0
.9
9
1
.0
3
0
.9
6
1
.0
1
0
.9
7
MCAZ7693.012.001.1r.esp
184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
1
6
5
.4
1
6
0
.9
1
4
9
.0
1
3
8
.6
1
3
7
.5
1
2
7
.9
1
2
7
.6
1
2
6
.4
1
2
6
.3
1
1
3
.2
1
1
2
.1
1
1
1
.1
7
9
.0
6
8
.0
5
9
.3
4
8
.8
2
9
.1
2
5
.6
1
4
.6
1
1
.8
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MCAZ7886.010.001.1r.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
3
.5
8
3
.0
0
2
.2
4
1
.1
7
2
.2
6
1
.0
9
1
.0
3
1
.0
3
0
.9
2
MCAZ7886.012.001.1r.esp
208 200 192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
2
0
2
.3
1
9
2
.1
1
6
9
.0
1
6
2
.0
1
5
4
.2
1
3
6
.4
1
2
8
.7
1
2
8
.0
1
2
7
.6
1
2
4
.6
6
1
.7
5
3
.9
3
9
.0
3
0
.0
1
4
.1
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MCAZ7947.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
3
.2
7
3
.4
0
2
.3
5
2
.2
9
0
.9
7
2
.1
7
1
.1
1
0
.9
8
3
.3
8
1
.0
5
1
.0
3
MCAR7947.020.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
1
6
5
.7
1
6
1
.3
1
4
8
.6
1
3
8
.3
1
3
8
.1
1
3
7
.7
1
2
8
.9
1
2
8
.0
1
2
7
.3
1
2
6
.7
1
2
6
.4
1
1
3
.7
1
1
2
.8
1
1
1
.3
5
9
.8
4
8
.6
1
4
.8
1
1
.7
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MCAZ7948.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
3
.2
1
6
.2
1
2
.1
5
0
.9
8
2
.0
4
1
.1
3
0
.9
6
1
.2
2
0
.9
9
1
.0
1
MCAR7948.020.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
1
6
5
.7
1
6
2
.6
1
6
0
.6
1
6
0
.1
1
4
7
.7
1
3
8
.9
1
3
7
.6
1
3
7
.4
1
3
2
.2
1
2
8
.6
1
2
8
.0
1
2
8
.0
1
2
6
.7
1
2
6
.5
1
2
6
.3
1
2
4
.5
1
1
6
.2
1
1
6
.0
1
1
3
.2
1
1
1
.8
1
1
1
.2
5
9
.9
1
4
.8
1
2
.5
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MCAR8968.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
3
.0
0
2
.9
9
1
.9
6
0
.9
1
0
.9
5
0
.9
3
3
.3
2
0
.8
1
0
.9
4
1
.0
0
MCAZ8968.020.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
5
.7
1
6
0
.8
1
6
0
.6
1
5
7
.3
1
4
7
.8
1
3
9
.3
1
3
7
.7
1
3
1
.3
1
3
1
.1
1
2
8
.6
1
2
8
.1
1
2
6
.8
1
2
6
.6
1
2
5
.0
1
1
7
.2
1
1
6
.9
1
1
3
.6
1
1
1
.8
1
1
1
.3
6
0
.0
1
5
.0
1
2
.2
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MCAZ8936.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
3
.1
0
3
.0
2
2
.0
8
0
.9
6
1
.3
1
0
.9
5
0
.5
5
1
.1
0
0
.8
1
1
.0
0
1
.0
0
1
.0
7
MCAZ8936.020.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
1
6
5
.3
1
6
4
.4
1
6
1
.1
1
6
0
.4
1
4
7
.3
1
3
9
.7
1
3
8
.4
1
3
7
.1
1
3
0
.4
1
2
8
.1
1
2
7
.7
1
2
7
.6
1
2
6
.4
1
2
4
.6
1
1
6
.5
1
1
6
.2
1
1
3
.1
1
1
1
.5
1
1
1
.2
5
9
.6
1
4
.5
1
2
.2
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MCAZ8935.010.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
3
.0
3
3
.0
0
2
.0
2
0
.9
2
0
.9
7
0
.9
8
1
.0
0
0
.5
9
2
.1
4
0
.9
2
0
.9
3
MCAZ8935.011.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
1
6
5
.3
1
6
4
.1
1
6
0
.8
1
6
0
.3
1
4
7
.4
1
3
8
.6
1
3
7
.1
1
3
4
.3
1
3
0
.4
1
3
0
.3
1
2
8
.3
1
2
7
.7
1
2
7
.6
1
2
6
.4
1
1
6
.4
1
1
6
.1
1
1
2
.9
1
1
1
.4
1
1
1
.0
7
7
.0
5
9
.5
1
4
.5
1
2
.2
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MCAZ9038.010.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
3
.2
9
3
.1
7
3
.1
3
2
.1
7
0
.9
8
1
.2
9
1
.3
7
0
.6
9
1
.0
4
1
.0
1
1
.0
2
0
.9
9
1
.0
8
MCAZ9038.021.001.1r.esp
184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
1
6
5
.6
1
6
0
.0
1
5
6
.0
1
4
7
.9
1
3
9
.3
1
3
7
.4
1
3
0
.6
1
3
0
.1
1
2
8
.2
1
2
7
.6
1
2
7
.6
1
2
7
.0
1
2
6
.3
1
2
0
.9
1
1
2
.5
1
1
2
.3
1
1
1
.2
1
0
9
.7
5
9
.4
5
5
.8
1
4
.6
1
1
.8
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MCAZ9012.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
3
.2
0
3
.0
9
3
.1
6
2
.1
5
0
.9
7
1
.0
4
1
.0
4
1
.5
8
0
.5
6
1
.0
0
0
.8
5
1
.0
1
MCAZ9012.011.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
1
6
5
.4
1
6
0
.4
1
6
0
.2
1
4
7
.4
1
3
9
.3
1
3
8
.7
1
3
7
.2
1
3
0
.1
1
2
8
.3
1
2
7
.6
1
2
6
.5
1
2
0
.8
1
1
5
.0
1
1
4
.2
1
1
2
.7
1
1
1
.5
1
1
0
.4
5
9
.5
5
5
.5
1
4
.6
1
2
.2
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MCAR9071.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
3
.3
9
3
.2
8
3
.3
6
2
.3
0
1
.0
2
2
.0
7
1
.2
2
2
.2
1
1
.0
1
1
.0
7
1
.0
7
MCAR9071.011.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
5
.5
1
6
0
.2
1
5
9
.8
1
4
7
.6
1
3
9
.1
1
3
7
.3
1
3
0
.9
1
2
9
.7
1
2
8
.6
1
2
7
.7
1
2
6
.5
1
1
4
.7
1
1
2
.6
1
1
1
.4
1
1
0
.3
5
9
.5
5
5
.5
1
4
.6
1
2
.2
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MCAZ8825.010.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
3
.3
3
3
.3
7
2
.2
3
2
.0
5
1
.0
1
1
.0
7
1
.1
7
0
.9
6
1
.0
9
0
.9
0
1
.0
4
0
.9
5
1
.0
0
MCAZ8825.011.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
1
6
5
.3
1
6
4
.7
1
6
1
.4
1
6
1
.1
1
4
8
.1
1
4
0
.6
1
3
7
.8
1
3
7
.3
1
3
0
.1
1
2
7
.8
1
2
6
.8
1
2
6
.4
1
2
1
.6
1
1
3
.9
1
1
3
.4
1
1
3
.0
1
1
2
.7
1
1
1
.0
5
9
.5
4
7
.9
1
4
.5
1
1
.4
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MCAZ8826.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
3
.1
5
3
.0
1
2
.1
1
2
.0
0
0
.9
4
3
.6
5
1
.0
4
0
.9
6
0
.9
9
1
.0
0
MCAZ8826.022.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
5
.3
1
6
3
.5
1
6
1
.1
1
6
0
.2
1
4
8
.2
1
3
7
.8
1
3
7
.3
1
3
3
.5
1
2
7
.8
1
2
7
.7
1
2
6
.8
1
2
6
.5
1
1
5
.5
1
1
5
.2
1
1
3
.5
1
1
2
.6
1
1
1
.0
5
9
.5
4
7
.7
1
4
.5
1
1
.4
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MCAR8854.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
3
.2
8
3
.2
1
3
.2
3
2
.2
2
2
.2
0
1
.1
1
1
.1
6
1
.0
9
1
.0
7
0
.9
3
1
.0
9
1
.1
3
1
.0
4
1
.0
2
MCAR8854.020.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
5
.5
1
6
0
.9
1
5
6
.0
1
5
0
.9
1
4
8
.3
1
3
8
.3
1
3
7
.5
1
2
8
.0
1
2
7
.7
1
2
7
.3
1
2
6
.4
1
2
6
.3
1
2
6
.2
1
2
0
.7
1
1
2
.9
1
1
2
.3
1
1
1
.1
1
0
9
.7
5
9
.5
5
5
.3
4
3
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1
4
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1
1
.2
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MCAZ7782.010.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
1
.2
0
2
.1
8
1
.0
5
2
.8
5
2
.3
5
2
.0
1
0
.8
8
1
.3
7
0
.8
5
1
.0
0
0
.8
6
0
.9
5
0
.9
9
MCAZ7782.012.001.1r.esp
160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
1
.2
1
6
1
.0
1
4
8
.6
1
4
1
.4
1
3
7
.5
1
2
8
.0
1
2
7
.7
1
2
6
.8
1
2
6
.5
1
1
3
.9
1
1
1
.7
1
1
1
.3
7
8
.9
6
8
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4
9
.0
2
9
.1
2
5
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1
2
.1
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MCAZ7979.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
3
.1
1
2
.0
5
1
.4
3
0
.7
9
1
.0
5
0
.9
4
1
.1
2
0
.9
7
3
.2
6
1
.0
4
1
.0
1
MCAZ7979.021.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
1
.6
1
6
1
.5
1
4
8
.2
1
4
1
.3
1
3
7
.7
1
2
9
.1
1
2
8
.3
1
2
8
.2
1
2
7
.9
1
2
7
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1
2
7
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6
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1
1
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1
1
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1
2
.1
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MCAR7985.012.001.1r.esp
160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
2
.5
1
4
.5
1
1
1
.7
1
1
1
.9
1
1
2
.1
1
1
5
.6
1
1
5
.8
1
2
4
.1
1
2
6
.3
1
2
6
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7
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1
2
7
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8
.8
1
3
2
.0
1
3
6
.7
1
3
7
.2
1
4
1
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1
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7
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1
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1
6
2
.3
 
MCAR7985.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
3
.2
1
3
.0
2
1
.6
1
0
.9
8
3
.2
7
0
.9
1
1
.2
6
1
.0
1
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MCAR9006.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
3
.0
8
1
.0
1
0
.9
3
1
.0
7
2
.5
7
1
.2
0
0
.7
8
1
.0
0
1
.1
3
MCAR9006.021.001.1r.esp
160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
M01(s)
1
6
1
.0
1
6
0
.6
1
5
9
.7
1
5
7
.2
1
4
7
.1
1
4
1
.9
1
3
7
.2
1
3
1
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0
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MCAZ8987.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
2
.9
2
0
.9
8
0
.8
4
1
.0
4
2
.2
0
1
.0
6
1
.7
8
1
.3
1
0
.9
8
MCAZ8987.021.001.1r.esp
160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
4
.3
1
6
1
.1
1
6
1
.0
1
6
0
.6
1
4
7
.1
1
4
1
.5
1
3
7
.1
1
3
4
.0
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0
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MCAZ9059.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
2
.8
6
2
.9
3
1
.0
4
0
.8
5
1
.0
9
1
.0
3
0
.9
4
1
.0
2
0
.9
6
0
.9
3
0
.9
9
1
.0
6
MCAZ9059.012.001.1r.esp
160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
1
.4
1
6
0
.1
1
5
5
.9
1
4
7
.6
1
4
2
.2
1
3
7
.4
1
3
0
.8
1
3
0
.0
1
2
8
.6
1
2
7
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6
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MCAZ9051.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
2
.8
4
3
.0
4
1
.6
1
0
.9
0
0
.9
5
0
.9
9
0
.9
9
0
.9
9
1
.8
6
1
.9
5
MCAZ9051.021.001.1r.esp
160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
1
.3
1
6
0
.5
1
6
0
.3
1
4
7
.1
1
4
1
.5
1
3
9
.0
1
3
7
.2
1
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0
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1
2
8
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.8
1
2
7
.7
1
2
6
.5
1
2
0
.8
1
1
5
.3
1
1
4
.0
1
1
2
.0
1
1
1
.2
5
5
.6
1
2
.5
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MCAR9092.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
Chemical Shift (ppm)
2
.8
0
3
.0
2
0
.9
2
0
.9
3
2
.9
8
2
.0
9
1
.8
5
0
.9
8
MCAR9092.021.001.1r.esp
160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
1
.4
1
6
0
.3
1
6
0
.0
1
4
7
.3
1
4
1
.9
1
3
7
.3
1
3
0
.6
1
2
9
.6
1
2
9
.1
1
2
7
.7
1
2
7
.6
1
2
6
.5
1
1
4
.7
1
1
1
.9
1
1
1
.8
1
1
1
.1
5
5
.6
1
2
.5
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MCAR8844.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
2
.9
5
1
.9
0
1
.4
2
1
.0
2
1
.0
0
1
.0
5
0
.9
7
1
.0
4
0
.9
5
0
.6
5
0
.9
9
1
.0
0
MCAR8844.020.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
1
6
4
.3
1
6
1
.9
1
6
1
.3
1
6
1
.0
1
4
7
.6
1
4
0
.7
1
4
0
.0
1
3
7
.2
1
3
0
.2
1
3
0
.2
1
2
7
.9
1
2
7
.8
1
2
7
.4
1
2
6
.6
1
1
4
.2
1
1
4
.1
1
1
3
.2
1
1
1
.8
1
1
1
.6
4
8
.1
1
1
.6
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MCAR8850.010.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
3
.0
4
2
.0
2
1
.1
7
4
.9
4
1
.0
5
0
.9
5
1
.0
1
1
.0
0
MCAR8850.020.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0
Chemical Shift (ppm)
1
6
3
.5
1
6
1
.6
1
6
1
.4
1
6
1
.1
1
4
8
.0
1
4
1
.0
1
3
7
.5
1
3
3
.3
1
2
8
.2
1
2
8
.2
1
2
7
.7
1
2
6
.9
1
1
6
.0
1
1
5
.7
1
1
4
.6
1
1
2
.1
1
1
1
.9
4
8
.2
1
2
.0
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MCAZ8000.010.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
1
.2
0
2
.3
3
1
.1
9
3
.0
9
3
.2
3
2
.2
5
2
.2
0
1
.0
4
0
.9
4
1
.0
2
1
.0
9
0
.9
8
1
.0
2
1
.0
0
MCAZ8000.012.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
6
.5
1
6
0
.9
1
4
9
.0
1
3
7
.5
1
3
6
.0
1
2
7
.9
1
2
7
.7
1
2
6
.5
1
2
6
.2
1
1
5
.1
1
1
2
.9
1
0
7
.7
7
9
.0
6
8
.0
4
8
.6
2
9
.1
2
6
.1
2
5
.6
1
1
.6
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MCAZ8020.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
1
.1
3
2
.5
9
1
.1
6
3
.1
6
6
.2
2
2
.2
0
2
.1
4
1
.0
8
1
.0
0
1
.0
8
0
.9
5
1
.0
0
1
.0
0
MCAZ8020.012.001.1r.esp
192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8 0 -8
Chemical Shift (ppm)
1
6
8
.8
1
6
0
.8
1
4
9
.3
1
3
7
.6
1
3
3
.2
1
2
7
.9
1
2
7
.5
1
2
6
.3
1
2
5
.7
1
1
5
.8
1
1
2
.7
1
0
9
.3
7
9
.2
6
7
.9
5
3
.4
4
8
.7
2
9
.1
2
5
.5
1
1
.7
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MCAR8986.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
3
.2
7
3
.2
3
0
.7
9
1
.0
0
1
.0
0
1
.9
9
1
.0
7
1
.0
8
1
.0
1
1
.1
5
0
.7
8
MCAR8986.020.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
6
.2
1
6
4
.1
1
6
1
.6
1
6
0
.6
1
4
7
.2
1
3
9
.7
1
3
7
.0
1
3
6
.6
1
3
0
.7
1
2
8
.0
1
2
7
.9
1
2
7
.8
1
2
6
.7
1
2
4
.7
1
1
6
.3
1
1
6
.1
1
1
5
.8
1
1
0
.4
1
0
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2
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.2
1
2
.0
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MCAZ9005.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
Chemical Shift (ppm)
3
.0
2
3
.0
1
0
.7
4
1
.0
3
1
.0
2
1
.0
9
4
.5
8
1
.0
3
1
.0
0
MCAZ9005.021.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
6
.7
1
6
4
.6
1
6
1
.3
1
6
0
.9
1
4
7
.7
1
3
7
.4
1
3
7
.2
1
3
4
.7
1
3
0
.9
1
3
0
.8
1
2
8
.6
1
2
8
.3
1
2
8
.2
1
2
7
.1
1
1
7
.1
1
1
6
.8
1
1
6
.1
1
1
0
.7
1
0
8
.7
2
6
.6
1
2
.4
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MCAR9065.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
2
.7
3
2
.6
8
2
.4
9
0
.9
7
0
.3
6
0
.7
9
0
.9
5
1
.8
2
0
.8
9
0
.9
0
0
.8
3
0
.9
1
MCAR9065.020.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
.0
0
1
6
6
.5
1
6
0
.2
1
5
6
.0
1
4
7
.7
1
3
7
.3
1
3
7
.2
1
3
0
.7
1
3
0
.3
1
2
8
.0
1
2
7
.7
1
2
7
.7
1
2
7
.0
1
2
6
.6
1
2
1
.0
1
1
5
.2
1
1
2
.3
1
0
8
.9
1
0
8
.0
5
5
.8
2
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1
1
.6
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MCAZ9055.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
2
.9
6
3
.1
1
3
.0
7
1
.0
4
0
.7
7
1
.0
0
1
.0
4
1
.0
0
2
.0
7
0
.8
9
1
.1
8
1
.0
3
MCAZ9055.020.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
6
.8
1
6
0
.9
1
6
0
.7
1
4
7
.7
1
3
9
.8
1
3
7
.5
1
3
7
.2
1
3
0
.7
1
2
8
.5
1
2
8
.2
1
2
7
.1
1
2
1
.3
1
1
5
.9
1
1
5
.5
1
1
4
.6
1
1
0
.3
1
0
8
.7
5
6
.0
2
6
.6
1
2
.4
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MCAZ9109.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5
Chemical Shift (ppm)
3
.1
1
3
.0
9
3
.1
2
0
.9
5
0
.9
3
1
.7
9
1
.0
9
1
.1
6
1
.9
6
1
.0
0
1
.0
0
MCAZ9109.011.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
6
.8
1
6
0
.6
1
6
0
.2
1
4
7
.9
1
3
7
.5
1
3
7
.5
1
3
1
.3
1
3
0
.1
1
2
8
.8
1
2
8
.1
1
2
7
.0
1
1
5
.7
1
1
5
.1
1
1
0
.1
1
0
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.5
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.0
2
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.5
1
2
.4
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MCAZ7593.010.001.1r.esp
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5
Chemical Shift (ppm)
3
.2
1
1
.0
2
0
.9
9
1
.0
0
MCAZ7599.011.001.1r.esp
200 192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64
Chemical Shift (ppm)
1
9
2
.1
1
4
4
.7
1
3
3
.9
1
2
8
.3
1
2
6
.9
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MCAZ8081.010.001.1r.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5
Chemical Shift (ppm)
3
.2
5
2
.0
7
1
.0
8
1
.0
5
1
.0
5
1
.0
0
MCAZ8081.012.001.1r.esp
200 192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24
Chemical Shift (ppm)
1
8
5
.8
1
6
1
.4
1
5
1
.8
1
2
7
.6
1
2
5
.5
1
2
4
.6
1
1
3
.7
1
0
8
.7
3
6
.9
3
3
.1
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MCAR8101.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
3
.1
6
1
.1
1
3
.2
7
3
.1
3
2
.1
9
3
.0
7
1
.1
0
2
.2
0
1
.1
2
1
.0
7
1
.0
1
1
.0
2
1
.0
3
1
.0
0
0
.5
2
MCAR8101.011.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
5
.4
1
6
0
.5
1
4
8
.4
1
3
8
.1
1
2
6
.9
1
2
6
.7
1
2
6
.6
1
1
2
.6
1
1
2
.3
1
1
2
.0
1
1
1
.1
1
0
8
.3
7
8
.4
6
7
.9
5
9
.3
4
8
.1
3
6
.8
2
8
.9
2
5
.4
1
4
.5
1
1
.7
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MCAR8154.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
1
.0
4
3
.1
0
2
.8
7
2
.0
9
3
.0
9
0
.9
9
1
.0
4
0
.9
8
1
.1
3
1
.0
0
0
.9
9
0
.9
6
1
.0
0
1
.0
0
MCAR8154.020.001.1r.esp
160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
1
.0
1
6
0
.5
1
4
7
.8
1
4
0
.8
1
2
7
.2
1
2
6
.5
1
1
2
.8
1
1
2
.5
1
1
1
.5
1
1
1
.1
1
0
8
.2
7
8
.1
6
7
.8
4
8
.2
3
6
.7
2
8
.8
2
5
.3
1
1
.8
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MCAZ8164.020.001.1r.esp
7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
1
.1
5
3
.4
3
3
.1
1
3
.1
1
2
.1
8
3
.3
1
0
.7
2
1
.0
6
1
.0
4
0
.9
4
1
.0
2
1
.0
5
0
.9
5
0
.9
8
1
.0
0
MCAZ8164.022.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
6
.5
1
6
0
.5
1
4
8
.4
1
3
5
.7
1
2
6
.8
1
2
6
.6
1
1
5
.0
1
1
2
.6
1
1
1
.9
1
0
8
.4
1
0
7
.6
7
8
.3
6
7
.9
4
8
.0
3
6
.9
2
9
.0
2
6
.1
2
5
.4
1
1
.5
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MCAZ8283.010.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0
Chemical Shift (ppm)
3
.3
9
2
.1
8
3
.4
4
1
.1
4
1
.0
0
1
.1
4
 
 
MCAZ8283.021.001.1r.esp
192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24
Chemical Shift (ppm)
1
8
6
.5
1
6
3
.9
1
5
2
.2
1
3
7
.7
1
3
0
.1
1
2
5
.5
1
2
4
.0
1
2
3
.6
1
2
2
.0
1
2
1
.3
1
1
0
.4
1
1
0
.3
3
4
.4
3
3
.7
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MCAR8295.010.001.1r.esp
8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
3
.2
2
1
.1
0
1
.9
5
1
.3
5
3
.2
2
2
.1
7
3
.0
6
1
.5
9
2
.0
4
1
.2
2
1
.0
7
0
.9
1
0
.9
2
1
.9
2
1
.4
5
0
.9
6
0
.9
5
MCAR8295.020.001.1r.esp
176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
5
.5
1
6
2
.3
1
4
8
.3
1
3
8
.2
1
3
7
.3
1
2
9
.1
1
2
7
.1
1
2
5
.1
1
2
2
.8
1
2
1
.1
1
2
0
.9
1
1
2
.0
1
1
1
.3
1
1
1
.1
1
1
0
.9
1
0
9
.8
7
8
.7
6
7
.9
5
9
.2
4
8
.4
3
3
.2
2
8
.9
2
5
.4
1
4
.6
1
1
.8
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MCAZ8341.010.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
1
.2
1
2
.4
5
0
.9
9
2
.9
7
2
.2
4
3
.0
2
1
.0
6
1
.0
4
1
.0
3
1
.3
3
1
.0
2
1
.0
1
1
.9
0
1
.3
3
0
.9
9
1
.0
0
MCAZ8341.021.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
2
.5
1
6
1
.3
1
4
7
.9
1
4
1
.0
1
3
7
.3
1
2
9
.1
1
2
7
.6
1
2
5
.2
1
2
2
.8
1
2
1
.2
1
2
0
.9
1
1
1
.9
1
1
1
.6
1
1
1
.3
1
1
1
.1
1
0
9
.8
7
8
.6
6
8
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4
8
.6
3
3
.2
2
9
.0
2
5
.5
1
2
.0
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MCAR8629.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
2
.8
3
1
.1
2
1
.7
2
1
.0
4
1
.2
1
1
.0
3
1
.2
2
2
.1
2
0
.8
0
0
.8
8
0
.7
4
1
.2
3
0
.8
7
0
.8
4
1
.0
2
MCAZ8629.021.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
1
6
3
.5
1
6
1
.9
1
4
8
.0
1
3
7
.4
1
3
1
.1
1
2
8
.5
1
2
8
.4
1
2
7
.3
1
2
3
.2
1
1
9
.6
1
1
9
.1
1
1
7
.1
1
1
3
.6
7
8
.7
6
8
.4
6
1
.1
5
1
.2
2
9
.5
2
5
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1
4
.6
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MCAR8918.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
1
.2
4
2
.1
9
1
.1
3
2
.3
1
1
.0
1
1
.0
5
1
.0
5
1
.0
2
0
.9
8
1
.0
8
0
.9
4
0
.9
8
1
.0
0
MCAR8918.021.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16
Chemical Shift (ppm)
1
6
6
.0
1
6
1
.6
1
4
7
.5
1
3
7
.0
1
3
1
.2
1
2
8
.1
1
2
8
.0
1
2
6
.9
1
2
2
.5
1
2
2
.2
1
1
9
.8
1
1
6
.4
1
1
1
.1
7
8
.3
6
8
.0
5
0
.6
2
9
.1
2
5
.5
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MCAR8955.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
0
.9
3
2
.8
5
1
.3
8
3
.0
0
1
.5
8
0
.7
3
0
.7
2
0
.7
0
0
.6
3
0
.6
5
0
.9
8
0
.7
0
0
.7
8
0
.7
5
MCAR8955.021.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24
Chemical Shift (ppm)
1
6
5
.2
1
6
1
.5
1
4
7
.7
1
3
7
.0
1
3
1
.2
1
2
8
.1
1
2
8
.0
1
2
7
.0
1
2
6
.9
1
2
3
.5
1
1
9
.0
1
1
6
.2
1
1
0
.6
7
8
.3
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5
0
.5
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9
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6
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5
.5
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MCAR8764.010.001.1r.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0
Chemical Shift (ppm)
2
.9
1
1
.4
0
2
.7
5
1
.0
9
1
.0
9
1
.8
3
1
.1
0
1
.0
1
1
.0
4
1
.0
0
MCAR8764.020.001.1r.esp
208 200 192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32
Chemical Shift (ppm)
2
0
3
.1
1
9
2
.1
1
6
9
.5
1
6
2
.3
1
5
4
.2
1
3
6
.6
1
2
9
.1
1
2
8
.2
1
2
7
.9
1
2
5
.0
7
7
.5
5
9
.7
5
3
.0
4
9
.2
3
9
.1
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MCAR8769.010.001.1r.esp
7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5
Chemical Shift (ppm)
1
.2
1
2
.3
9
1
.5
3
2
.8
6
2
.3
1
3
.1
7
1
.0
4
1
.0
2
0
.9
6
2
.1
0
0
.8
8
1
.0
5
0
.6
8
0
.9
6
1
.0
0
MCAR8769.020.001.1r.esp
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24
Chemical Shift (ppm)
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